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when goals are so strong that obstacles failure and when loss only act as motivation. 
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Abstract  
 
Approximately 75% of all deaths in patients with schizophrenia are caused by physical 
illness. Cardiovascular disease is the commonest cause of death. Unhealthy lifestyle 
choices, such as lack of physical activity (PA), poor sleep quality, unhealthy diets and 
tobacco smoking as well as psychological determinants (i.e., low autonomous motivation 
and self-esteem) contribute to this excessive morbidity and mortality. In addition, the 
overlapping of lifestyle-related factors and psychological determinants and with 
additional factors (e.g., psychiatric medication), affects the quality of life (QoL) of this 
population. In the last decade, the relevance of healthy lifestyle behaviours in patients 
with schizophrenia has been reported. However there are still several research gaps that 
need to be clarified. Specifically, in the Portuguese reality, research focusing in this 
population is almost non-existent. Therefore, the main purpose of this doctoral thesis 
was to explore lifestyle-related factors and psychological determinants, and to analyse 
the impact of these in QoL in patients with schizophrenia. This doctoral thesis included 
six studies that aimed to: i) examine the construct validity of the Portuguese version of 
the Behavioural Regulation in Exercise Questionnaire – 2 (BREQ-2) as well as the 
Portuguese version of the BREQ–3; ii) investigate among a number of barriers what 
predicts the most on PA; iii) assess the associations between PA levels and sleep quality; 
iv) compare the sleep quality and QoL between regular physical active and the non-
physical active patients with schizophrenia; v) assess the dietary intake and adherence 
to Mediterranean Diet, specifically analysing the difference between treatment setting 
(i.e., inpatients and outpatients); and vi) explore the association between lifestyle-related 
factors, psychological determinants and QoL. In order to accomplish these aims, 118 
patients with schizophrenia (25% women and 50% inpatients) were included. 
Standardized assessment tools (i.e., questionnaires and field test) were applied to 
evaluate lifestyle-related factors, psychological determinants and QoL. Results of the 
studies showed that: i) the Portuguese version of the BREQ–3 revealed to be an 
appropriate measure to assess controlled and autonomous motivation towards PA; ii) 
autonomous motivation and global domain of QoL was found to be the most significant 
predictors of PA; iii) sleep quality was positively associated with time of moderate and 
total PA per week; iv) patients of regular physical active group have better sleep quality 
and QoL; v) patients reported a high consumption of caffeine, while deficits were evident 
for fibre and folate intakes. Outpatients showed a significant higher consumption of meat 
and meat products, and fruits and nuts, compared with inpatients; and vi) PA behaviours 
and self-esteem predicted better QoL across all domains of QoL. This doctoral thesis 
provided new and relevant evidence regarding lifestyle-related factors and psychological 
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determinants in patients with schizophrenia. Several practical considerations could be 
highlighted in order to influence interventions integrated in patient’s treatment. 
 
 
KEYWORDS: PHYSICAL ACTIVITY, SLEEP QUALITY, DIETARY PATTERNS, 
MOTIVATION, QUALITY OF LIFE, SCHIZOPHRENIA 
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Resumo  
 
Em pacientes com esquizofrenia, 75% da mortalidade é causada por comborbidades 
físicas. A doença cardiovascular é a causa de morte mais comum. Estilos de vida não 
saudáveis, como a falta de atividade física (AF), má qualidade de sono, hábitos 
alimentares inadequados, hábitos tabágicos bem como determinantes psicológicas (i.e., 
baixa motivação autónoma e autoestima), contribuem para este excesso de 
comorbidades e mortalidade. Em acréscimo, a sobreposição de estilos de vida e 
determinantes psicológicas, bem como com fatores adicionais (e.g., medicação 
psiquiátrica), afetam a qualidade de vida (QV) desta população. Na última década, tem 
sido reportada a importância da adoção de estilo de vida saudável em pacientes com 
esquizofrenia. Contudo existem ainda diversas lacunas na investigação que necessitam 
ser esclarecidas. Especificamente na realidade Portuguesa, investigação focada nesta 
população é praticamente inexistente. Neste sentido, o objetivo geral da presente 
dissertação foi explorar os fatores de estilos de vida e determinantes psicológicas, bem 
como analisar o impacto destes fatores na QV de pacientes com esquizofrenia. A 
presente dissertação inclui seis estudos originais que pretenderam: i) examinar a 
validade de constructo da versão Portuguesa do Behavioural Regulation in Exercise 
Questionnaire – 2 (BREQ-2), bem como da versão Portuguesa do BREQ–3; ii) identificar 
os fatores que são reconhecidos como barreiras para a AF; iii) avaliar a associação entre 
níveis de AF e qualidade de sono; iv) comparar a qualidade de sono e a QV entre 
pacientes fisicamente ativos e pacientes não fisicamente ativos; v) avaliar o consumo 
alimentar e a adesão à Dieta Mediterrânica, especificamente analisando as diferenças 
entre situação de tratamento (i.e., pacientes em situação de internamento versus 
pacientes residentes na comunidade); e vi) explorar a associação entre estilos de vida, 
determinantes psicológicas e QV. De forma a corresponder aos objetivos propostos, 118 
pacientes com esquizofrenia (25% sexo feminino e 50% pacientes em situação de 
internamento) foram incluídos. Instrumentos de avaliação (i.e., questionários e teste de 
terreno) foram aplicados para avaliar os estilos de vida, determinantes psicológicas e a 
QV. Os resultados dos estudos demonstraram que: i) a versão Portuguesa do BREQ–3 
demonstra ser uma medida apropriada para avaliar a motivação controlada e autónoma 
para a AF; ii) motivação autónoma e domínio global da QV foram identificados como os 
preditores mais significantes da AF; iii) qualidade de sono está positivamente associada 
com o tempo de AF moderada e AF total por semana; iv) pacientes que praticam AF 
regular revelam melhor qualidade de sono e QV comparativamente com pacientes que 
não praticam AF regularmente; v) pacientes reportaram elevado consumo cafeina, e 
apresentaram défices no consumo de fibra e folato. Pacientes residentes na 
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comunidade reportaram maior consumo de carne e produtos derivados, bem como de 
frutas e frutos secos, comparativamente com pacientes em situação de internamento; e 
vi) AF e autoestima são preditores de melhor QV em todos os domínios da QV. A 
presente dissertação demonstra nova e relevante evidência acerca dos estilos de vida 
e determinantes psicológicas em pacientes com esquizofrenia. Diversas implicações 
práticas podem ser evidenciadas no sentido de influenciar as intervenções integradas 
no tratamento de cada paciente.  
 
 
PALAVRAS-CHAVE: ATIVIDADE FÍSICA, QUALIDADE DE SONO, HÁBITOS 
ALIMENTARES, MOTIVAÇÃO, QUALIDADE DE VIDA, ESQUIZOFRENIA 
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General introduction  
 
 
Schizophrenia: the clinical expression of the disorder 
 
Schizophrenia is a severe mental disorder, which affects a person’s global functioning 
and causes changes in almost all mental functions. It is characterized by a wide spectrum 
of signs and symptoms, which include delusions and hallucinations, distortions of 
thinking and perception, cognitive impairments, psychomotor abnormalities, difficulties 
in communication, restricted affective expression and loss of motivation and initiative 
(American Psychiatric Association, 2013; Carpenter & Tandon, 2013; Kahn et al., 2015; 
Tandon, Nasrallah, & Keshavan, 2009).  
Symptoms of schizophrenia are generally classified into positive, negative, cognitive, 
mood and psychomotor symptom dimensions, with psychopathology differentially 
expressed across patients and through the course of the disorder (Kahn et al., 2015; 
Tandon et al., 2009). Positive symptoms consist of psychotic symptoms, involve impaired 
reality testing and include hallucinations, delusions, disorganized speech and behaviour 
(Kahn et al., 2015; Tandon et al., 2013; Tandon et al., 2009). Negative symptoms are 
associated with disruptions to normal emotions and behaviours. These include 
impairments in affective experience and expression, poverty of speech, reduced social 
drive, lack of motivation, initiative and interest (Heiden, Leber, & Hafner, 2016; Kahn et 
al., 2015; Tandon et al., 2013; Tandon et al., 2009). Cognitive symptoms comprise 
deficits in working memory, processing speed, attention and in executive functions (i.e., 
ability to organize and abstract) (Carpenter & Tandon, 2013; Tandon et al., 2013). Mood 
symptoms are characterized by depression and mania that occur in different stages of 
the disorder (Carpenter & Tandon, 2013; Tandon et al., 2013). Finally, psychomotor 
symptoms are frequently manifest in patients with schizophrenia. For one hand, slowing 
of psychomotor activity is associated with negative and depressive symptom clusters, 
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and portends a poor outcome (Bervoets et al., 2014; Morrens, Hulstijn, & Sabbe, 2007). 
For another hand, excessive motor activity is more often associated with exacerbations 
of positive symptoms. Disturbances of psychomotor activity can range from complex 
motion patterns such as catatonic states (Bervoets et al., 2014; Carpenter & Tandon, 
2013), to simple isolated movements in posture, mannerisms and stereotypes (Morrens, 
Hulstijn, Lewi, De Hert, & Sabbe, 2006). 
 
In schizophrenia, the severity of different symptom clusters varies across patients and 
through the course of the disorder (Kahn et al., 2015; Tandon et al., 2009). The disorder 
is characterized by a sequential trajectory that involves different phases. A premorbid 
phase where patients exhibit a range of developmental behavioural, emotional and 
cognitive problems (e.g., delays in motor development, attentional dysfunction, deficits 
in receptive language and emotional detachment), accompanied by premorbid 
impairments in academic and social function (Schenkel & Silverstein, 2004). A prodromal 
phase characterized by attenuated positive symptoms or basic symptoms and declining 
function (Schultze-Lutter, 2009). This phase could last from months to years, with a mean 
of approximately five years (Klosterkotter, Schultze-Lutter, & Ruhrmann, 2008). The 
development of psychotic symptoms marks the formal onset of the first psychotic episode 
of schizophrenia. This onset typically occurs between 20 and 24 years of age (Kirkbride 
et al., 2006), specifically between 18-25 years for men and 25 and the mid-30s for women 
(American Psychiatric Association, 2000). Approximately, one third of individuals 
develop this disorder before the age of 18 years (Madaan, Dvir, & Wilson, 2008). The 
initial decade of disorder is marked by repeated episodes of psychosis with partial and 
variable degrees and duration of inter-episode remission with accrual of disability with 
each episode of disorder (McGlashan & Fenton, 1993). Episodes of psychosis can be 
triggered by stress, non-adherence to treatment or substance abuse (Tandon et al., 
2009). Finally, a stable phase, when psychotic symptoms are less prominent and 
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negative symptoms and the stable cognitive deficits increasingly predominant (Tandon 
et al., 2009). 
 
Schizophrenia is considered one of the most debilitating psychiatric disorders (Rossler, 
Salize, van Os, & Riecher-Rossler, 2005), estimated to affect more than 21 million people 
worldwide (World Health Organization, 2016). Due to its seriousness, it is one of the 
mental disorders which leads to most disability, and is amongst the top 20 health causes 
of serious disability worldwide, both in developed and developing nations (World Health 
Organization, 2008). Schizophrenia is more common among males (12 million), than 
females (9 million) (World Health Organization, 2016).  
In Portugal, the prevalence of schizophrenia is estimated between 0.5% and 1% of the 
population and it is one of the most disabling disorders for productive activities (Direção-
Geral da Saúde, 2013; Silva, Negreiro, Silva, & Vicente, 2013). The disorder is also more 
common in males (65.1%) and in the 35-64 age group (60.3%) (Silva et al., 2013). The 
psychiatric census of 2001 showed that schizophrenia was the most frequent pathology 
with 3917 patients (26.43%). This disorder was also the main cause for care (36,5%) at 
health care institutions, divided into hospitalization (66.9%), consultations (30.5%) and 
emergency episodes (2.7%) (Silva et al., 2013). The study of Simões do Couto et al. 
(2011), in 478 Portuguese patients with schizophrenia revealed the following 
characteristics, an average age of 43 years, single (73.5%), living in a family environment 
(i.e., outpatients) (70%), and unemployed (85%). In addition, 22.5% of the patients lived 
permanently in psychiatric hospitals (i.e., inpatients). Regarding clinical characteristics, 
the most frequent diagnosis was paranoid schizophrenia (54%), of moderate severity 
(39.7%) and with a duration of more than 5 years.  
 
In schizophrenia, comprehensive treatment entails a multi-modal approach, including 
pharmacological treatment and psychosocial interventions. The broad aims of treatment 
are to reduce the mortality and morbidity of the disorder by decreasing the frequency 
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and severity of psychotic episodes and improving the functional capacity and quality of 
life of the patients (Tandon, Nasrallah, & Keshavan, 2010). Regarding antipsychotic 
medications, is essential for the pharmacological treatment of schizophrenia. It is 
recognized that medication is effective in reducing overall symptoms and risk of relapse 
with primary efficacy mainly against positive and disorganization symptom domains 
(Leucht, Arbter, Engel, Kissling, & Davis, 2009). Over 60 antipsychotic medications have 
been developed and are classified into the first- and second-generation agents. The first-
generation antipsychotics (e.g., chlorpromazine, fluphenazine, haloperidol) were 
developed in the 1950s. These medications has been hindered by intolerability, 
particularly extrapyramidal symptoms (e.g., akathisia, Parkinsonism, dystonia, 
dyskinesia), which are risk factors for reduced adherence and persistence to medications 
(Pierre, 2005; Warikoo, Chakrabarti, & Grover, 2014). In addition, first-generation 
antipsychotics medications showed to be minimally effective against negative and 
cognitive symptom domains which contribute to the disorder related disability (Tandon 
et al., 2009).  
The second-generation antipsychotics (e.g., amisulpride, aripiprazole, asenapine, 
iloperidone, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone) emerged in the 
1980s. These medications are associated with a lower risk of extrapyramidal side-effects 
but also a higher risk of metabolic adverse effects (e.g., weight gain, diabetes, 
dyslipidaemia and cardiovascular problems) (American Diabetes, American Psychiatric, 
American Association of Clinical, & North American Association for the Study of, 2004; 
Crossley, Constante, McGuire, & Power, 2010; Miyamoto, Duncan, Marx, & Lieberman, 
2005). In Portugal, a study revealed that first-generation antipsychotics are applied in 
48% of the patients with schizophrenia, and second-generation antipsychotics in 51% 
(Simões do Couto et al., 2011).  
Both types of antipsychotic medications cause a range of neurological, metabolic, 
cardiovascular, gastrointestinal, hematological, genito-urinary, musculoskeletal, 
endocrine, and other side effects. In contrast to its broadly similar efficacy, antipsychotic 
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agents clearly differ in their propensity to cause these adverse effects (De Hert et al., 
2009; Ozbilen & Adams, 2009). Antipsychotic treatment responsiveness varies as a 
function of disorder stage, with first-episode patients responding faster and at a higher 
rate than those at later stages of the disorder (Salimi, Jarskog, & Lieberman, 2009). 
Since non-adherence to medication during treatment of schizophrenia is common, long-
acting injectable antipsychotic regimens have been found to be variably advantageous 
over oral antipsychotic treatment approaches in reducing rates of relapse (Adams, 
Fenton, Quraishi, & David, 2001; Nasrallah, 2007).  
In view of the limitations of antipsychotic medication in many symptom domains of 
schizophrenia, several other psychotherapeutic medications have been utilized in its 
treatment (Tandon et al., 2010). These include various anticonvulsants – to targeting 
aggression and impulsivity; antidepressants – to targeting depressive and anxiety 
symptoms; and benzodiazepines – to targeting anxiety, agitation, and insomnia (Thomas 
et al., 2009; Tiihonen, Wahlbeck, & Kiviniemi, 2009). In Portugal, benzodiazepines were 
the most common psychotropic medication prescribed as co-therapy (68.7%), followed 
by antidepressants (29.5%) (Simões do Couto et al., 2011).  
 
Although pharmacological treatment represents the first-line treatment of choice in 
schizophrenia, the extent to which such treatment improves lifespan and psychosocial 
function in these patients is less clear (Lehman et al., 2004). In fact, according to Tandon 
et al. (2010) pharmacological treatment alone produces only limited improvement in 
negative symptoms, cognitive function, social functioning and quality of life (QoL).  
This underlines the need for multi-modal care including psychosocial therapies as 
adjuncts to antipsychotic medications (Glynn, 2001; Kern, Glynn, Horan, & Marder, 2009) 
to help at symptom relief, the enhancement of self-confidence and the improvement of 
QoL (Probst, 2017). Specifically, psychosocial interventions are recognized to promote 
a reduction on psychotic symptoms and relapse, as well as improving patients' long-term 
outcomes (e.g., recovery, remission and disorder progression) (Kern et al., 2009; 
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Patterson & Leeuwenkamp, 2008). Therapies for patients with schizophrenia focus on 
the patient, as well as on family caregivers (Fallahi Khoshknab, Sheikhona, Rahgouy, 
Rahgozar, & Sodagari, 2014) and include case management, supported employment, 
cognitive remediation, psychoeducation, and cognitive-behavioural therapies (e.g., 
Social Skills Training, Cognitive Therapy) (Morin & Franck, 2017). These psychosocial 
approaches have proven their effectiveness in reducing the impact of cognitive 
impairment, negative symptoms, relapses, and the intensity of distress related to positive 
symptoms. In addition, the psychosocial approaches also try to promote the recovery 
process by encouraging self-determination and active empowerment (Morin & Franck, 
2017). 
 
However, patients with schizophrenia have poor access to health care (Mitchell, Malone, 
& Doebbeling, 2009). Specifically in Portugal, only 38% of the patients were involved in 
psychosocial approaches (18% occupational therapy, 12% psychotherapy, 8% 
rehabilitation and 8% community support) (Simões do Couto et al., 2011). Despite the 
benefits of multi-modal care for patients with schizophrenia, clinical and functional 
outcomes among patients participating in such services are still suboptimal. Among such 
patients, psychiatric hospitalizations can occur, substance use (especially tobacco) is 
high (Brown, Birtwistle, Roe, & Thompson, 1999; Kalman, Morissette, & George, 2005; 
Lasser et al., 2000; McCreadie, 2002), poor physical health outcomes are the norm 
(Cimo, Stergiopoulos, Cheng, Bonato, & Dewa, 2012; Correll et al., 2017; Crump, 
Winkleby, Sundquist, & Sundquist, 2013), and rates of participation in competitive 
employment remain lower than their age-matched peers without psychotic-spectrum 
disorders (Rosenheck et al., 2006).  
The literature demonstrated that patients with schizophrenia have an excess premature 
mortality, being two or three times as high as that in the general population (Laursen, 
Nordentoft, & Mortensen, 2014; McGrath, Saha, Chant, & Welham, 2008; Tiihonen, 
Lonnqvist, et al., 2009). These patients have 11 to 20 years shorter lifespan compared 
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to general population (Laursen et al., 2013). Decreased life expectancy may be caused 
by suicide or somatic illnesses (e.g., cardiovascular diseases) (Brown, Inskip, & 
Barraclough, 2000; Osby, Westman, Hallgren, & Gissler, 2016). However, a recent study 
(Westman et al., 2017) revealed that cardiovascular diseases were the main reason for 
premature death in patients with schizophrenia, accounting for more excess deaths than 
suicide. Patients with schizophrenia are more likely to have more than one major risk 
factor for cardiovascular diseases, namely, overweight, smoking habits, high blood 
pressure and metabolic syndrome (Deuschle et al., 2013; Gardner-Sood et al., 2015; 
Gutierrez-Rojas et al., 2016; Olsson et al., 2015). In addition, they also are less likely to 
receive preventive care for these risk factors (Docherty, Stubbs, & Gaughran, 2016). 
Antipsychotic medications, particularly second-generation antipsychotics, may cause 
major adverse cardiovascular events (Khasawneh & Shankar, 2014). In Portugal, 28.4% 
of patients with schizophrenia suffer from somatic disorders, and the majority (26.5%) 
presented risks factors for cardiovascular diseases (i.e., hypertension, diabetes and high 
values of glycerides and cholesterol) (Simões do Couto et al., 2011).  
Smoking, obesity, low physical activity, raised glucose levels, high cholesterol level and 
hypertension are considered as modifiable lifestyle and health associated mortality risk 
factors (World Health Organization, 2009). Due to the high prevalence of these factors 
in patients with schizophrenia (Cimo et al., 2012; Correll et al., 2017; Kalman et al., 2005; 
Lasser et al., 2000; Manu et al., 2015; Stubbs, Firth, et al., 2016; Stubbs, Williams, 
Gaughran, & Craig, 2016) preventive and rehabilitative strategies, such as lifestyle 
programs are highly needed.  
 
 
Lifestyle-related factors: the impact on the disorder  
 
Unhealthy lifestyle choices is one of the most cited modifiable determinants in patients 
with schizophrenia. Therefore, delivering lifestyle and life skills interventions, including 
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dietary education, physical activity (PA) and smoking cessation, to reduce 
cardiometabolic risk factors is a priority (Teasdale, Samaras, Wade, Jarman, & Ward, 
2017). 
 
Regarding lack of sufficient PA and a sedentary lifestyle, it is recognized that patients 
with schizophrenia are more sedentary than the general population (Faulkner, Cohn, & 
Remington, 2006; Stubbs, Firth, et al., 2016; Stubbs, Williams, et al., 2016; Vancampfort 
et al., 2010). Total energy expenditure of patients with schizophrenia is more than 20% 
lower than the minimum recommendations of the World Health Organisation (Sharpe, 
Stedman, Byrne, Wishart, & Hills, 2006). Additionally, only a minority (about 25%) of 
patients with schizophrenia follow the guidelines of public health recommendation of 150 
minutes of PA per week (Beebe & Harris, 2013; Faulkner et al., 2006; Lindamer et al., 
2008).  
In schizophrenia, physical inactivity is identified as one of the most important modifiable 
factors strongly associated with cardiovascular disease-related mortality (Kilbourne et 
al., 2009). Patients with schizophrenia spend less time during the week performing 
strenuous activities than the general population, while during leisure time a greater 
proportion are not involved in sport activities (Roick et al., 2007; Stubbs, Firth, et al., 
2016). In addition, an association between sedentary behaviour (i.e., time spent laying 
or sitting) and increased incidence of metabolic syndrome (Ford, Kohl, Mokdad, & Ajani, 
2005), as well as neuro-cognitive deficits (Leutwyler, Hubbard, Jeste, Miller, & 
Vinogradov, 2014) was reported.  
The benefits of PA and exercise in the population with schizophrenia are well established 
in the literature. When performed regularly, PA and exercise are associated with 
improved psychological well-being (Dauwan, Begemann, Heringa, & Sommer, 2016), 
QoL (Holley, Crone, Tyson, & Lovell, 2011), and physical health (Gorczynski & Faulkner, 
2010). This is why PA has been recommended to be routinely integrated into psychiatric 
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services as an adjunct treatment for patients with schizophrenia (Richardson et al., 2005; 
Vancampfort, De Hert, et al., 2012). 
 
Additionally, patients with schizophrenia also experience poor sleep quality compared to 
general population (Wulff, Dijk, Middleton, Foster, & Joyce, 2012). Around 30 to 80% of 
these patients suffer from some form of disturbed sleep (Cohrs, 2008). In this population, 
frequently sleep disturbances are reported  such as initiating or maintaining sleep (Cohrs, 
2008), advanced sleep phase syndrome and hypersomnia with short naps (Wirz-Justice, 
Haug, & Cajochen, 2001). To deal with sleep disturbances often sleep-inducing 
medication is prescribed or antipsychotics are chosen because of their enhanced 
sedative properties (Wilson & Argyropoulos, 2012). However, even clinically stable, 
medicated patients maintain sleep disturbances (Afonso, Brissos, Canas, Bobes, & 
Bernardo-Fernandez, 2014). Sleep disturbances are positively associated with 
difficulties in daytime activities (Waters, Faulkner, Naik, & Rock, 2012), greater positive 
symptoms (Afonso, Brissos, Figueira, & Paiva, 2011), impaired cognitive functions 
(Bromundt et al., 2011) and poor QoL (Brissos et al., 2013; Hofstetter, Lysaker, & 
Mayeda, 2005; Ritsner, Kurs, Ponizovsky, & Hadjez, 2004). Moreover, sleep 
disturbances are a contributor to obesity and cardiovascular disease (Czeisler, 2011) 
which are highly prevalent in patients with schizophrenia (Mitchell et al., 2013; Ringen, 
Engh, Birkenaes, Dieset, & Andreassen, 2014). 
 
Unhealthy dietary habits are also frequent in patients with schizophrenia (Brown et al., 
1999; Dipasquale et al., 2013; McCreadie, 2003; Stokes & Peet, 2004), and are 
characterized by a high intake of saturated fat (Amani, 2007; Brown et al., 1999; 
Henderson et al., 2010; Strassnig, Brar, & Ganguli, 2005), sugar (Stokes & Peet, 2004) 
and low intake of fibre, fruit and vegetables (Brown et al., 1999; Gupta & Craig, 2009; 
Henderson et al., 2006; McCreadie, 2003). In addition, a significantly increased intake of 
calories (Strassnig, Brar, & Ganguli, 2003) and a low consumption of both 
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monounsaturated and polyunsaturated fatty acids (Henderson et al., 2006) were also 
reported. This behaviour partly explains the higher incidence of metabolic abnormalities 
(Dipasquale et al., 2013; Stokes & Peet, 2004), and these nutritional factors seem to 
have a key role in the development of diabetes, osteoporosis and on the disorder 
aggravation (Kishimoto, De Hert, Carlson, Manu, & Correll, 2012; Peet, 2004).  
Patients under antipsychotic medication seem to develop disordered dietary behaviours 
in response to altered appetite sensations and increased susceptibility to hunger, a factor 
which may influence the extent of body weight gain (Blouin et al., 2008). Additionally, 
adverse eating styles including disordered eating habits (e.g. only eating one main meal 
daily), fast-eating syndrome, and increased consumption of junk food and low food 
literacy were also observed (Blouin et al., 2008; Treuer et al., 2009). It is important to 
highlight that, in this population, discrimination, lower education and low socio-economic 
status may limit opportunities for access to healthier food (Thornicroft, Brohan, Rose, 
Sartorius, & Leese, 2009).  
Due to the importance of an adequate diet on some comorbidities in patients with 
schizophrenia (e.g., obesity, insulin resistance, dyslipidaemia and hypertension) 
(Bonfioli, Berti, Goss, Muraro, & Burti, 2012; Bruins et al., 2014; Wu, Wang, Bai, Huang, 
& Lee, 2007), traditional dietary patterns with proven benefits on health was been 
recommended (Teasdale et al., 2017). 
 
In a state-wide population survey of all patients with a mental disorder within a public 
mental health system, Morris et al. (2006) found that males were more likely to smoke 
tobacco than females, and that patients with a diagnosis of schizophrenia or bipolar 
disorder, were more likely to smoke tobacco than patients with other diagnoses. In fact, 
most patients with schizophrenia have tobacco smoking addiction (Kalman et al., 2005; 
McCreadie, 2002). Usually, these patients smoke tobacco 3-4 times more than the 
average of the general population (Lasser et al., 2000). Patients with schizophrenia who 
smoke are irrespective of age and gender more likely to suffer a cardiovascular event in 
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10 year when compared with subjects of the same spectrum disorder who do not smoke 
tobacco (Bobes, Arango, Garcia-Garcia, & Rejas, 2010). In addition, patients with 
schizophrenia who smoke are more likely to be physically inactive (Bobes et al., 2010), 
greater neuro-cognitive deficits and social, juridical and medical problems may occur 
(Bahorik, Newhill, & Eack, 2014). For this population, smoking feeling could alleviate 
schizophrenia symptomatology, particularly negative symptoms, by improving the 
sensory gating and cognitive deficits (Kumari & Postma, 2005; Winterer, 2010). 
 
 
Psychological determinants: as a process to improve health 
 
The adoption of a healthy lifestyle is a process that also involves motivation to plan a 
change, but also physical, psychological and material resources to adhere to the plan. 
Due to the disorder characteristics (i.e., cognition, perception, affect and volition) patients 
with schizophrenia could present difficulties in each step of this process (Hasnain, Victor, 
& Vieweg, 2011).  
 
Motivation is described as a multidimensional construct (Tremeau, Goldman, Antonius, 
& Javitt, 2013) that generally means to be moved to do something. Without motivation, 
a person is passive, apathetic and unresponsive (Medalia & Brekke, 2010). In patients 
with schizophrenia, amotivation (i.e., lack of motivation) is considered a barrier to achieve 
a positive functional outcome (Blanchard, Mueser, & Bellack, 1998). For example, 
patients with schizophrenia often demonstrate decreased motivation to participate in 
treatment and in learning activities (Blanchard et al., 1998), which consequently affects 
the treatment outcomes (Strauss, Waltz, & Gold, 2014). Similarly, patients with 
schizophrenia often exhibit limited motivation to engage in physical activities and 
maintain an active lifestyle (Soundy, Stubbs, Probst, Hemmings, & Vancampfort, 2014; 
Vancampfort, De Hert, et al., 2015; Vancampfort, De Hert, et al., 2013). 
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The self-determination theory (SDT) (Deci & Ryan, 1985, 2000) is a theoretical 
framework for the research of motivation in exercise. This theory has generated 
particular interest due to its multidimensional conceptualization of intrinsic and extrinsic 
motivation (Markland & Tobin, 2004). SDT explains why individuals pursue specific goals 
and behaviours, such as PA. Broadly, SDT emphasizes that individuals set goals and 
engage in behaviours to meet intrinsic psychological needs (i.e., intrinsic motivation) or 
to move towards external rewards or away from punishment (i.e., extrinsic motivation) 
(Deci & Ryan, 2000). SDT consists of a continuum ranging from amotivation to intrinsic 
motivation. At the lowest end of the continuum is amotivation, when the person is in a 
state of not intending to act or lacks the motivation to act. The person is intrinsically 
motivated when adopting a behaviour for his/her inherent enjoyment, which represents 
the most self-determined form of regulation. Between amotivation and intrinsic 
motivation, four types of extrinsic motivation are found, namely external, introjected, 
identified and integrated regulation, and are placed on a continuum that is based on the 
extent to which the regulation is self-determined (Deci & Ryan, 1985, 2000). External 
and introjected regulation are often grouped and refer to controlled forms of motivation 
(i.e., less self-determination), while identified regulation, integrated regulation, and 
intrinsic motivation are often referred to as autonomous motivation (i.e., more self-
determination). 
In healthcare and rehabilitation settings, self-determined motivation has been linked to 
positive behavioural health outcomes (Fortier, Sweet, O'Sullivan, & Williams, 2007; 
Moran, Russinova, Yim, & Sprague, 2014; Williams et al., 2006; Williams, McGregor, 
Zeldman, Freedman, & Deci, 2004). Specifically, in patients with schizophrenia, higher 
levels of autonomous motivation, self-efficacy and readiness for PA are positively related 
to an increase of PA (Lindamer et al., 2008; Vancampfort, De Hert, et al., 2015; 
Vancampfort, De Hert, et al., 2013; Vancampfort, Vansteenkiste, De Hert, et al., 2014). 
Therefore, autonomous motivation can add value to the adoption and maintenance of 
health-promoting behaviours in patients with schizophrenia (Vancampfort, De Hert, et 
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al., 2013; Vancampfort, Vansteenkiste, De Hert, et al., 2014). For example, mental health 
professionals have repeatedly reported that motivation is a problem when trying to 
engage psychiatric patients in PA (Sorensen, 2006). Therefore, it is important to identify 
the motivation process, namely the self-determined types of motivation to PA in this 
population.   
 
Self-esteem refers to an individual’s sense of value or worth, or the extent to which a 
person appreciates, or likes himself (Blascovich & Tomaka, 1991). In general population, 
self-esteem is associated with mental health, with low self-esteem linked to depression 
and anxiety (Sowislo & Orth, 2013) and also with adverse reactions such as anger and 
irritability, aggressiveness and feelings of non-satisfaction from life (Campbell, Chew, & 
Scratchley, 1991). Low self-esteem is considered as a possible consequence and a 
possible cause of psychiatric symptoms (Blairy et al., 2004; Karatzias, Gumley, Power, 
& O'Grady, 2007). Previous studies indicated that lowered self-esteem frequently 
accompanies or became an etiological factor in many psychiatric conditions (Salsali & 
Silverstone, 2003; Silverstone & Salsali, 2003).  
In patients with schizophrenia, Barrowclough et al. (2003a) reported significant 
correlations between negative self-evaluation and a wider variety of positive symptoms. 
Jones et al. (2010) found that a reduction in the severity of negative symptoms was 
significantly associated with improvement in self-esteem. Specifically, patients with high 
self-esteem exhibit better adaptation abilities, have confidence and are highly motivated. 
Contrarily, patients with low self-esteem have feelings of loneliness and underestimate 
their actual capabilities (Jones et al., 2010). Link et al. (2001) reported that 24% of the 
patients with schizophrenia scored below the mid-score (i.e., reflecting low score and 
low self-esteem). Silverstone and Salsali (2003), also found that these patients had 
intermediate levels of self-esteem. Patients with schizophrenia have significantly low 
self-esteem in comparison to other psychiatric conditions and they are expected to have 
15 
 
a compromised QoL and poor psychosocial functioning (Brekke, Kohrt, & Green, 2001; 
Gureje, Harvey, & Herrman, 2004). 
Regarding its applications in PA behaviours, self-esteem processes are associated with 
motivated behaviour in PA settings in general population (Biddle & Mutrie, 2008). In 
patients with schizophrenia, detailed data on the relationship between self-esteem in PA 
behaviour is lacking. Faulkner and Biddle (1999) previously noted that in patients with 
schizophrenia, improvements in self-esteem are reported, albeit inconsistently, after 
exercise training. In accordance, Faulkner and Sparkes (1999) indicated that PA is 
instrumental in raising self-esteem in this population. Yoon et al., (2016) reported that an 
applied PA programme promoted psychological changes, namely improvements on self-
esteem, competence and self-efficacy.  
 
 
Quality of life: as a major outcome of treatment 
 
Quality of life is a multidimensional concept that emphasizes the individual’s satisfaction 
with all aspects of life and includes physical, social, environmental, and psychological 
well-being (Hays et al., 1995). In patients with severe mental disorders (e.g., 
schizophrenia and bipolar disorder) severe impairment in QoL was observed among 46% 
of patients (Hansson, 2006). In patients with schizophrenia, several factors are 
associated with poor QoL. The most important factors are sociodemographic factors 
(e.g., gender, ethnicity, financial situation and educational level) (Munikanan et al., 2017; 
Pinikahana, Happell, Hope, & Keks, 2002), pharmacotherapy (i.e., side effects of 
antipsychotic medication) (Loga-Zec & Loga, 2010) and severity of psychopathology 
(e.g., disorder duration, depressive and negative symptoms) (Browne et al., 1996; 
Pinikahana et al., 2002; Rocca et al., 2009). Also, physical health conditions (e.g., 
obesity, hypertension and metabolic syndrome) (Allison, Mackell, & McDonnell, 2003; 
Malhotra, Kulhara, Chakrabarti, & Grover, 2016) and lifestyle-related factors, such as 
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lack of PA (Acil, Dogan, & Dogan, 2008; Deenik et al., 2017; Gomes et al., 2014b; 
Vancampfort, Probst, et al., 2011) and poor sleep quality (Hofstetter et al., 2005; Ritsner 
et al., 2004) are related with low QoL in this population. 
Finally, such psychosocial determinants as emotional distress, self-esteem, self-efficacy, 
and some coping styles with stressful situations, expressed emotion and social support 
have been found to play a significant role in satisfaction with QoL (Brekke et al., 2001; 
Gureje et al., 2004; Ritsner, Gibel, & Ratner, 2006; Ritsner, Lisker, & Grinshpoon, 2014; 
Ritsner et al., 2000). In patients with schizophrenia, QoL has been recognized as an 
important outcome of treatment (Faulkner, Cohn, Remington, & Irving, 2007; Maat, Fett, 
& Derks, 2012; Narvaez, Twamley, McKibbin, Heaton, & Patterson, 2008). Moreover, 
identifying determinants of schizophrenia specific QoL levels may improve the focus of 
health care treatment for this population.  
 
 
Gaps in lifestyle-related factors and schizophrenia research  
 
The poor physical health of patients with schizophrenia associated with unhealthy habits, 
attitudes and behaviours, has long been known. For that reason and due the interest of 
patients with schizophrenia in achieving lifestyle change (Archie et al., 2007), research 
into lifestyle-related factors in this population is increasing. According to Ward et al. 
(2017), targeted interventions have a major role to play in a holistic approach to 
addressing the major health inequalities in this vulnerable population. Ingrained 
inequality is one key reason why lifestyle interventions are an essential part of integrated 
best practice care. Adequate sleep, regular PA, and a healthy diet should be key 
contributors to well-being and a healthy life for everyone in society, but these are sadly 
absent for most patients with schizophrenia. In addition, this population often have poor 
self-management abilities and are frequently seen to have fewer health-promoting 
behaviours than non-psychiatric subjects or the general population (Chuang, Wu, Wang, 
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Liu, & Pan, 2016). In order to develop effective psychoeducational interventions to 
enhance and maintain health outcomes, it is important to understand the factors that 
influence the perseverance of health-promoting behaviours in schizophrenia.  
Although the relevance of healthy lifestyle behaviours in patients with schizophrenia is 
reported, there are still several research gaps that need to be clarified, namely when 
analysing the Portuguese reality. Firstly, is important to considerer that motivation is 
important for the adoption of a healthy lifestyle. The increased autonomy towards PA 
may have a positive impact on research about PA adoption and adherence in patients 
with schizophrenia. Specifically, it is recognized when patients with schizophrenia who 
are more autonomously regulated towards PA are more likely to voluntarily exercise over 
longer periods of time and are therefore more likely to benefit from the multitude of health 
benefits conferred by an active lifestyle (Vancampfort, Vansteenkiste, Hert, et al., 2014). 
However, there is a lack of reliable and valid instruments to determine the motivation 
processes of patients with schizophrenia to practice PA. Therefore Study 1 was 
developed. The existence of valid and reliable instruments to assess the motivation to 
PA in patients with schizophrenia is an important issue for research and clinical practice 
in the field of mental health. 
 
PA in patients with schizophrenia have been the focus of attention from researchers and 
clinicians in relation to the impact on psychopathology. Regarding the Portuguese 
context, few studies explore this theme. Gomes et al. (2014b) aimed to evaluate the 
effects of a 16-week group PA program on physical fitness and QoL in outpatients with 
schizophrenia. Results revealed that a PA program can be successfully implemented for 
outpatients with schizophrenia and can influence their QoL and PA levels. Other study 
(Gomes et al., 2014a) aimed to determine which type of PA (i.e., walking, dancing and 
small-sided games) is the most enjoyable and effective for patients with schizophrenia. 
The authors reported that outpatients with schizophrenia identified the walking sessions 
as the most effective (i.e., minimal target heart rate and PA levels), and the small-sided 
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games as the most enjoyable. However, to date, was not possible to identify any study 
exploring the barriers that Portuguese patients with schizophrenia could experience 
when try to adopt an active behaviour.  
Several and distinct variables, such as side-effects of antipsychotic medication, 
psychiatric symptoms, lack of social support and biological and psychological correlates, 
has described in the literature for compromised the attempting of patients with 
schizophrenia to become more active (Carter-Morris & Faulkner, 2003; Firth et al., 2016; 
McDevitt, Snyder, Miller, & Wilbur, 2006; Vancampfort, Knapen, et al., 2012). Although, 
it was not possible to identify any study that simultaneous analized the association 
between several factors which are recognized as a barrier to PA in patients with 
schizophrenia. To overcome this limitation, Study 2 was carried out, to provide new 
evidence in the international literature, and specifically understand the factors that may 
influence participation and delusional beliefs about PA. 
 
The poor sleep quality in patients with schizophrenia is well described in the literature. 
Problems affectting the components of sleep are commonly reported in this population.    
In general population, PA has been extensively recommended to improve sleep quality, 
due to the beneficial effects on sleep components (Chennaoui, Arnal, Sauvet, & Leger, 
2015; Kredlow, Capozzoli, Hearon, Calkins, & Otto, 2015). However, there is lack of 
scientific evidence supporting the relevance of PA in mental health field. For that reason, 
Study 3 aimed to assess the associations between PA levels and sleep quality in patients 
with schizophrenia. 
Recognized that poor sleep quality is associated with greater positive symptoms (Afonso 
et al., 2011), difficulties in daytime activities (Waters et al., 2012), and poor QoL (Brissos 
et al., 2013; Hofstetter et al., 2005; Ritsner et al., 2004) the Study 4 examined the 
differences in sleep quality and QoL between physical and non-physical active patients 
with schizophrenia.  
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Both, Study 3 and 4, highlight the importance of PA as an adjunctive treatment for sleep 
quality, and consequently in QoL in this population. PA should be considered as an 
option of non-pharmacological approach to deal with sleep disturbances. This situation 
will be in agreement with patient’s preferences regarding the reduction of medication, 
and the interest in alternative non-pharmacological interventions to improve sleep quality 
(Peacey, Miller, Huthwaite, & Romans, 2012).  
 
While the literature examining relationships between diet, lifestyle, and cardiovascular 
disease within the general population is broad, little has been assess among patients 
with schizophrenia. Specifically in the Portuguese context, there is a lack of research 
exploring the dietary habits in the population with mental disorders. Low socioeconomic 
status is recognized as an influent factor to the adherence to an adequate dietary intake 
(Roick et al., 2007; Samele et al., 2007). However, data on smoking status remain 
inconsistent (Dipasquale et al., 2013). Concerning that, Study 5 was carried out, to 
provide new evidence in the field of mental health. A better understanding of the 
characteristics of dietary patterns in patients with schizophrenia revealed great 
importance because diet are major and modifiable cause of cardiovascular disease 
(Dipasquale et al., 2013). Furthermore, interventions targeting dietary patterns in 
patients with schizophrenia could offer a greater benefit if synergetic effects can be 
detected in relation to metabolic syndrome-related conditions. Therefore, dietary intake, 
adherence to Mediterranean diet and the relationship with lifestyle-related factors (PA, 
tobacco smoking and sleep quality) were analysed. 
 
Despite the high prevalence of inadequate lifestyles in patients with schizophrenia, and 
the potentially disabling consequences, there has been little research on the impact of 
lifestyle-related factors on various domains of a patient’s life. Studies revealed that PA 
(Dauwan et al., 2016) and sleep quality (Brissos et al., 2013; Hofstetter et al., 2005; 
Ritsner et al., 2004), have a negative effect on QoL of this population. However, no 
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previous research has simultaneously analysed lifestyle-related factors (i.e., PA, sleep 
quality, smoking and dietary habits) and its impact on QoL. To overcome this limitation, 
Study 6 was carried out. In addition, psychological determinants such as self-esteem 
and motivation to PA were included in the analyses. The identification of the strongest 
predictors of QoL could be an added value for effective psychoeducational interventions 
related with lifestyles risks in patients with schizophrenia. The findings achieved could 
promote implications for lifestyle risk stratification in this population and work to develop 
and implement individualized physical health promotion interventions targeting 
modifiable lifestyle factors. 
 
 
Aims of this body of work 
 
Due to the lack of clarity in the literature related with lifestyle behaviours in patients with 
schizophrenia, the main purpose of this research was to develop strategies and tools 
related with lifestyle-related factors and psychological determinants, to improve the QoL 
in this population. A variety of study methods was used to address this goal, including a 
validation study and cross-sectional researches. 
The specific aims were to: 
i. Examine the construct validity of the Portuguese version of the Behavioural Regulation 
in Exercise Questionnaire – 2 (BREQ-2) as well as the Portuguese version of the 
Behavioural Regulation in Exercise Questionnaire – 3 (BREQ-3) in people with 
schizophrenia (Study 1).  
ii. Identify the factors, which are recognized as a barrier to PA in patients with 
schizophrenia (Study 2). 
iii. Assess the associations between PA levels and sleep quality in patients with 
schizophrenia (Study 3). 
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iv. Compare the sleep quality and QoL between the physical active and the non-physical 
active patients with schizophrenia (Study 4). 
v. Assess the dietary intake and adherence to Mediterranean Diet, specifically analysing 
the difference between treatment setting (i.e., inpatients and outpatients), and also 
explore the adherence to Mediterranean diet in relation with lifestyle-related factors 
(Study 5). 
vi. Explore the association between lifestyle-related factors, psychological determinants 
and QoL in people with schizophrenia (Study 6). 
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Behavioural Regulation in Exercise Questionnaire in people with schizophrenia: 
construct validity of the Portuguese versions. 
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Abstract 
People with schizophrenia have low physical activity levels that can be explained by the 
restriction in motivation. The Behavioural Regulation in Exercise Questionnaire-2 is a 19-
item scale commonly used to assess five different motivational subtypes for physical 
activity. However, there are limited psychometric analyses of this version in the 
schizophrenia context. Moreover, there is a lack of information related to the 
psychometric properties of version 3 of this questionnaire, with 24 items and six different 
motivational subtypes. The aim of this study was to examine the construct validity of both 
Portuguese versions in people with schizophrenia. Methods: A total of 118 persons with 
schizophrenia were included (30 women). Cronbach’s alpha was used for internal 
consistency, Pearson’s correlation for the retained motivation-types, confirmatory factor 
analysis for the structural validity of version 2 and exploratory factor analysis for the 
factor structure of version 3. Results and conclusions: Analyses of version 2 provided an 
adequate fit index for the structure of the five factors. Exploratory analyses suggested 
retaining 2 factors of version 3. The results of this study suggest that version 3 was an 
appropriate measure to assess controlled and autonomous motivation for physical 
activity in people with schizophrenia and support its use in clinical practice and research. 
 
Keywords: Behavioural Regulation in Exercise Questionnaire; construct validity; 
motivation to physical activity; schizophrenia 
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1. Introduction 
The benefits of physical activity (PA) and exercise in the population with schizophrenia 
are well established in the literature. When performed regularly, PA and exercise are 
associated with improved psychological well-being (Dauwan, Begemann, Heringa, & 
Sommer, 2016a), quality of life (Holley et al., 2011), and physical health (Gorczynski & 
Faulkner, 2010). This is why the inclusion of PA is recommended as an adjunct treatment 
in psychiatric rehabilitation (Vancampfort, De Hert, et al., 2012). However, only 25% of 
people with schizophrenia meet the minimum public health recommendation of 150 
minutes a week of at least moderately-intense activity (Faulkner et al., 2006). The 
minimal engagement in PA by people with schizophrenia can be explained, among 
others, by the restriction in motivation (Vancampfort, De Hert, et al., 2012; Vancampfort, 
De Hert, et al., 2013; Vancampfort, Stubbs, Venigalla, & Probst, 2015).  
Motivation is described as a multidimensional construct (Tremeau et al., 2013) that 
generally means to be moved to do something. It is a goal-oriented process where tasks 
are instigated and sustained over time. Moreover, motivation is related with differences 
in the intensity of behaviour. For example, more intense behaviours are considered to 
be the result of higher levels of motivation (Petri, 1996). Overall, motivation requires 
motor or mental activity. The motor activity entails persistence and effort. While mental 
activity includes cognitive actions such as planning, rehearsing, organizing, monitoring, 
making decisions, solving problems, and assessing progress (Pintrich & Schunk, 1996). 
Without motivation, a person is passive, apathetic and unresponsive (A. Medalia & 
Brekke, 2010). In people with schizophrenia, amotivation is considered a barrier to 
achieving a positive functional outcome (Blanchard et al., 1998), with several studies 
(Foussias, Mann, Zakzanis, van Reekum, & Remington, 2009; Gard, Fisher, Garrett, 
Genevsky, & Vinogradov, 2009; Nakagami, Hoe, & Brekke, 2010) reporting the 
relationship between lower motivation and poorer neurocognition, functioning, and 
outcome in this population. For example, people with schizophrenia often demonstrate 
decreased motivation to participate in treatment and in learning activities (Blanchard et 
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al., 1998), which consequently affects the treatment outcomes (Strauss et al., 2014). 
Specifically, people with schizophrenia may miss sessions or forget medications or 
assignments (A. Medalia & Brekke, 2010). 
Similarly, people with schizophrenia often exhibit limited motivation to engage in physical 
activities and maintain an active lifestyle (Soundy et al., 2014; Vancampfort, De Hert, et 
al., 2015; Vancampfort, De Hert, et al., 2013). Several factors influence the motivation 
for PA in this population, namely the presence of negative and depressive symptoms 
(Bassilios, Judd, & Pattison, 2014; Vancampfort, De Hert, et al., 2013; Vancampfort, 
Stubbs, et al., 2015), low self-efficacy and lack of confidence (Bassilios et al., 2014; 
Vancampfort, Probst, Sweers, et al., 2011a) and somatic co-morbidities associated with 
the disorder (e.g., metabolic syndrome and clinical pain) (Stubbs et al., 2014; 
Vancampfort, Sweers, et al., 2011). This is why multidimensional research on the 
motivation process in people with schizophrenia is crucial (Choi, Choi, Felice Reddy, & 
Fiszdon, 2014). 
The self-determination theory (SDT) (Deci & Ryan, 1985, 2000) is a theoretical 
framework for the research of motivation in exercise. This theory has generated 
particular interest due to its multidimensional conceptualization of intrinsic and extrinsic 
motivation (Markland & Tobin, 2004). SDT explains why individuals pursue specific goals 
and behaviours, such as PA. Broadly, SDT emphasizes that individuals set goals and 
engage in behaviours to meet intrinsic psychological needs (i.e., intrinsic motivation) or 
to move towards external rewards or away from punishment (i.e., extrinsic motivation) 
(Deci & Ryan, 2000). SDT consists of a continuum ranging from amotivation to intrinsic 
motivation. At the lowest end of the continuum is amotivation, when the person is in a 
state of not intending to act or lacks the motivation to act. On the other hand, the person 
is intrinsically motivated when adopting a behaviour for their inherent enjoyment, which 
represents the most self-determined form of regulation. Between amotivation and 
intrinsic motivation, four types of extrinsic motivation are found, namely external, 
introjected, identified and integrated regulation, and are placed on a continuum that is 
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based on the extent to which the regulation is self-determined (Deci & Ryan, 1985, 2000). 
External and introjected regulation are often grouped and refer to controlled forms of 
motivation (i.e., less self-determination), while identified regulation, integrated regulation, 
and intrinsic motivation are often referred to as autonomous motivation (i.e., more self-
determination). 
In healthcare and rehabilitation settings, self-determined motivation has been linked to 
positive behavioural health outcomes (Fortier et al., 2007; Moran et al., 2014; Williams 
et al., 2006; Williams et al., 2004). Specifically, in people with schizophrenia, higher 
levels of autonomous motivation, self-efficacy and readiness for PA are positively related 
to an increase of PA (Leas & McCabe, 2007; Lindamer et al., 2008; Vancampfort, De 
Hert, et al., 2015; Vancampfort, De Hert, et al., 2013; Vancampfort, Vansteenkiste, De 
Hert, et al., 2014). Therefore, autonomous motivation can add value to the adoption and 
maintenance of health-promoting behaviours in people with schizophrenia (Vancampfort, 
De Hert, et al., 2013; Vancampfort, Vansteenkiste, De Hert, et al., 2014). For example, 
mental health professionals have repeatedly reported that motivation is a problem when 
trying to engage psychiatric patients in PA (Sorensen, 2006). Therefore, it is important 
to identify the motivation process, namely the self-determined types of motivation to PA 
in this population.   
However, there is a lack of reliable and valid instruments to determine the processes that 
motivate people with schizophrenia to practice PA. To our knowledge, the Behavioural 
Regulation in Exercise Questionnaire – 2 (BREQ-2) (Markland & Tobin, 2004), which 
assesses participants’ motivation for exercising, was the only instrument aiming to 
determine the continuum of motivation (i.e., a 19-item scale with 5 subscales: 
amotivation, external, introjected, identified and intrinsic regulations) applied to 
individuals with severe mental disorders, namely, affective disorders (i.e., major 
depressive disorder and bipolar disorder) (Vancampfort et al., 2016; Vancampfort, 
Stubbs, et al., 2015) and schizophrenia (Vancampfort, De Hert, et al., 2015; 
Vancampfort, De Hert, et al., 2013; Vancampfort, Stubbs, et al., 2015; Vancampfort, 
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Vansteenkiste, De Hert, et al., 2014). Moreover, only Vancampfort et al. (2013) explored 
the structure validity of the BREQ-2 in people with schizophrenia using exploratory factor 
analysis. The previously mentioned authors found sufficient convergence for the 
amotivation, external and introjected regulation subscales. In the same study, the 
identified and intrinsic regulation subscales were loaded on a single factor that the 
authors labelled “autonomous regulation”. This study was conducted with Belgian 
patients. However, the factorial validity of the BREQ-2 using confirmatory factor analysis 
has not yet been performed in people with schizophrenia.  
Due to the limited comprehensive psychometric analyses of the BREQ-2 in people with 
schizophrenia, specifically in the Portuguese context, the purpose of this study was to 
examine the construct validity of the Portuguese version of the BREQ-2 (Markland & 
Tobin, 2004; Palmeira, Teixeira, Silva, & Markland, 2007) (Study 1) as well as the 
Portuguese version of the Behavioural Regulation in Exercise Questionnaire – 3 (BREQ-
3) (i.e., a 24-item scale with one additional subscale: integrated regulation) (Cid, Moutão, 
Monteiro, Teixeira, & Palmeira, in preparation) (Study 2) in this population. 
 
2. Materials and Methods 
2.1. Participants  
One hundred and eighteen patients diagnosed with schizophrenia and recruited from 7 
psychiatric centres situated in the north region of Portugal participated voluntarily in this 
study. All participants met the following criteria: i) more than 18 years old; ii) a diagnosis 
of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 
– 5 (DSM-5) (American Psychiatric Association, 2013) established by experienced 
psychiatrists responsible for the patients’ treatment; and iii) psychiatrically stable on 
psychotropic medication (i.e., no medication changes within the last month). Exclusion 
criteria included an inability to provide informed consent or to speak Portuguese, an 
inability to concentrate for at least 20 minutes (as determined by the treating psychiatrist), 
neurological disorders, and substance abuse in the last six months or hospitalization in 
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the previous three months. This study was carried out following the Declaration of 
Helsinki guidelines for human research. The study procedure was approved by the 
Faculty Ethics Committee and by all 7 ethical committees. All participants gave their 
written informed consent. 
 
2.2. Behavioural Regulation in Exercise Questionnaire (BREQ-2 and BREQ-3) 
The BREQ-2 (Markland & Tobin, 2004) evaluates behavioural regulation in the PA 
context, assessing the following five dimensions: i) amotivation (four items, e.g., “I do not 
see the point in doing physical activities”); ii) external regulation (four items, e.g., “I do 
physical activities because other people say I should”); iii) introjected regulation (three 
items, e.g., “I feel ashamed when I miss my physical activities”); iv) identified regulation 
(four items, e.g., “It is important to me to do physical activities regularly”); and v) intrinsic 
regulation (four items, e.g., “I do physical activities, it is fun”). Responses were scored 
on a 5-point Likert scale ranging from 0 (“not true for me”) to 4 (“very true for me”). The 
mean of the 5 retrieved subscales is calculated on a five-point scale to score the extent 
of each motivation type separately. The BREQ-2 presents adequate psychometric 
properties when applied to the general population. The BREQ-2 is accepted worldwide 
and is translated into different languages. 
The Portuguese version of the BREQ-2 was validated by Cid et al. (2012) and Palmeira 
et al. (2007). The BREQ-2 was applied in Portuguese samples of adolescents 
(Quaresma, Palmeira, Martins, Minderico, & Sardinha, 2014), adolescents with obesity 
(Fonseca, Palmeira, Martins, Falcato, & Quaresma, 2014), elderly people (Moutão, 
Rosário, Vitorino, Alves, & Cid, 2014) and a healthy population (Cid et al., 2012; A. R. 
Gomes & Capelão, 2012) but not in people with mental disorders.  
An improvement of the BREQ-2 was suggested by Wilson et al. (2006) regarding the 
inclusion of the subscale “integrated regulation” (four items, e.g., “I consider PA a part of 
my identity”), specific to PA contexts and in line with SDT. The inclusion of the subscale 
did not compromise the instrument’s validity. The addition of this new regulation subscale 
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has been considered a third version of the questionnaire (BREQ-3). The BREQ-3 has 
been validated in Spain (Gonzalez-Cutre, Sicilia, & Fernandez, 2010; Sicilia, Saenz-
Alvarez, Gonzalez-Cutre, & Ferriz, 2015), and preliminary assessments of the BREQ-3 
have been developed in Portugal (Cid et al., in preparation). 
The Portuguese version of the BREQ-3 (Cid et al., in preparation) consisted of 24 items, 
the 19 BREQ-2 items completed by four items proposed by Wilson et al. (2006) and one 
additional item (“I consider exercise consistent with my values”) (Cid et al., in preparation; 
Markland, 2014). The BREQ-3 intended to assess the 6 subscales of SDT, and the mean 
of the subscales is calculated as the BREQ-2.  
To include patients with literacy problems an interviewer-administered questionnaire was 
used. Two adaptations to the original questionnaire were made. First, the term “exercise” 
was replaced by the term “physical activity” (Vancampfort, De Hert, et al., 2013). Second, 
points 1 and 3 of the Likert scale were also labelled to improve the participants 
understanding of the scale (1 – “few times true for me”; 3 – “many times true for me”). 
This is because in the English and Portuguese original versions, only point 0 (“not true 
for me”), point 2 (“sometimes true for me”), and point 4 (“very true for me”) were labelled.  
 
2.3. Statistical analyses  
To test how well the measured variables represent the factor structure of the BREQ-2, 
we used confirmatory factor analysis (CFA). Five continuous latent variables were 
regressed on 19 BREQ-2 items, as suggested by Markland and Tobin (Markland & 
Tobin, 2004). 
Maximum likelihood estimation (MLE) is used to assess the fit of the model; however, 
this method assumes that the data must have a normal multivariate distribution (Kline, 
2005), so the more robust chi-square statistic, the Satorra-Bentler scaled statistic (SBχ²) 
(Satorra & Bentler, 1994), was used. This test corrects for the non-normality of the data 
distribution and produces more accurate results (Bentler, 2007). The goodness of fit for 
each factor structure was evaluated using several descriptive criteria: the Comparative 
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Fit Index (CFI), which quantifies how much better the model fits compared to a baseline 
model in which the observed items are assumed to be uncorrelated, and the 
Standardized Root Mean Square, Residual (SRMR), and the Root Mean Square Error 
of Approximation (RMSEA), which quantifies the divergence between the data and the 
proposed model per degree of freedom, with a 90% confidence interval (RMSEA 90% 
CI).  
As recommended by Brown (2006), the model was considered to have “adequate fit” if 
the RMSEA and SRMR were less than 0.08 and the CFI was greater than 0.9; “good fit” 
was indicated by an RMSEA and SRMR less than 0.05, a CFI greater than 0.95 and 
X2/df values less than 3. For each variable, the magnitudes of factor loadings were 
considered. Variables with a factor loading of 0.3 or greater (T. A. Brown, 2006) were 
considered representative of the construct being measured in each domain. The 
confirmatory factor analysis was performed with the use of EQS 6.1 software (Bentler, 
2002). 
Exploratory factor analysis (EFA) was chosen to analyse the main components of BREQ-
3 factor structure (Study 2) using varimax rotation and eigenvalues greater than 1 
(Kaiser, 1960). An item with a factor loading higher than 0.40 on a factor was considered 
to load sufficiently high on the relevant factor. Cronbach's alpha was calculated to 
determine the internal consistency of the items of the retained factors. Subsequently, 
Pearson's correlations among the retained motivation-types were inspected. Descriptive 
statistics (mean and standard deviations) were calculated. The significance level was set 
at p<0.05. 
 
3. Results  
A total of 118 Portuguese persons with a DSM-5 (American Psychiatric Association, 
2013) diagnosis of schizophrenia with an average age of 44.53 years (± 9.74) were 
included in the analysis. Thirty (25.4%) were women, fifty-eight (50.8%) were inpatients 
and ninety-three were single (78.8%). On average, the duration of education was 8.75 
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years (±3.58), the illness duration was 19.79 (± 9.21) years (data available for 53.4% of 
the sample), and the number of hospitalizations was 2.82 (± 2.76) (data available from 
52.5% of the sample). Participants were treated with either a single first-generation 
(n=11; 9.3%), single second-generation (n=42, 35.6%); or a combination of first- and/or 
second-generation (n=60; 50.8%) antipsychotic medication. There were seventy-seven 
(65.3%) smokers in the sample who smoked an average of 15.8 (± 8.9) cigarettes per 
day. Seventy-seven (65.3%) participants were engaged in PA, and no significant 
differences were found between groups in the six subscales of motivation.  
The results of the CFA on the Portuguese version of the BREQ-2 (Study 1) revealed that 
the 19-item, 5-factor model of the Portuguese BREQ-2 (latent variables: amotivation, 
external, introject, identified and intrinsic) provided an acceptable fit for the data from 
people with schizophrenia (see Figure 1). All items significantly loaded their 
hypothesized factors and acceptable fit indices, S-Bχ2=209.0; df=142; p<0.001; S-
Bχ2/df=1.47; CFI=0.85; SRMR=0.09; RMSEA=0.06; 90% CI=[0.06, 0.08]. Standardized 
factor loadings greater than 0.3 were also observed for all items on the BREQ-2. 
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Figure 1. Factor loadings of confirmatory factor analysis for the Portuguese BREQ-2 
(Standardized Parameters Estimates) 
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Table 1. Mean (standard deviations), internal consistency and intercorrelations of subscales of 
the Portuguese version of BREQ-2 in people with schizophrenia. 
 M ± SD 
Cronbach’s 
Alpha 
1. 2. 3. 4. 
1. Amotivation 0.62 ± 0.76 α=.61     
2. External 1.29 ± 0.98 α=.65 0.38**    
3. Introjected 1.33 ± 1.04 α=.59 0.31 0.42**   
4. Identified 2.46 ± 0.85 α=.59 -0.32** 0.13 0.40**  
5. Intrinsic 2.98 ± 0.89 α=.81 -0.20* 0.11 0.17 0.53** 
M ± SD = mean ± standard deviation; **p < 0.01; *p < 0.05. 
 
An EFA of the BREQ-3 (Study 2) showed that six factors had an eigenvalue higher than 
one. Four factors were retained with an eigenvalue above 1 and with 61% of the total 
variance explained. 
The results of the four- and three-factor analyses did not fit with the theoretical 
framework. Amotivation and external regulation loaded on a single factor; integrated 
regulation and intrinsic regulation loaded on a single factor; identified regulation loaded 
on different factors; and two items (4 and 10) showed cross-loadings of 0.35 and 0.52, 
respectively, with other factors. A new exploratory factor analysis was made with the 
amotivation subscale deleted from the model, as previously suggested by Cid et al. 
(2012) in the Portuguese version of the BREQ-2. 
Descriptive statistics, internal consistency and intercorrelations of the subscale were 
analysed. For controlled motivation, the results showed a mean of 1.33 ± 0.8 and a 
Cronbach’s alpha of .73. For autonomous motivation, a mean of 2.67 ± 0.81 and a 
Cronbach’s alpha of .87 was found. The correlation between subscales showed a low 
negative value (r = -0.343; p < 0.01). 
Table 2 presents the results of the exploratory factor analysis. Two factors were retained 
with an eigenvalue above 1 and with 59% of the total variance explained. External 
regulation and introjected regulation loaded in a single factor representing controlled 
motivation. Identified, integrated and intrinsic regulation loaded in another single factor 
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representing autonomous motivation. Two items (21 and 16) showed cross-loadings of 
0.47 and 0.19, respectively, with other factors.  
 
Table 2. Results of exploratory factor analysis of the Portuguese version of BREQ-3, based on 
two factors, in people with schizophrenia (n= 118). 
Factor 1 2 h2 
I External regulation 
   
2. I do physical activities because other people say I should.  0.42 0.24 
8. I do physical activities because my friends/family/partner say I should.  0.68 0.49 
14. I do physical activities because others will not be pleased with me if I don't.  0.70 0.39 
20. I feel under pressure from my friends/family to do physical activities.  0.60 0.31 
II Introjected regulation    
3. I feel guilty when I don't do physical activities.  0.53 0.42 
9. I feel ashamed when I miss my physical activities.  0.67 0.41 
15. I feel like a failure when I haven't done physical activities in a while.  0.46 0.48 
21. I get restless if I don’t do physical activity regularly. 0.47 0.45 0.59 
III Identified regulation    
4. I value the benefits of physical activity. 0.54  0.24 
10. It’s important to me to do physical activities regularly. 0.72  0.52 
16. I think it is important to make the effort to do physical activities regularly. 0.32 0.19 0.25 
22. I would feel bad about myself if I was not making time to do physical 
activity.  
0.47  0.51 
IV Integrated regulation    
5. I do physical activities because it is consistent with my life goals. 0.72  0.57 
11. I consider physical activity part of my identity. 0.78  0.66 
17. I consider physical activity a fundamental part of who I am. 0.64  0.56 
23. I consider physical activity consistent with my values. 0.71  0.56 
V Intrinsic regulation    
6. I do physical activities because it’s fun. 0.63  0.50 
12. I enjoy my physical activity sessions. 0.69  0.50 
18. I find physical activity a pleasurable activity. 0.71  0.55 
24. I get pleasure and satisfaction from participating in physical activity. 0.74  0.60 
Eigenvalue 5.94 2.56 - 
Factor variance 29.70 42.49 - 
Total variance 29.70 12.79  - 
h² (communality) = the sum of the squared factor loadings; it represents the amount of variance 
in that variable accounted for by all the factors. 
 
4. Discussion 
The first part of this study examines the construct validity of the Portuguese version of 
the BREQ-2 in people with schizophrenia. The BREQ-2 motivational continuum is suited 
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to examine motivational changes across a period of behavioural change, such as PA 
adoption. This increased autonomy towards PA may have a positive impact on research 
about PA adoption and adherence in people with schizophrenia. The BREQ-2 is a widely 
used measure among motivation researchers in the PA setting and has been shown to 
have good psychometric features (Markland & Tobin, 2004; P. M. Wilson, Rodgers, & 
Fraser, 2002). The BREQ-2 has been applied successfully in different populations (Cid 
et al., 2012; Fonseca et al., 2014; A. R. Gomes & Capelão, 2012; Markland & Tobin, 
2004; Vancampfort et al., 2016; Vancampfort, Stubbs, et al., 2015; Vancampfort, 
Vansteenkiste, De Hert, et al., 2014) and cultures, providing evidence for the factorial 
validity of the questionnaire (Chung & Liu, 2012; Cid et al., 2012; Murcia, Gimeno, & 
Camacho, 2007). 
In the present study, CFA demonstrated that the BREQ-2 provided an acceptable fit for 
the data from people with schizophrenia. The 5-factor model of the Portuguese BREQ-2 
(latent variables: amotivation, external, introject, identified and intrinsic) met the criteria 
for adequate fit for RMSEA but was borderline for SRMR (T. A. Brown, 2006). The 
incremental indices values, which provide a better estimate of model fit than the null 
model, were lower than expected, probably due to the small sample. 
In general, the results of the mean and standard deviation in all subscales were similar 
to validation studies by Markland and Tobin (2004) and Cid et al. (2012). The subscale’s 
internal consistency applied acceptable borders (α=.59 - .81) (Table 1). Vallerand (1989) 
suggested appropriate values of internal consistency ranging between .70 and .85. 
However, Loewenthal (2001) indicated that an alpha of .60 is also acceptable for 
subscales containing four items. In general, the results of the present work are in line 
with previous studies. Markland and Tobin (2004) reported internal consistency ranging 
between .73 - .86 and Cid et al. (2012) values ranged between .45 - .80. Palmeira et al.’s 
(2007) internal consistency ranged between .63 - .79. In the same clinical group, 
Vancampfort et al. (2013) found higher internal consistency, with values ranging between 
.73 - .90. 
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With regard to the intercorrelation between the different subscales, very low to moderate 
correlations were found in the present study. As expected, the different subscales 
measured different types of motivation. These results agreed with previous studies (Cid 
et al., 2012; Markland & Tobin, 2004; Palmeira et al., 2007; Vancampfort, De Hert, et al., 
2013) where the correlations between the subscales exhibited an organized pattern of 
relationships, such that types of motivation closer along the motivational continuum are 
strongly and positively correlated. However, the types of motivation that are further apart 
are correlated more weakly or are negatively correlated (Ryan & Deci, 2007). 
The second part of this study examines the construct validity of the Portuguese version 
of the BREQ-3 in people with schizophrenia. EFA with 2-factors demonstrated a good fit 
for the data from people with schizophrenia. Moreover, the new additional item (“I 
consider exercise consistent with my values”) (Cid et al., in preparation; Markland, 2014) 
seems adequate to include in the integrated subscale, with a factor loading of 0.71. In 
the present study, internal consistency and correlation values were similar to Cid et al. 
(2012), who performed CFA for the Portuguese version of the BREQ-2. Cid et al. (2012) 
tested different hierarchical models and found appropriate measures for controlled and 
autonomous motivation. Therefore, the Portuguese BREQ-3 in people with 
schizophrenia provides an acceptable measure of controlled motivation and autonomous 
motivation that is consistent with the motivational continuum of SDT (Deci & Ryan, 1985, 
2000). In the same way, different studies in the fields of education (Zhou, Ma, & Deci, 
2009), health (Ingledew & Ferguson, 2007; Pavey & Sparks, 2008), sports (Ntoumanis 
& Standage, 2009), and exercise (Ingledew & Markland, 2008) developed an integrated 
approach with the different types of regulation forming a global index for autonomous 
and controlled motivation.  
Controlled motivation is described as an index incorporating the factors of external and 
introjected regulation. In SDT, external regulation is related to controlled and external 
behaviours mediated by the presence of contingencies. When contingencies are 
withdrawn, the behaviours are poorly maintained (Ryan & Deci, 2007). Introjected 
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regulation involves the internalization of external controls, which are then applied through 
self-imposed pressures to avoid guilt or to maintain self-esteem (Markland & Tobin, 
2004). Globally, in controlled motivation, one's behaviour is a function of external 
contingencies of reward or punishment, pressuring the person to be more active. When 
people with schizophrenia are controlled, they experience pressure to think, feel, or 
behave in particular ways (e.g., “should,” guilt, or seeking social approval), which in turn 
is associated with less PA participation (Vancampfort, De Hert, et al., 2013). 
Autonomous motivation is presented as an index incorporating the factors of identified, 
integrated and intrinsic regulations. In SDT, identified regulation consists of an 
acceptance of the behaviour as being important in order to achieve personally valued 
outcomes (Markland & Tobin, 2004). Integrated regulation comprises the assimilation of 
identified regulation so that engaging in the behaviour is fully congruent with one’s sense 
of self (Markland & Tobin, 2004). Intrinsic regulation involves participating in an activity 
for the enjoyment and satisfaction inherent in engaging in the behaviour itself (Markland 
& Tobin, 2004). Globally, in autonomous motivation, people are identified with the goals 
and value of PA and, consequently, volitionally adopt PA as a lifestyle. When people with 
schizophrenia are autonomously motivated, they exhibit an open curiosity and interest 
about PA that is related with long-term and successful participation in PA. 
However, some inconsistencies were identified in the BREQ-3 structure analyses that 
may make it difficult to make a clear distinction between the different subscales along of 
the continuum of motivation. In the present study, cross-loadings between controlled and 
autonomous motivation were reported. A similar situation has also been reported in the 
general population (Verloigne et al., 2011), as well as in people with schizophrenia 
(Vancampfort, De Hert, et al., 2013). Likely, the difference between the controlled and 
autonomous types of motivation is related to gradual and continuum motivational 
changes (i.e., from external and inner pressures to personal convictions and volition). 
Specifically, inconsistencies in introjected regulation (i.e., controlled motivation) and 
identified regulation (i.e., autonomous motivation) may be due to the differences in the 
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PA lifestyle of the sample. The present study comprised people with schizophrenia who 
are physically active (i.e., participants in a structured PA program) and others who are 
not (i.e., do not have any participation in PA). Patients who are not physically active may 
be unable to identify the value of the beneficial outcomes associated with PA (Bassilios 
et al., 2014; Vancampfort, De Hert, et al., 2015; Vancampfort, De Hert, et al., 2013) and 
possibly never experience negative feelings (e.g., frustration, shame, and restlessness) 
associated with PA. 
The existence of cross-validation items could also be due to the relatively small sample 
size to analyse the factor structure of the questionnaire. However, the Portuguese 
version of the BREQ-3 is being developed, and this version has been used for the first 
time in people with schizophrenia. Therefore, more validation studies are needed to 
determine if the questionnaire is able to distinguish the different types of motivation, if 
the rating scale is accurate, if the items are properly phrased and, consequently, if 
specific items should be excluded from the Portuguese version on the BREQ-3.  
Finally, our findings need to be interpreted with caution due to some methodological 
issues. This is the first study with the BREQ-2 and BREQ-3 in a Portuguese clinical 
population of people with schizophrenia. The sample size is limited due to the specificity 
of the group. Further empirical studies are needed to confirm the psychometric 
robustness of the Portuguese version of the BREQ-3 in people with schizophrenia. 
Additionally, further research should examine the impact of different variables, such as 
age, gender, anthropometric characteristics, PA levels, treatment setting, disorder stage 
and psychopathological symptoms that can influence the motivation for PA in patients 
with schizophrenia. 
 
5. Conclusion  
The present study demonstrates that the 19-item 5-factor model of the Portuguese 
BREQ-2 has acceptable construct validity and is adequate to be used in clinical and 
research settings. 
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After the preliminary analysis of the construct validity of the Portuguese version of the 
BREQ-3, it is possible to conclude that the BREQ-3 is an appropriate measure to assess 
controlled and autonomous motivation for PA in people with schizophrenia. The 
existence of valid and reliable instruments to assess the motivation to PA in people with 
schizophrenia is an important issue for research and clinical practice in the field of mental 
health. It allows mental health professionals to identify and follow the motivational 
processes related to PA in people with schizophrenia, and consequently, to promote 
interventions that are experienced as pleasant and enjoyable so that patients are 
engaged for intrinsic reasons. 
Further research is necessary to establish cross-cultural psychometric properties and 
more deeply analyse the Portuguese version of the BREQ-3 in people with 
schizophrenia. This would be an important step to ultimately validate the instrument. 
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Abstract 
Being physically active is a complex behaviour in patients with schizophrenia. Several 
factors were identified as barriers to achieving active behaviours in this population, 
therefore, the purpose of this study was to investigate among a number of barriers what 
predicts the most on physical activity (PA) in patients with schizophrenia. Methods: A 
total of 114 patients (28♀) with schizophrenia were included. Body mass index (BMI) 
was calculated. Autonomous and controlled motivation (Behavioural Regulation in 
Exercise Questionnaire – 3), self-esteem (Rosenberg Self-esteem scale), quality of life 
(World Health Organization Quality of Life Scale – Brief version) and functional exercise 
capacity (6-minute walk test – 6MWT) were evaluated. Multiple Regression Analysis was 
applied to assess the effect of these variables on Total PA per week (International 
Physical Activity Questionnaire – short version). Results: Autonomous motivation and 
domains of quality of life were positively correlated with Total PA per week. Stepwise 
multiple regression analyses showed that of all the candidate factors to predict PA, 
autonomous motivation and global domain of quality of life were found as significant 
predictors. Conclusions: Our findings help to understand the importance of autonomous 
motivation and quality of life for PA in patients with schizophrenia. Knowledge about 
these predictors may provide guidance to improve PA behaviour in this population. 
 
Keywords: physical activity; autonomous motivation; quality of life; schizophrenia. 
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1. Introduction   
There is a clear scientific evidence that proves the physical and psychological health 
benefits of physical activity (PA) in patients with schizophrenia (Dauwan, Begemann, 
Heringa, & Sommer, 2016; Gorczynski & Faulkner, 2010).  As such, PA has been 
strongly recommended as an adjunct treatment in psychiatric rehabilitation (Beebe et al., 
2005; Richardson et al., 2005). However, patients with schizophrenia are more likely to 
be less physically active than the general population (Faulkner, Cohn, & Remington, 
2006; Lindamer et al., 2008; Stubbs, Firth, et al., 2016; Stubbs, Williams, Gaughran, & 
Craig, 2016) and are consequently at a high risk for chronic medical conditions 
associated with physical inactivity (Vancampfort et al., 2010; Vancampfort, Probst, et al., 
2013). Therefore, only a minority (about 25%) of patients with schizophrenia meet the 
minimum public health recommendation of 150 minutes a week of at least moderate-
intensity PA (Faulkner et al., 2006). 
Distinct variables undermine the attempt of patients with schizophrenia to become more 
active. Studies revealed that side-effects of antipsychotic medication (Carter-Morris & 
Faulkner, 2003; McDevitt, Snyder, Miller, & Wilbur, 2006), psychiatric symptoms (Carter-
Morris & Faulkner, 2003; McDevitt et al., 2006) and lack of social support (Carter-Morris 
& Faulkner, 2003; Firth et al., 2016) are the most often reported barriers to PA. The study 
of Vancampfort et al. (2012) revealed that other determinants, such as demographic, 
biological and psychological determinants, were also associated with PA. In regards to 
demographic determinants, the authors found that less-educated patients, lower socio-
economic status and longer illness duration demonstrated lower PA participation. Due to 
the prevalence of overweight characteristics and lower PA levels in low educational 
levels groups, patients with schizophrenia with lower education could be considered as 
a vulnerable subgroup (Vancampfort et al., 2012). Regarding biological determinants, 
cardio-metabolic comorbidity was the most consistent (Vancampfort et al., 2012). 
Patients with a better physical fitness and functional exercise capacity were more 
physically active. According to Vancampfort et al. (2011a) functional exercise capacity is 
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reduced in patients with schizophrenia compared to healthy controls. Finally, regarding 
psychological determinants, Vancampfort et al. (2012) demonstrated that increased self-
efficacy, physical self-perception and quality of life were related with higher PA 
participation. Contrarily, data on body weight–related self-esteem or self-image were 
inconsistent. Several studies demonstrated that higher PA partcipation is positively 
associated with better quality of life in patients with schizophrenia (Acil, Dogan, & Dogan, 
2008; Gomes et al., 2014; Vancampfort, Probst, Scheewe, et al., 2011). Patients with 
schizophrenia and higher self-esteem exhibit better adaptation abilities, are confident 
and highly motivated (Vancampfort, Probst, et al., 2011a). Contrarily, patients with lower 
self-esteem have feelings of loneliness and underestimate their actual capabilities 
(Jones, Hansen, Moskvina, Kingdon, & Turkingto, 2010).  
Soundy et al. (2014) explored the perceptions of physical therapists who work within 
mental health services regarding barriers of PA among patients with schizophrenia. 
Results revealed that the most frequently cited barriers were patients’ lack of motivation. 
Motivational deficits in patients with schizophrenia were described as a crucial feature of 
this mental illness since early definitions (Bleuler, 1911; Kraepelin, 1919). Recently, there 
has been an increased interest in the impact of motivation on the lifestyle of patients with 
schizophrenia (Barch, 2008; Gard et al., 2014; Vancampfort, De Hert, et al., 2015; 
Vancampfort, De Hert, et al., 2013; Vancampfort et al., 2014). Several studies reported 
that lower motivation is associated with poorer neurocognition and functioning (Gard, 
Fisher, Garrett, Genevsky, & Vinogradov, 2009; Nakagami, Xie, Hoe, & Brekke, 2008), 
as well as lower rates in treatment adherence and in learning activities (Choi & Medalia, 
2010; Medalia & Freilich, 2008).  
Self-determination theory (SDT) (Deci & Ryan, 1985, 2000) is used as a theoretical 
framework to evaluate key elements of the treatment in psychiatric rehabilitation 
(Fitzgerald et al., 2015). This theory examines the diverse effects of different types of 
motivation that can determine behaviour and can explain why patients adopt and 
maintain certain health behaviours. Particularly, SDT distinguishes between controlled 
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(i.e., external and introjected regulation) and autonomous (i.e., identified, integrated and 
intrinsic regulation) motivation based on the underlying attitudes and goals that give rise 
to action (Deci & Ryan, 1985, 2000). With autonomous motivation, the patients behave 
with a full sense of volition and choice. On the other hand, with controlled motivation, 
patients engage in an activity out of internal and/or external pressures (Deci & Ryan, 
2008). The theory predicts that autonomous motivation will facilitate and sustain 
changes, whereas controlled motivation will interfere negatively with changes. Controlled 
and autonomous motivation has also been investigated in the field of PA and exercise. 
Studies revealed that in patients with schizophrenia, higher levels of autonomous 
motivation were correlated to the maintenance of frequent participation in PA over a 
longer period (Vancampfort et al., 2014) and with higher PA participation (Vancampfort, 
De Hert, et al., 2013).  
Considering the health benefits associated to PA and the low levels of PA participation 
in the majority of patients with schizophrenia, understanding the predictors of PA levels 
and consequently improving the PA participation of these patients represents a clinical 
challenge. Therefore, the present study aimed to investigate among a number of barriers 
(i.e., BMI, autonomous and controlled motivation, self-esteem, quality of life domains and 
functional exercise capacity) what predicts the most on physical activity in patients with 
schizophrenia. 
 
2. Material and methods 
2.1. Participants and procedures 
A cross-sectional design was used incorporating 7 health centres that treat persons with 
schizophrenia (see acknowledgements). The centres were located in the north region of 
Portugal. All participants of the study met the following criteria: over the age of 18, without 
substance dependence and with a stable medication regimen (i.e., no medication 
changes within the last month). Psychiatric diagnosis of the participants was based on 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric 
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Association, 2013) criteria and was established by experienced psychiatrists responsible 
for the patients’ treatment. This study was carried out following the Declaration of 
Helsinki guidelines for human research. The study procedure was approved by the 
Faculty Ethics Committee and by all the 7 centres’ ethical committees. All participants 
gave their written informed consent.  
 
2.2. Demographic and anthropometric variables 
Demographic variables included gender, age, years of study and anthropometric 
measures. Weight was measured using a Tanita scale (BC-418MA, Tanita Corporation, 
Tokyo, Japan). Patients wore light clothing with shoes removed. Height was measured 
with shoes removed using a portable stadiometer (Siber Hegner). Body mass index 
(BMI) (kg/m2) was calculated. 
In addition, dichotomous variables were constructed for employment situation (with 
versus without employment) and treatment setting (in- versus out- patients). 
 
2.3. Medication use 
Current antipsychotic medication use was recorded for each patient and converted into 
a daily equivalent dosage of chlorpromazine (Gardner, Murphy, O'Donnell, Centorrino, 
& Baldessarini, 2010). 
 
2.4. Short-Form International Physical Activity Questionnaire (IPAQ-SF) 
Physical activity levels were assessed using the Portuguese version of the Short-Form 
International Physical Activity Questionnaire (IPAQ-SF) (Craig et al., 2003). IPAQ-SF 
comprises seven items and provides information on the time spent on PA (Craig et al., 
2003). Participants were asked to recall the number of days they performed each activity 
(frequency) and the length of time (duration) they were involved daily in each activity 
during the last 7 days. Data from the IPAQ-SF were summed up within each item (i.e., 
vigorous intensity, moderate intensity, and walking) to estimate the total amount of time 
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spent on PA per day. Previous research in patients with schizophrenia (Faulkner et al., 
2006) shows that the IPAQ is a reliable and valid tool to assess PA levels in this 
population. 
 
2.5. Behavioural Regulation in Exercise Questionnaire-3 (BREQ-3) 
The Portuguese version of the BREQ-3 (Cid, Moutão, Monteiro, Teixeira, & Palmeira, in 
preparation) was used as an interviewer-administered questionnaire in order to ensure 
the participation of all patients regardless of their level of literacy. The BREQ-3 comprises 
24 items and evaluates behavioural regulation in the PA context, assessing the following 
six dimensions: (i) amotivation (four items, e.g., “I don't see why I should have to do 
physical activities”); (ii) external regulation (four items, e.g., “I do physical activities 
because others will not be pleased with me if I don't”); (iii) introjected regulation (four 
items, e.g., “I feel guilty when I don't do physical activities.”); (iv) identified regulation 
(four items, e.g., “I value the benefits of physical activity.”); (v) integrated regulation (four 
items, e.g., “I do physical activities because it is consistent with my life goals.”) and; (vi) 
intrinsic regulation (four items, e.g., “I do physical activities, it is fun”).  Each item is 
measured on a five-point Likert-scale, from 0 (“Not true for me”) to 4 (“Very true for me”). 
The mean of the six retrieved subscales is calculated on a five-point scale to score the 
extent of each motivation type separately. For the purpose of the present study, 
amotivation dimension was not included in the data analysis.  
We adapted the BREQ-3 by replacing the term “exercise” with the term “physical activity” 
(Vancampfort, De Hert, et al., 2013). Secondly, we added a designation for option 1 and 
3 (i.e., “few times true for me” and “many times true for me”, respectively), to make the 
answer option more clear to the participants (Costa et al., 2017). 
In the present study, motivation for PA was investigated according to controlled (i.e., 
external and introjected regulation) and autonomous (i.e., identified, integrated and 
intrinsic regulation) motivation. This because previous research (Costa et al., 2017) 
demonstrated that the Portuguese BREQ-3 provides an acceptable measure of 
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controlled motivation and autonomous motivation in patients with schizophrenia that is 
consistent with the motivational continuum of SDT. 
 
2.6. Rosenberg Self-Esteem Scale  
Self-esteem was assessed using the Portuguese version of the Rosenberg Self-Esteem 
Scale (Vasconcelos-Raposo, Fernandes, Teixeira, & Bertelli, 2012). The scale consists 
of 10 items (five positively e.g., “I feel that I have a number of good qualities”; and five 
negatively e.g., “I feel I do not have much to be proud of”) measured on a 4-point Likert-
scale, from 1 (“strongly disagree”) to 4 (“strongly agree”). Negatively worded items were 
reversed before any subsequent analysis, allowing for the calculation of a global score 
with possible values range between 10 and 40, where higher values represent higher 
levels of self-esteem.  
 Although the Rosenberg Self-Esteem Scale is widely used in a mental illness context 
(Carter & Kelly, 2015; Kahng & Mowbray, 2005; Kumar & Mohanty, 2016; Lysaker, 
Ringer, Maxwell, McGuire, & Lecomte, 2010), little is known about its psychometric 
properties in this population (Torrey, Mueser, McHugo, & Drake, 2000). Reliability 
assessed in previous studies with patients with severe mental illness found internal 
consistency exceeding 0.80 and test – retest reliability of 0.87 (Torrey et al., 2000). 
Specifically in patients with schizophrenia, the Rosenberg Self-Esteem Scale is applied 
at the national (Salgado, Rocha, & Marques, 2008) and international level (Kumar & 
Mohanty, 2016; Lysaker et al., 2010; Wykes, Reeder, Corner, Williamson, & Everitt, 
1993). Data regarding psychometric properties in patients with schizophrenia is non-
existent, studies suggests that these patients can also reliably complete the 
questionnaire (Lysaker et al., 2010; Wykes et al., 1993). 
 
2.7. World Health Organization Quality of Life Scale – Brief version (WHOQOL-
BREF) 
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Quality of life was assessed using the Portuguese version of the World Health 
Organization Quality of Life Scale – Brief version (WHOQOL-BREF) (Vaz-Serra et al., 
2006). The WHOQOL-BREF includes 26 items categorised into four domains: i) physical 
(e.g., mobility, pain, fatigue and energy); ii) psychological (e.g., positive and negative 
feelings, memory and concentration); iii) social relationships (e.g., personal relationships 
and social support); and iv) environment (e.g., physical safety, health and leisure 
activities) and two questions related to global perception of quality of life and health. 
Each domain consists of three to eight items and each item is assigned a score on a 
five-point Likert scale. The domain scores of the WHOQOL-BREF were calculated 
according to the instructors’ manual. Higher scores mean better quality of life. The 
Portuguese version of the WHOQOL-BREF was found to be a valid and reliable 
instrument, with an intra-class correlation coefficient (R) of 0.65 and a Cronbach's alpha 
of .92 (Vaz-Serra et al., 2006). 
 
2.8. Functional exercise capacity 
The 6-minute walk test (6MWT) was used to quantify functional exercise capacity. This 
test assimilates responses of the pulmonary and cardiovascular systems. The changes 
of functional exercise capacity are measured according to the number of meters walked 
(American Thoracic Society, 2002). Participants were asked to walk in an indoor corridor 
at their own preferred pace for 6 minutes. Walks were timed with a stopwatch for 6 
minutes and measured to the nearest foot. 
Analyses of reproducibility of the 6MWT for individuals with schizophrenia demonstrated 
that the 6MWT is both reproducible and reliable (intra-class correlation coefficient was 
equivalent to 0.94 [95% IC = 0.90 - 0.97] (Gomes et al., 2016) and 0.96 [95% IC = 0.94 
- 0.98] (Vancampfort, Probst, et al., 2011b), indicating that it can be used to quantify the 
functional exercise capacity in this population.  
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2.9. Statistical analysis  
Characteristics of the sample were expressed either as means and standard deviations 
or proportions. Cronbach's alpha was calculated to determine the internal consistency of 
the items of Rosenberg Self-esteem scale and of each BREQ-3 subscale. Pearson 
correlations were calculated in order to examine the bivariate relation between measured 
variables. 
Multiple regression analysis, with the stepwise method, was used to explore the years of 
study, BMI, equivalent dosage of chlorpromazine, autonomous and controlled 
motivation, self-esteem, domains of quality of life and functional exercise capacity as 
significant predictors of Total PA per week. Regression assumptions were evaluated and 
a significance level of 0.05 was used. All analyses were carried out using the Statistical 
Package for Social Sciences (SPSS), version 24.0. 
 
 
3. Results 
A total of 114 Portuguese patients with a DSM-5 diagnosis of schizophrenia (American 
Psychiatric Association, 2013) with an average age of 44.25 (± 9.72) years were included 
in the study. Twenty eight (24%) were women, fifty-seven (50%) were inpatients and 
thirty (26%) were employed. Descriptive statistics, Cronbach’s alpha, and Pearson 
correlations coefficient between the measured variables are presented in Table 1. 
Significant low to moderate linear correlations were found between autonomous and 
controlled motivation, self-esteem, domains of quality of life and total PA per week (Table 
1).  
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Table 1. Mean (standard deviations), internal consistency and intercorrelations between variables measured. 
Variable Mean ± SD 𝛼 1 2 3 4 5 6 7 8 9 10 11 12 
1. Years of study 8.89 ± 4.06 -             
2. BMI (Kg/m2) 28.61 ± 5.64 - .12            
3. Chlorpromazine (mg/day) 550.22 ± 528.39 - .70 -.009           
4. Autonomous motivation 2.65 ± 0.79 .90 .09 .13 .13          
5. Controlled motivation 1.33 ± 0.83 .82 -.16 .14 -.08 .37**         
6. Self esteem 29.63 ± 4.26 .63 .13 .05 .01 .16 -.16        
7. WHOQOL-BREF Global 65.23 ± 21.24 - -.02 -.01 -.002 .18* .05 .23*       
8. WHOQOL-BREF Physical 68.37 ± 13.29 - -.03 -.10 .04 .26** -.01 .48** .60**      
9. WHOQOL-BREF Psychological 65.92 ± 16.39 - .15 -.19* .02 .26** -.11 .47** .62** .56**     
10. WHOQOL-BREF Social 61.20 ± 20.00 - -.10 -.18* .12 .16 .04 .14 .37** .40** .36**    
11. WHOQOL-BREF Environmental 63.77 ± 14.77 - -.08 -.04 .02 .25** .10 .35** .57** .49** .56** .47**   
12. Functional exercise capacity 467.43 ± 76.88 - -.02 -.30** .01 .13 .06 .01 .09 .21* .17 .09 .15  
13. Total PA per week 77.02 ± 67.33 - -.05 .16 -.008 .25** -.05 .15 .33** .29** .25** .12 .25** .00 
 
SD = standard deviation; 𝛼 = Cronbach’s alpha; BMI = body mass index; WHOQOL-BREF = World Health Organization Quality of Life Scale – Brief version; 
PA = physical activity.  
* p<0.05 
** p<0.01 
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The stepwise linear regression model indicated that autonomous motivation and global 
domain of quality of life were significantly associated with Total PA per week (see Table 
2). More autonomous motivation (B = 16.73, p = 0.045) and a better global domain of 
quality of life (B = 0.94, p = 0.003) were associated with higher Total PA per week. 
 
 
Table 2. Results of multiple regression analyses with total minutes PA per week as the dependent 
variable and years of study, BMI, chlorpromazine, psychological measures and functional 
exercise capacity as independent variables. 
 
 
B = unstandardised regression coefficient; CI = confidence interval; SE = standard error; β = 
standardized coefficients beta; BMI = body mass index; WHOQOL-BREF = World Health 
Organization Quality of Life Scale – Brief version; 
 
 
4. Discussion  
The promotion of active lifestyles is an increasing health priority in patients with 
schizophrenia. Investigating the factors that correlate with PA is important to understand, 
support and apply therapeutic rehabilitation strategies. To our knowledge, this is the first 
Predictors  B (95% CI) SE  β t p 
Years of study   -0.06 -0.65 0.516 
BMI (Kg/m2)   0.14 1.45 0.150 
Chlorpromazine (mg/day)   -0.03 -0.35 0.729 
Autonomous motivation 16.73 (0.41 to 33.06) 8.22 0.20 2.04 0.045 
Controlled motivation   -0.17 -1.61 0.111 
Self-esteem   0.06 0.59 0.556 
WHOQOL-BREF Global 0.94 (0.33 to 1.55) 0.31 0.30 3.04 0.003 
WHOQOL-BREF Physical   0.09 0.75 0.458 
WHOQOL-BREF Psychological   0.02 0.15 0.882 
WHOQOL-BREF Social   0.02 -0.21 0.831 
WHOQOL-BREF Environmental   0.05 0.42 0.67 
Functional exercise capacity   -0.06 -0.56 0.575 
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study to analyse the association between several factors recognized as barriers to PA in 
patients with schizophrenia. The goal of this study was to investigate among a number 
of barriers what predicts the most on physical activity in patients with schizophrenia. 
Among the different factors identified as determinants for PA in patients in schizophrenia 
(Vancampfort et al., 2012), results showed that autonomous motivation and global 
domain of quality of life are the strongest predictors of PA in this population. There were 
no other significant associations between the measured factors (i.e., years of education, 
BMI, psychiatric medication, self-esteem or functional exercise capacity) and PA. 
The present results are consistent with previous studies that examined relationships 
between autonomous motivation and PA in patients with schizophrenia (Vancampfort, 
De Hert, et al., 2013) and with other severe mental illnesses (Vancampfort, Stubbs, 
Venigalla, & Probst, 2015). The importance of autonomous motivation towards PA on 
active behaviour in patients with schizophrenia could be justified because in autonomous 
motivation, people are identified with the goals and value of PA and, consequently, 
volitionally adopt PA as a lifestyle. When patients with schizophrenia are autonomously 
motivated, they exhibit an open curiosity and interest about PA that promote successful 
participation in PA. Based on SDT, autonomous motivation is facilitated in environments 
that support three psychological constructs, namely need for autonomy (i.e., 
experiencing a sense of psychological freedom when engaging in PA), competence (i.e., 
ability to attain desired outcomes) and relatedness (i.e., being socially connected) (Deci 
& Ryan, 1985, 2000). Consequently, if the patients are physically active in an 
environment that is perceived as need supportive, they are more likely to be 
autonomously motivated and experience increased levels of well-being.  
In patients with schizophrenia, quality of life is a complex construct influenced by several 
factors (e.g., sociodemographic, severity of psychopathology and physical health 
conditions) (Malhotra, Kulhara, Chakrabarti, & Grover, 2016; Munikanan et al., 2017; 
Pinikahana, Happell, Hope, & Keks, 2002). The results of the present study support that 
quality of life influences PA. Reciprocally, previous studies (Acil et al., 2008; Deenik et 
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al., 2017; Gomes et al., 2014; Vancampfort, Probst, Scheewe, et al., 2011) showed that 
higher PA can contribute to better quality of life in patients with schizophrenia. Positive 
interactions between PA and quality of life suggest a reciprocal relationship, where PA 
could represent an important modifiable factor to improve quality of life in this population. 
Our results demonstrated that, with the exception of the social domain, all other domains 
of quality of life correlated with Total PA per week. Pesek, Mihoci, Medved, and Solinc 
(2011) found that higher PA scores were associated with better quality of life, but only in 
the physical domain. In the regression analysis, the global domain was found as a 
significant predictor of PA. Further empirical studies are needed to confirm the 
relationship between PA behaviours and the domains of quality of life. 
Moreover, practical implications of the present findings are that PA interventions ideally 
should consider and target changes in anthropometric, physical and psychological 
factors so as to achieve adequate active behaviours in patients with schizophrenia. A 
major focus in clinical practice should be considered to guide this population to be 
physically active and to help them to overcome potential barriers. Therefore, clinical 
practice guidelines should highlight the importance of autonomous motivation in order to 
improve PA behaviour in patients with schizophrenia. However, how to motivate patients 
with schizophrenia to adopt and maintain an active lifestyle is one of the greatest 
challenges facing researchers and clinicians (Sorensen, 2006). To increase autonomous 
motivation of this population, clinicians should minimize pressure and rewards; adopt 
supportive language and positive feedback; promote pleasant and enjoyable activities in 
a positive environment (Farholm & Sorensen, 2016; Vancampfort, De Hert, et al., 2015; 
Vancampfort, De Hert, et al., 2013). Adopting active behaviours and consequently a 
clearer perception about the benefits of PA could improve the quality of life of patients 
with schizophrenia.  
 
4.1. Limitations and future research 
 63 
 
The current findings should be interpreted with some caution due to some 
methodological considerations. This is a cross-sectional study, consequently the 
directionality of the relationships observed cannot be deduced with certainty. In this 
sense, longitudinal studies about how motivation towards PA might contribute to the 
identification of the causal pathways between the variables and about the relationships 
between PA behaviours and the domains of quality of life are needed. Second, the use 
of self-reported measures could be considered as a limitation. Namely in the IPAQ-SF, 
patients with schizophrenia might experience difficulties to properly identify the 
frequency, duration and intensity of PA. Moreover, although all participants were 
informed that data were analysed anonymously, we cannot rule out a bias in the sense 
of social desirability when self-reported measures are applied. Third, psychopathology 
symptoms were not formally assessed. Despite the current limitations, the present 
results could help to understand the importance of autonomous motivation and global 
domain of quality of life in adequate PA behaviours in patients with schizophrenia.  
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Abstract 
Patients with schizophrenia experience poor sleep quality that affects their physical and 
mental health. In the general population, physical activity (PA) is considered as a 
beneficial non-pharmacological intervention for sleep quality. However, there is a lack of 
research concerning its implications in the sleep quality of patients with schizophrenia. 
Therefore, the purpose of this study was to assess the associations between PA levels 
and sleep quality. One hundred and thirteen patients (28 women and 56 inpatients) with 
schizophrenia participated in the study. PA levels and sleep quality were assessed via 
standardized questionnaires, Short-Form International Physical Activity Questionnaire 
(IPAQ-SF) and Pittsburgh Sleep Quality Index (PSQI) respectively. Multiple linear 
regression models were conducted. Results demonstrated that sleep quality was 
positively associated with time of moderate and total PA per week. No associations were 
found between PA levels and anxiolytics and antipsychotic medication. Pearson’s 
correlations showed that some of IPAQ-SF measures are negatively correlated with 
some PSQI components. More research is needed to explore the potential interaction 
between sleep quality and PA levels in patients with schizophrenia.   
 
Keywords: physical activity levels, sleep quality, schizophrenia 
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1. Introduction  
The lower levels of physical health in patients with schizophrenia is a major concern (De 
Hert, Schreurs, Vancampfort, & Winkel, 2009) specifically considering the alarming 
disparity compared with the general population (Hoang, Goldacre, & Stewart, 2013; 
Nielsen, Uggerby, Jensen, & McGrath, 2013). Patients with schizophrenia exhibit 
unhealthy lifestyle choices such as physical inactivity (G. Faulkner, Cohn, & Remington, 
2006; Lindamer et al., 2008; Vancampfort et al., 2010), poor diet (Strassnig, Brar, & 
Ganguli, 2003) and high rates of cigarette smoking (Bobes, Arango, Garcia-Garcia, & 
Rejas, 2010). This unhealthy lifestyle causes poor physical health conditions such as 
cardiovascular disease, obesity, metabolic syndrome and diabetes (Cimo, 
Stergiopoulos, Cheng, Bonato, & Dewa, 2012; Crump, Winkleby, Sundquist, & 
Sundquist, 2013). 
Additionally, these patients also experience poor sleep quality compared to the general 
population (Wulff, Dijk, Middleton, Foster, & Joyce, 2012). The term ‘‘sleep quality’’ 
encompasses perceived and/or objective measures of sleep aspects (e.g., onset) and 
effects (e.g., tiredness during the day) (Krystal & Edinger, 2008). Around 30 to 80% of 
patients with schizophrenia suffer from some form of disturbed sleep (Cohrs, 2008). In 
early course of schizophrenia, sleep disturbance occurs before the presence of psychotic 
symptoms (Davies, Haddock, Yung, Mulligan, & Kyle, 2017) and often persists after other 
symptoms have been treated (Baandrup, Jennum, Lublin, & Glenthoj, 2013). In patients 
with schizophrenia, frequent sleep disturbances include difficulties in initiating or 
maintaining sleep (Cohrs, 2008), advanced sleep phase syndrome (i.e., early evening 
bedtimes and early morning awakenings) and hypersomnia with short naps (Wirz-
Justice, Haug, & Cajochen, 2001). Reduced sleep efficiency and total sleep time, 
increased sleep latency, decreased slow wave sleep and rapid eye movement (REM) 
latency were also observed in most patients with schizophrenia (Keshavan et al., 1998; 
Tandon et al., 1992; Wirz-Justice et al., 2001; Wulff et al., 2012). In these patients, 
positive symptoms (e.g., hallucinations, disorganized speech and behaviour) have been 
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reported to be correlated with short REM latency, reduced sleep efficiency (i.e., 
proportion of hours slept to hours spent in bed) and increased sleep latency (i.e., 
prolonged sleep onset time) (Poulin, Daoust, Forest, Stip, & Godbout, 2003; Tandon et 
al., 1992). On the other hand, negative symptoms (i.e., impairments in affective 
experience and expression) have been associated with short REM latency and slow-
wave sleep deficits (Goder et al., 2004; Tandon et al., 1992).  
Both inpatients (Ritsner, Kurs, Ponizovsky, & Hadjez, 2004; Waters, Faulkner, Naik, & 
Rock, 2012) and outpatients (Afonso, Figueira, & Paiva, 2014; Freeman, Pugh, 
Vorontsova, & Southgate, 2009; Palmese et al., 2011) with schizophrenia are affected 
by sleep disturbances. In first-episode patients, individuals with sleep disturbance 
reported low economic status, low educational level and higher depressive and anxiety 
symptoms (Ma, Song, Xu, Tian, & Chang, 2016). To deal with sleep disturbances sleep-
inducing medication is often prescribed or antipsychotics are chosen because of their 
enhanced sedative properties (Wilson & Argyropoulos, 2012). However, even clinically 
stable, medicated patients maintain sleep disturbances (Afonso, Brissos, Canas, Bobes, 
& Bernardo-Fernandez, 2014). Sleep disturbances are positively associated with 
difficulties in daytime activities (Waters et al., 2012), greater positive symptoms (Afonso, 
Brissos, Figueira, & Paiva, 2011), impaired cognitive functions (Bromundt et al., 2011) 
and worse quality of life (Brissos et al., 2013; Hofstetter, Lysaker, & Mayeda, 2005; 
Ritsner et al., 2004). Moreover, sleep disturbances are a major contributor to obesity and 
cardiovascular illness (Czeisler, 2011) which are highly prevalent in patients with 
schizophrenia (Mitchell et al., 2013; Ringen, Engh, Birkenaes, Dieset, & Andreassen, 
2014). 
Faulkner and Bee (2017) indicated that management of sleep disturbance is neglected 
in clinical guidance of psychotic illnesses (including schizophrenia) when compared to 
other mental illnesses. According to the previously mentioned authors, psychological 
approaches (e.g., Cognitive Behavioural Therapy for Insomnia) for treatment of sleep 
disturbances in the general population has recently been applied to populations with 
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serious mental illness. In the general population, physical activity (PA) has been 
extensively recommended for the improvement of sleep quality (Chennaoui, Arnal, 
Sauvet, & Leger, 2015; Kredlow, Capozzoli, Hearon, Calkins, & Otto, 2015). However, it 
is still difficult to understand exactly how PA impacts on sleep and vice versa. In fact, 
sleep and PA influence each other through complex and reciprocal interactions involving 
multiple physiological and psychological pathways (Chennaoui et al., 2015). Hypotheses 
such as thermoregulation (i.e., the increase in body temperature facilitates the sleep 
induction) and energy conservation (i.e., the increase of calorie output promoted during 
sleep because exercise increases the need for sleep) provide a positive energetic 
balance, establishing a condition for the sleeping cycle (Chennaoui et al., 2015). The 
effects of PA on sleep are modulated by several factors such as individual (e.g., age, 
sex, and fitness level) and PA characteristics (e.g., exercise type, intensity duration and 
adherence) (Chennaoui et al., 2015; Kredlow et al., 2015). Regarding components of 
sleep, it is recognized that regular PA has beneficial effects on total sleep time, sleep 
efficiency, sleep onset latency, and sleep quality (Kredlow et al., 2015). Additionally, 
these authors suggested that regular PA leads to greater subjective and objective sleep 
benefits over time, with subjective benefits being comparable to those produced by 
behaviour therapy or pharmacotherapy for insomnia.  
Although a significant body of research has investigated the effects of PA on sleep quality 
in the general population, there is lack of scientific evidence in the field of mental illness 
(Chien, Chung, Yeh, & Lee, 2015; Stanton, Donohue, Garnon, & Happell, 2016). 
Specifically, in schizophrenia, only one study was found regarding PA and sleep 
interactions. Lalande et al. (2016) reported that an 8-week PA programme (i.e., strength-
training and cardiovascular fitness) improved sleep quality in outpatients. The authors 
suggested that sleep quality was associated with more energy and self-esteem and less 
depression, suggesting that PA could potentially act as an alternative to medication. 
However, limited information was provided regarding the different sleep components. In 
addition, it was not possible to identify the impact of the PA programme on good and 
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poor sleepers. Therefore, further research is needed to confirm this preliminary evidence 
and provide detail analyses regarding PA and sleep interactions in both inpatients and 
outpatients. This knowledge could be important for future PA approaches, helping to 
improve clinical outcomes and the efficiency and effectiveness of service provision to 
patients with schizophrenia. Thus, the purpose of this study was to assess the 
associations between PA levels and sleep quality. 
 
 
2. Method  
2.1. Participants and procedure 
One hundred and thirteen patients diagnosed as schizophrenia and recruited from seven 
psychiatric centres, located in the north region of Portugal participated in this study. All 
participants of the study met the following criteria: more than 18 years old, without 
substance dependence and with a stable medication regimen (i.e., no medication 
changes within the last month). Psychiatric diagnosis of the participants was based on 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric 
Association, 2013) criteria and was established by experienced psychiatrists responsible 
for the patients’ treatment. The study was approved by the Faculty Ethics Committee 
and by all the seven ethical committees. All participants gave their written informed 
consent. 
  
2.2. Demographic and anthropometric variables 
Demographic variables included gender, age and anthropometric measures. Weight was 
measured to the nearest 0.1 kg using a Tanita scale (BC-418MA, Tanita Corporation, 
Tokyo, Japan). Height was measured to the nearest 0.1 cm using a portable stadiometer 
(Siber Hegner). Body mass index (BMI) (kg/m2) was calculated. Patients wore light 
clothing with shoes removed. 
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In addition, dichotomous variables were constructed for employment (with and without 
employment), treatment setting (in- versus out- patients) and educational level (lower: 
basic education [i.e., grade 1 to grade 9] versus higher: secondary education or 
university). 
 
2.3. Short-Form International Physical Activity Questionnaire (IPAQ-SF) 
PA levels were assessed using the Portuguese version of the Short-Form International 
Physical Activity Questionnaire (IPAQ-SF) (Craig et al., 2003). IPAQ-SF comprises 
seven items and provides information on the time spent on PA (Craig et al., 2003). 
Participants were asked to recall the number of days they performed each activity 
(frequency) and the length of time (duration) they were involved daily in each activity 
during the last 7 days. Data from the IPAQ-SF were summed up within each item (i.e., 
vigorous intensity, moderate intensity, and walking) to estimate the total amount of time 
spent on PA per day. Previous research in patients with schizophrenia (G. Faulkner et 
al., 2006) shows that the IPAQ-SF is a reliable and valid tool to assess PA levels in this 
population. 
 
2.4. Pittsburgh Sleep Quality Index (PSQI) 
The Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989) is a frequently used international questionnaire on sleep quality research in the 
general population (Afonso, Figueira, et al., 2014; João, Becker, Jesus, & Martins, 2017; 
Zhang et al., 2017) and in patients with schizophrenia (Afonso, Brissos, et al., 2014; 
Afonso, Figueira, et al., 2014; Brissos et al., 2013; Ma et al., 2016). PSQI comprises 18 
self-rated questions designed to measure sleep quality during the previous month and 
evaluates 7 components of sleep: subjective quality, latency, duration, usual efficiency, 
sleep disturbances, medication use, and daytime dysfunction. These components 
consisted of the four-grade system (i.e. 0, 1, 2, 3) (Buysse et al., 1989). Subjective sleep 
quality was assessed 0–3 points (0 – very good sleep quality; 1 – fairly good sleep 
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quality; 2 – fairly bad sleep quality; 3 – very bad sleep quality). Sleep latency was 
assessed 0–3 points (minutes required to go to sleep each night and frequency of getting 
to sleep within 30 minutes). Sleep duration was assessed 0–3 points (0 – sleep duration 
>7 hours; 1 – 6 to 7 hours; 2 – 5 to 6 hours; 3 – <5 hours). Habitual sleep efficiency was 
assessed 0–3 points (proportion of hours slept to hours spent in bed, 0 – ≥85%; 1 – 75 
to 84%; 2 – 65 to 74%; 3 – <65%). Sleep disturbance was assessed 0–3 points (having 
trouble sleeping because of some reasons and the frequency of those). Use of sleep 
medication was assessed 0–3 points (0 – not use during the past month; 1 – less than 
once a week; 2 – once or twice a week; 3 – three or more times a week). Daytime 
dysfunction was assessed 0–3 points (frequency of having trouble staying awake while 
eating meals, or engaging in social activity and frequency of having trouble keeping up 
enough enthusiasm to get things done). All component scores are summed up to 
produce a total score (range 0–21). The higher the score, the lower the sleep quality. 
The total score < 5 discriminates between good and poor sleepers.  
PSQI is a valid, reliable and standardised measure of sleep quality to be used in 
psychiatric patients (Buysse et al., 1989). It discriminates good and poor sleepers and 
allows for an easy administration during clinical practice (Buysse et al., 1989). This 
questionnaire has favourable psychometric properties, with internal consistency 
reliability of .83 and test-retest reliability of .85 (Buysse et al., 1989).  
In this study, the reliability of the total score was assessed using a test-retest procedure 
(two-week interval) with a random sub-sample of 40 patients with schizophrenia. For the 
total score of PSQI, intra-class correlation coefficient (R) was R ≤ 0.85.  
 
2.5. Medication use 
Current antipsychotic medication use was recorded for each patient and converted into 
a daily equivalent dosage of chlorpromazine (Gardner, Murphy, O'Donnell, Centorrino, 
& Baldessarini, 2010). In addition current anxiolytics medication use was recorded for 
each patient, and the mean of milligram (mg) per day was calculated. 
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2.6. Statistical analysis  
Descriptive statistics (means and standard deviations) were calculated. Multiple linear 
regression models, using the enter method, were constructed where the dependent 
variable were PA levels measured by IPAQ-SF. Independent variables included age, 
gender, educational level, employment, treatment condition, chlorpromazine, anxiolytics, 
and sleep quality. Pearson’s correlation coefficients were calculated to investigate the 
association between IPAQ-SF and PSQI components. Significance level was set at 0.05 
throughout the analyses. Statistical procedures were done using SPSS 24.0. 
 
 
3. Results  
One hundred and thirteen Portuguese patients with a DSM-5 diagnosis of schizophrenia 
(American Psychiatric Association, 2013), were included in the study. Patients were 
predominantly male (n= 85) and fifty-six were inpatients. Their demographic and clinical 
characteristics are presented in Table 1, which shows that a greater proportion of 
participants reported attaining a low level of educational achievement. Similarly, a 
greater proportion of participants reported attaining low PA levels, with only five patients 
achieving 150 minutes/ week of MVPA as recommended by ACSM (American College 
of Sports Medicine, 2016). Regarding sleep quality, no difficulties (i.e., scores around 
zero) were reported in the sleep duration (0.29) and habitual sleep efficiency (0.39) 
components.  In contrast, the use of sleep medication (2.27) component revealed that 
patients take frequently sleep medication (i.e., scores around three that means use of 
sleep medication three or more times per week). 
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Table 1. Demographic and clinical characteristics of 113 patients with schizophrenia, and scores 
on the IPAQ-SF and PSQI. 
 
Variables M ± SD (range) 
Age (years) 44.33 ± 9.84 (20 - 63) 
Sex n(%) female 28 (24.8%) 
Low education level n(%) 70 (61.9%) 
With employment n(%) 28 (24.8%) 
Treatment condition n(%) inpatients 56 (49.6%) 
Chlorpromazine equivalent dose 
(mg/day) 
567.81 ± 517.88 (0 – 3400.0) 
Anxiolytics (mg/day) 9.83 ± 15.28 (0 – 80.0) 
BMI 28.68 ± 5.37 (17.9 - 46.1) 
IPAQ-SF 
    Walking PA (min/ week) 31.48 ± 25.53 (0 - 120) 
    Moderate PA (min/ week) 32.14 ± 43.71 (0 - 300) 
    Vigorous PA (min/ week) 7.39 ± 22.85 (0 - 180) 
    Total score PA (min/ week) 71.01 ± 57.43 (0 - 375) 
    Sedentary time (min/ day) 343.93 ± 163.85 (30 - 675) 
    MVPA (min/ week) 39.53 ± 49.69 (0 - 300) 
       ≥ 150 MVPA (min/ week) n(%) 5 (4.4%) 
PSQI 
    Subjective sleep quality 0.72 ± 0.60 (0 - 3) 
    Sleep latency 1.03 ± 1.59 (0 - 6) 
    Sleep duration 0.29 ± 0.47 (0 - 2) 
    Habitual sleep efficiency 0.39 ± 0.80 (0 - 3) 
    Sleep disturbances 1.05 ± 0.65 (0 - 3) 
    Use of sleep medication 2.27 ± 1.28 (0 - 3) 
    Daytime dysfunction 1.50 ± 1.54 (0 - 6) 
    Total score 7.25 ± 3.50 (1 - 18) 
Poor sleepers n(%) 76 (67.3%) 
 
M= mean; SD = standard deviation; mg/day = milligram per day; BMI = body mass index; IPAQ-SF = 
International Physical Activity Questionnaire – Short form; PA = physical activity; min/ week = minutes per 
week; min/ day = minutes per day; MVPA = moderate and vigorous physical activity; PSQI = Pittsburgh 
Sleep Quality Index 
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Adjusted coefficients and 95% CI with IPAQ-SF measures as the dependent variables in 
multiple regression analyses are presented in table 2. Education level was positively 
associated with sedentary time, employment was positively associated with total PA, 
treatment condition was positively associated with time of vigorous PA and sedentary 
time. Also, sleep quality was positively associated with time of moderate and total PA. 
No significant associations were observed between independent variables and the 
walking PA. 
The results showed that 13% of the variability of moderate PA was explained by sleep 
quality, 11% of the variability of vigorous PA was explained by treatment condition, 14% 
of the variability of total PA was explained by employment and sleep quality and 17% of 
sedentary time was explained by education level and treatment condition. 
 82 
 
Table 2. Results of multiple linear regression analyses with the IPAQ-SF measures as the dependent variables and age, gender, educational level, treatment condition, 
chlorpromazine, anxiolytics, and sleep quality as independent variables. 
 
 
PA = physical activity; (Gender: female = 0, male = 1; Educational level: lower = 0, higher = 1; Employment: without = 0, with = 1; Treatment condition: inpatients = 0, outpatients = 1; Sleep 
quality: poor sleep = 0, good sleep = 1)
 Walking PA  Moderate PA  Vigorous PA   Total PA 
 
Sedentary time 
 R2 = 0.10  R2 = 0.13  R2 = 0.11  R2 = 0.14  R2 = 0.17 
 
B 
 (95% CI) 
p  
B 
 (95% CI) 
p  
B 
 (95% CI) 
p  
B  
(95% CI) 
p 
 B  
(95% CI) 
p 
Age 
0.25 
 (-0.27 to 0.77) 
0.34  
-0.05 
 (-0.92 to 0.83) 
0.92  
-0.25 
 (-0.71 to 0.22) 
0.43  
-0.04 
 (-1.19 to 1.10) 
0.94 
 
1.64 
(-1.57 to 4.85) 
0.31 
Gender 
-6.44 
 (-18.13 to 5.25) 
0.28  
-5.71 
 (-25.35 to 13.93) 
0.57  
-4.14  
(-14.52 to 6.24) 
0.29  
-16.29 
 (-41.92 to 9.33) 
0.21 
 
43.51 
(-28.25 to 115.28) 
0.23 
Educational level 
2.12 
 (-8.41 to 12.64) 
0.69  
-3.45  
(-21.14 to 14.24) 
0.70  
-1.67 
 (-11.02 to 7.68) 
0.72  
-3.00 
(-26.09 to 20.08) 
0.80 
 
67.29 
(2.64 to 131.94) 
0.04 
Employment 
8.83 
 (-2.65 to 20.30) 
0.13  
17.33 
 (-1.96 to 36.62) 
0.08  
5.79  
(-4.41 to 15.98) 
0.26  
31.95 
 (6.78 to 57.12) 
0.01 
 
-33.67 
(-104.15 to 36.82) 
0.35 
Treatment condition 
-7.30  
(-18.06 to 3.46) 
0.18  
-4.42 
 (-22.49 to 13.66) 
0.63  
12.07  
(2.52 to 21.63) 
0.01  
0.35 
 (6.77 to 57.12) 
0.98 
 
83.02 
(16.97 to 149.07) 
0.01 
Chlorpromazine (mg/day) 
0.006  
-0.004 to 0.02) 
0.28  
-0.007  
(-0.02 to 0.01) 
0.43  
0.008 
 (-0.001 to 0.02) 
0.08  
0.007 
 (-0.02 to 0.03) 
0.55 
 
-0.007 
(0.07 to 0.05) 
0.82 
Anxiolytics (mg/day)  
-0.09 
 (-0.43 to 0.24) 
0.58  
0.07  
(-0.50 to 0.63) 
0.82  
-0.02 
 (-0.32 to 0.28) 
0.91  
-0.04 
 (-0.78 to 0.70) 
0.91 
 
-0.29 
(-2.36 to 1.79) 
0.78 
Sleep quality 
3.23  
(-6.89 to 13.35) 
0.53  
23.83 
 (6.82 to 40.83) 
0.006  
2.41  
(-6.58 to 11.39) 
0.60  
29.46  
(7.27 to 51.65) 
0.01 
 
-46.61 
(108.75 to 15.54) 
0.14 
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Table 3 shows Pearson correlation’s between IPAQ-SF and PSQI components. The 
results indicated that walking PA was significantly correlated with sleep latency (r=-.20) 
and total score of PSQI (r=-.21); moderate PA was significantly correlated with total score 
of PSQI (r=-.20); total PA was significantly correlated with subjective sleep quality (r=-
.20), with daytime dysfunction (r=-.20) and with total score of PSQI (r=-.26). 
 
Table 3. Correlations between components of PSQI and PA levels of IPAQ-SF in patients with 
schizophrenia 
 
P
S
Q
I 
c
o
m
p
o
n
e
n
ts
 
PA levels – IPAQ-SF 
 Walking PA 
(min/ week) 
Moderate PA 
(min/ week) 
Vigorous PA 
(min/ week) 
Total PA 
(min/ week) 
Sedentary time 
(min/ day) 
Subjective sleep quality - .04 -.19 -.10 -.20* .06 
Sleep latency - .20* -.09 -.01 -.16 -.07 
Sleep duration - .12 -.05 -.12 -.05 .13 
Habitual sleep efficiency -.11 -.09 -.01 -.12 .02 
Sleep disturbances -.06 -.12 -.05 -.10 .02 
Use of sleep medication -.06 -.01 -.02 -.04 -.13 
Daytime dysfunction -.10 -.16 -.09 -.20* .06 
Total score -.21* -.20* -.04 -.26** -02 
 
PA = physical activity; min/ week = minutes per week; min/ day = minutes per day 
** p<0.01. 
* p<0.05. 
 
 
4. Discussion  
 
4.1 Main findings 
The purpose of the present study was to assess the associations between PA levels and 
sleep quality. This study demonstrated that sleep quality was positively associated with 
time of moderate and total PA per week. No associations were found between PA levels 
 84 
 
and anxiolytics and antipsychotic medication. Comparative studies in patients with 
schizophrenia are lacking.  
The majority of the participants reported lower educational level. According to 
Vancampfort et al. (2012) lower educated patients with schizophrenia are considered a 
vulnerable subgroup. The literature revealed that in the general population, individuals 
with lower educational level or economic status were more affected by sleep 
disturbances (Benbir et al., 2015; Xiang et al., 2008). In the present study, only 5 patients 
meet public health recommendations of 150 minutes of MVPA per week (American 
College of Sports Medicine, 2016). Therefore, more research is needed to determine the 
influence of active PA behaviours in sleep quality. Low adherence to PA 
recommendations is consistently reported in patients with schizophrenia (G. Faulkner et 
al., 2006; Vancampfort et al., 2012).  
Regarding sleep quality, 67% of the patients reported a PSQI total score above 5, which 
is considered as poor sleep quality. A PSQI total score above 5 was also reported in 
previous studies in patients with schizophrenia (Afonso et al., 2011; Afonso, Figueira, et 
al., 2014; Ma et al., 2016; Ritsner et al., 2004; Waters et al., 2012). In addition, the PSQI 
total score reported in this study is higher than in patients with schizophrenia without 
sleep disturbances (Afonso, Brissos, et al., 2014) and in the general population (Afonso, 
Figueira, et al., 2014; Zhang et al., 2017). 
Overall, the results of the present study showed a positive association between PA levels 
and sleep quality. These findings are in accordance with the Lalande et al. (2016) study 
in patients with schizophrenia, and also with different reviews in the general population 
(Chennaoui et al., 2015; Kredlow et al., 2015; Yang, Ho, Chen, & Chien, 2012), showing 
that potential intervention on PA levels could improve sleep quality. Specifically, the 
results found in the correlations analyses, demonstrated that PA levels were significantly 
and positively associated with some PSQI components. Although the correlation values 
were low, these results help to understand the importance of PA in sleep quality. 
Therefore, more research is needed to explore the potential interaction between sleep 
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quality and PA levels in patients with schizophrenia. Considering that similar evidence in 
the positive association between PA levels and sleep quality was reported between both 
schizophrenia and general population, it is possible to argue that patients with 
schizophrenia follow the same physiological mechanisms. For example, PA may improve 
sleep quality through increasing endorphin secretion, energy consumption, and body 
temperature (Chennaoui et al., 2015) in patients with schizophrenia. However, future 
research is needed to deeply understand the psychological and physiological effects of 
PA on sleep characteristics and its reciprocal relationship. 
Treatment condition was positively associated with time of vigorous PA and sedentary 
time. Inpatients presented higher PA levels than outpatients, higher values of active 
minutes (with the exception of vigorous PA), and less sedentary time. These results are 
not in line with previous research (Kurebayashi & Otaki, 2017) where outpatients 
presented higher amounts of PA and less sedentary time in comparison with inpatients. 
In the present study, inpatients could present higher amounts of PA due to the activities 
available in psychiatry centres, such as PA sessions, walking activities, therapies and 
work activities. Additionally, the patients’ adherence to the activities offered in the 
psychiatric centres is directly controlled by the practitioners. Similarly, it is important to 
highlight that the lower levels of PA reported for outpatients could be related with low 
confidence and motivation towards PA (Soundy, Stubbs, Probst, Hemmings, & 
Vancampfort, 2014; Vancampfort et al., 2013), as well as with lack of confidence, social 
support (Johnstone, Nicol, Donaghy, & Lawrie, 2009), finances, facilities and resources 
(Carter-Morris & Faulkner, 2003; McDevitt, Snyder, Miller, & Wilbur, 2006).  
 
 
4.2 Practical implications 
Sleep disturbances are frequently reported as a complaint by patients with 
schizophrenia. Therefore, the attention for sleep disturbances should be incorporated 
into standard clinical care for this population. Moreover, patients often indicate the 
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preference to take less medication (Peacey, Miller, Huthwaite, & Romans, 2012) and to 
be more interested in behavioural sleep interventions (Huthwaite, Miller, McCartney, & 
Romans, 2014). Therefore, non-pharmacological approaches are becoming increasingly 
important in daily clinical practice. Practitioners should highlight the importance of non-
pharmacological interventions, and one of these interventions could be PA, which is low 
cost, widely available and has no side effects. In order to improve PA behaviour in 
patients with schizophrenia, practitioners could offer psycho-education sessions. 
Psychoeducation refers to the process of providing education and easy, understandable 
and valuable information, support and feedback regarding the benefits of PA to patients 
with schizophrenia (and their family members). With this insightful information, patients 
are often better able to address the challenges, and also experience more control and 
better well-being. It is considered as an essential component of the therapy programme.  
The combination between an active lifestyle and behaviour strategies for sleep quality 
(e.g., regular waking, sleep times and avoiding naps) may represent adequate and 
effective measures to improve sleep quality and quality of life, as well as reduce sleep 
medication. 
 
 
4.3 Limitations and future research  
The current findings should be interpreted with caution due to some methodological 
considerations. First, this study is a cross-sectional study and the directionality of the 
relationships observed cannot be deduced with certainty. Longitudinal and intervention 
studies should analyse the consequences of regular PA in the sleep quality in patients 
with schizophrenia. Second, the use of self-reported measures to asses PA and sleep 
quality can present a limitation in this population. For example, in the IPAQ-SF, patients 
with schizophrenia might experience difficulties in properly identifying the frequency, 
duration and intensity of PA. Although all participants were informed about the 
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anonymous analysis of the data, a bias in the sense of social desirability cannot be ruled 
out.  
Despite the current limitations, the study provides preliminary data regarding PA levels 
and its relationship with sleep quality in patients with schizophrenia. Higher amounts of 
PA were associated with good sleep quality in patients with schizophrenia. The 
improvements in sleep quality may contribute to physical and mental health and 
consequently the quality of life in patients with schizophrenia. 
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Abstract 
Patients with schizophrenia present sleep disturbances affecting their quality of life 
(QoL). Physical activity (PA) is beneficial for QoL, however sleep quality has been 
understudied in this population. Objective: This study aims to compare the sleep quality 
and QoL between regular physical active and the non-physical active patients with 
schizophrenia. Methods: One hundred and eleven patients with schizophrenia (28 
women and 54 inpatients) participated in the study. Sleep quality and QoL were 
assessed using Pittsburgh Sleep Quality Index and World Health Organization Quality 
of Life – brief version, respectively. International Questionnaire of Physical Activity – 
short form was applied to ensure the difference of PA behaviours between both groups. 
Results: Patients of regular physical active group presented significantly better sleep 
quality and less daytime dysfunction and use of sleep medication. Regarding QoL, 
patients of regular physical active group also showed better QoL across all domains, with 
statistical significance in global and physical domain. Conclusions: This study indicate 
that potentially intervening on regular PA could improve sleep quality and QoL in patients 
with schizophrenia.  
 
Keywords: physical activity; sleep quality; quality of life; schizophrenia 
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1. Introduction 
In schizophrenia, 30 to 80% of patients present some form of disturbed sleep (Cohrs, 
2008). Increased sleep latency, reduced sleep efficiency and total sleep time are sleep 
disturbances frequently reported in this population (Tandon et al., 1992). Although sleep 
medication is frequently used in schizophrenia,  it presents limited efficacy as a treatment 
for sleep disturbances (Waters, Faulkner, Naik, & Rock, 2012). Even clinically stable, 
medicated patients report sleep disturbances (Afonso, Brissos, Canas, Bobes, & 
Bernardo-Fernandez, 2014), that are positively associated with greater positive 
symptoms (Afonso, Brissos, Figueira, & Paiva, 2011), difficulties in daytime activities 
(Waters et al., 2012), and poor quality of life (QoL) (Brissos et al., 2013; Hofstetter, 
Lysaker, & Mayeda, 2005). In patients with schizophrenia, QoL is associated with 
emotional distress, low self-esteem and self-efficacy, lack of emotional and social 
support (Ritsner, Lisker, & Grinshpoon, 2014).  
In general population, the importance of regular physical activity (PA) on sleep quality 
and QoL has been extensively documented (Kredlow, Capozzoli, Hearon, Calkins, & 
Otto, 2015; Yang, Ho, Chen, & Chien, 2012). In patients with schizophrenia, some 
studies associated PA with improved QoL (Gomes et al., 2014; Vancampfort et al., 2011) 
however there is a lack of studies exploring associations between PA and sleep quality. 
Only one study explored the relationship between PA and sleep quality in patients with 
schizophrenia. Lalande et al. (2016) found that an 8-week PA program (i.e., strength-
training and cardiovascular fitness) improved sleep quality in outpatients. In addition, 
sleep quality was associated with more energy and self-esteem and less depression.  
Considering the high prevalence of poor sleep quality and QoL in patients with 
schizophrenia, research regarding sleep components and the role of regular PA as an 
adjunctive approach to prevent its onset, is needed. The purpose of the present study is 
to compare the sleep quality and QoL between regular physical active and the non-
physical active patients with schizophrenia. 
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2. Methods 
2.1. Participants  
One hundred and eleven patients diagnosed with schizophrenia recruited from seven 
Portuguese psychiatric centres participated in this study. All participants met the 
inclusion criteria: more than 18 years old, no substance dependence and a stable 
medication regimen within the last month. Psychiatric diagnosis was based on Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 
2013) criteria established by experienced psychiatrists. The study was approved by the 
Faculty Ethics Committee and by the 7 ethical committees. All participants gave their 
written informed consent. 
 
2.2. Instruments and procedure 
Demographic variables and use of medication were collected. Current antipsychotic 
medication use was converted into a daily equivalent dosage of chlorpromazine 
(Gardner, Murphy, O'Donnell, Centorrino, & Baldessarini, 2010) and current anxiolytics 
medication use was calculated in milligram (mg) per day.  
Regarding PA behaviours, patients were included in the regular physical active group if 
PA practice were offered as a part of the treatment (i.e., if they were at least 1 to 3 times 
per week involved in PA practice). The Portuguese version of the International Physical 
Activity Questionnaire short-form (IPAQ-SF) (Craig et al., 2003) was used to ensure the 
difference of total PA per week between groups. IPAQ-SF provides information on time 
spent walking, in vigorous- and moderate intensity activity. Data from the IPAQ-SF were 
summed within each item (i.e., vigorous intensity, moderate intensity, and walking) to 
estimate the total amount of time spent in PA per week. Validity and reliability data from 
12 countries (including Portugal) showed that the IPAQ-SF is a valid and reliable 
measure of PA (Craig et al., 2003). Previous studies have used the IPAQ-SF to assess 
the PA levels of persons with schizophrenia (Faulkner, Cohn, & Remington, 2006; 
Vancampfort et al., 2013; Vancampfort et al., 2010). 
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The Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989) is a reliable self-report questionnaire which rates sleep quality during the previous 
month, and evaluates 7 components of sleep: subjective quality, latency, duration, 
habitual efficiency, sleep disturbances, medication use, and daytime dysfunction. A 
score greater than five represents worse sleep quality. This questionnaire was included 
in Portuguese studies in patients with schizophrenia (Afonso, Brissos, et al., 2014; 
Afonso et al., 2011; Brissos et al., 2013).  
The Portuguese version of the World Health Organization Quality of Life – Brief version 
(WHOQOL – BREF) (Vaz-Serra et al., 2006) comprises 26 items composed by physical, 
psychological, social and environmental domains of QoL. Higher scores mean better 
QoL. This Portuguese version is considered as valid and reliable (Vaz-Serra et al., 2006). 
 
2.3. Statistical analysis  
Descriptive statistics were calculated. Independent sample t-test and Chi-square were 
used to compare the variables between physical active group and non-physical active 
group. Pearson’s correlation was used to investigate the association between sleep 
quality and QoL. Effect size was calculated using eta-squared (η2) and interpreted as 
small (0.01), medium (0.06) or large (0.14) (Cohen, 1988). Significance level was set at 
0.05 throughout the analyses. Statistical procedures were done using SPSS 24.0. 
 
 
3. Results 
Demographic, anthropometric and clinical characteristics of the sample are presented in 
Table 1. Significant statistical differences between physical active group and non-
physical active group were found in anxiolytics medication and also in total minutes of 
PA per week. Both groups presented a score above 5 on the PSQI, which is considered 
as poor sleep quality (Table 2). Patients of physical active group have better sleep quality 
and components of sleep, with significant lower use of sleep medication and daytime 
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dysfunction. These patients, also reported better QoL in all domains, compared to 
patients of non-physical active group. Statistical differences were found in global and 
physical domain (Table 2). High effect-size was found for the PSQI total score and the 
WHOQOL – BREF domains. 
 
Table 1. Comparison of the demographic, anthropometric and clinical characteristics between the 
physical active and non-physical active patients with schizophrenia. 
 
Characteristics Total sample 
Non-physical active 
group 
Physical active 
group 
Chi2 
Gender 
Men= 83 
Women=28 
Men= 29 
Women=6 
Men= 54 
Women=22 
0.183 
Treatment condition 
Inpatients= 54 
Outpatients=57 
Inpatients= 20 
Outpatients=15 
Inpatients= 34 
Outpatients=42 
0.224 
  M ± SD M ± SD p-value 
Age 44.25 ± 9.91 42.57 ± 9.90 45.03 ± 9.88 0.22a 
Education (years) 8.92 ± 3.59 8.17 ± 3.20 9.27 ± 3.72 0.13a 
BMI 28.75 ± 5.34 28.03 ± 4.65 29.08 ± 5.62 0.33a 
Chlorpromazine (mg/day) 575.25 ± 519.38 629.44 ± 551.89 550.30 ± 505.53 0.45a 
Anxiolytics (mg/day) 9.83 ± 15.39 15.97 ± 19.38 7.00 ± 12.30 0.01a 
Total PA (min/week) 71.30 ± 57.90 52.29 ± 64.37 80.05 ± 52.84 0.02a 
 
M = mean; SD = standard deviation; BMI = body mass index; mg/day = milligram per day; PA = physical 
activity; min/week = minutes per week 
a Independent samples t-test. 
 
 
 
 
 
 
 
 
 
 
 100 
 
Table 2. Comparison of sleep quality and quality of life between the physical active and non-
physical active patients with schizophrenia. 
 
Scales 
Non-physical 
active group 
(n=35) M ± SD 
Physical active 
group  
(n=76) M ± SD 
t-test p-value η2 
PSQI:      
    Subjective sleep quality 0.74 ± 0.56 0.68 ± 0.61 0.47 0.63 0.01 
    Sleep latency 1.06 ± 1.55 0.95 ± 1.54 0.34 0.72 0.01 
    Sleep duration 0.29 ± 0.45 0.30 ± 0.49 -0.17 0.86 0.004 
    Habitual sleep efficiency 0.49 ± 1.01 0.34 ± 0.70 0.76 0.45 0.04 
    Sleep disturbances 1.17 ± 0.61 0.99 ± 0.62 1.45 0.14 0.03 
    Use of sleep medication 2.66 ± 0.96 2.07 ± 1.38 2.58 0.01 0.05 
    Daytime dysfunction 2.03 ± 1.75 1.26 ± 1.38 2.48 0.01 0.10 
    Total score 8.43 ± 3.13 6.59 ± 3.33 2.74 <0.01 0.19 
WHOQOL – BREF:      
    Global domain 58.33 ± 25.70 67.90 ± 17.07 -1.95 0.05 0.20 
    Physical domain 61.68 ± 15.83 70.41 ± 11.87 -2.83 <0.01 0.36 
    Psychological domain 65.78 ± 19.20 66.32 ± 15.02 -0.15 0.87 0.24 
    Social domain 56.31 ± 21.55 62.72 ± 17.45 -1.62 0.10 0.21 
    Environmental domain 61.64 ± 16.48 63.22 ± 14.12 -0.50 0.61 0.29 
 
M = mean; SD = standard deviation; η2= eta-squared; PSQI = Pittsburgh Sleep Quality Index; 
WHOQOL – BREF = World Health Organization Quality of Life – Brief version 
 
Significant negative correlations were found between WHOQOL – BREF and PSQI, 
indicating that lower QoL correlates with worse sleep quality. WHOQOL – BREF global 
domain correlated [r= -0.20 to -0.29; p<0.05] with total PSQI score, subjective sleep 
quality, sleep disturbances and daytime dysfunction. WHOQOL – BREF physical domain 
was related [r= -0.25 to -0.43; p<0.01] with total PSQI score, subjective sleep quality, 
sleep latency, sleep disturbances and daytime dysfunction. WHOQOL – BREF 
psychological domain was associated [r= -0.19 to -0.25; p<0.05] with total PSQI score, 
subjective sleep quality, sleep disturbances, and daytime dysfunction. WHOQOL – 
BREF social domain correlated with daytime dysfunction (r= 0.22; p= 0.01). WHOQOL – 
BREF environmental domain correlated with habitual sleep efficiency and daytime 
dysfunction with the exact same values (r= 0.19; p= 0.04). 
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4. Discussion 
This study examined the differences in sleep quality and QoL between physical and non-
physical active patients with schizophrenia. Patients of the physical active group showed 
significantly better sleep quality. These findings are in line with research in general 
population, suggesting that PA improves sleep quality (Kredlow et al., 2015; Yang et al., 
2012). In general population, better sleep quality was also found in PA groups compared 
with inactive groups (Zhang et al., 2017). Similar results were found in patients with major 
depression (Chien, Chung, Yeh, & Lee, 2015), affective disorder (Stanton, Donohue, 
Garnon, & Happell, 2016) and schizophrenia (Lalande et al., 2016).  
The physical active group showed better subjective sleep quality and daytime 
dysfunction. Concerning the components of sleep quality, patients of the physical active 
group revealed lower use of sleep medication and daytime dysfunction (i.e., trouble 
staying awake while engaging in social activity). Similarly, Yang et al. (2012) found that, 
in general population, the physical active group had significantly reduced sleep latency 
(i.e., prolonged sleep onset time) and medication use, but did not differ significantly in 
sleep duration, sleep efficiency (i.e., proportion of hours slept to hours spent in bed), 
sleep disturbance, or daytime functioning. Is important to highlight that in the non-
physical active group the portion of inpatients is higher compared with physical active 
group. Inpatients could present worse prognostic of the disease, which represents higher 
dosage of anxiolytics and suffering more often from daytime dysfunction. More research 
is necessary in order to explore the difference of sleep components between inpatients 
and outpatients. Physical active patients reported better QoL in all domains, compared 
to non-physical active patients, which is consistent with previous studies in patients with 
schizophrenia (Gomes et al., 2014; Vancampfort et al., 2011). 
Although with low values, the results of correlation analysis showed that lower QoL 
correlates with worse sleep quality. Only two components of sleep (i.e., sleep duration 
and use of sleep medication) were not related with domains of QoL. Afonso et al., (2011) 
reported that patients with schizophrenia presented significantly higher periods of sleep 
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when compared with healthy controls. This situation can occur due to sedative effects of 
antipsychotics, high dosage of anxiolytics, absence of time schedules and psychological 
reasons (e.g. depressive symptoms). However, due to the disease characteristics, 
patients could not realize the negative effects in their QoL. For other hand, sleep 
disturbances and daytime dysfunction correlate with almost all the domains of QoL. This 
could be justified by daytime napping and night-time fragmentation that are common in 
patients with schizophrenia (Afonso et al., 2011). This uncontrollably irregular pattern of 
sleep could increase daytime sleepiness, also common in this population (Afonso et al., 
2011), which could interfere with work, social and family activities (Afonso et al., 2011), 
compromised their QoL. 
This study indicate that potentially intervening on regular PA could improve sleep quality 
and QoL in patients with schizophrenia. In mental illness context, patients reported 
preferences in the reduction of medication, and are interest in alternative non-
pharmacological interventions to improve sleep quality (Peacey, Miller, Huthwaite, & 
Romans, 2012). Therefore, PA should be considered as an option of non-
pharmacological approach. This would improve the QoL in patients with schizophrenia 
and could lead to a more successful rehabilitation and social integration (Afonso, 
Figueira, & Paiva, 2014). Other strategies, focusing on regular waking and sleep times, 
avoiding naps and morning bright light are also recommend (Afonso, Figueira, et al., 
2014). 
However due to some methodological considerations, these findings should be read with 
caution. This cross-sectional study did not observe the directionality of the relationships. 
In addition, the use of self-reported measures and the non-inclusion of 
psychopathological symptoms could be a limitation. Future longitudinal intervention 
studies should analyse the consequences of regular PA in sleep quality, considering the 
severity of the illness and type of medication used by the patients. 
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Abstract 
The purpose of the present study was to examine the dietary intake of both inpatients 
and outpatients with schizophrenia in the Portuguese population as a potential key 
contributing factor to the poor physical health profiles, and understand the relationship 
of diet quality to other lifestyle factors. Material and methods: Participants of this cross-
sectional study completed a semi quantitative food frequency questionnaire. Diet quality 
was determined by adherence to the Mediterranean Diet. In addition participants 
completed the International Physical Activity Questionnaire- Short Form and Pittsburgh 
Sleep Quality Index. Tobacco smoking was assessed through a series of general 
questions. Results: A total of 100 patients (50% inpatients and 28% female) with 
schizophrenia were included in the final analysis. Overall diet quality (Mediterranean Diet 
score) was low to moderate. Patients reported a high consumption of caffeine, while 
deficits were evident for fibre and folate intakes, when compared to the European Food 
Safety Authority recommendations. Outpatients had higher consumption of meat and 
meat products (p = 0.002), fruits and nuts (p = 0.001). Smokers reported poorer diet 
quality when compared to non-smokers (p < 0.001). Conclusions: Characteristics of 
dietary intake should be considered in further lifestyle interventions, in order to improve 
physical health of this population. 
 
Keywords: dietary patterns; diet quality; smoking; physical activity; sleep quality; 
schizophrenia 
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1. Introduction 
People with schizophrenia present two to three times higher rates of mortality when 
compared with general population (Brown, Inskip, & Barraclough, 2000; Brown, Kim, 
Mitchell, & Inskip, 2010; Correll et al., 2017; Saha, Chant, & McGrath, 2007). While a 
proportion of the excess of mortality is caused by suicide, the majority is related to natural 
causes (Brown et al., 2000). People with schizophrenia are at a more than fourfold 
increased risk for abdominal obesity (odds ratio [OR] of risk = 4.43), and more than 
double the risk of low HDL cholesterol (OR = 2.35), metabolic syndrome (OR = 2.35) and 
hypertriglyceridemia (OR = 2.73), and finally, almost twice the risk (by odds) for diabetes 
(OR = 1.99) and hypertension (OR = 1.36), when compared with general population 
(Vancampfort et al., 2013). The association of these comorbidities and schizophrenia is 
a complex interplay between lifestyle-related factors, illness related factors (e.g., 
negative symptoms), and also effects of psychotropic medication treatment. 
Psychotropic medication treatment is associated with several metabolic side effects 
namely, weight gain, glucose intolerance, leptin and insulin resistance, dyslipidemia and 
alterations of cardiac function (Osby, Correia, Brandt, Ekbom, & Sparen, 2000; Stahl, 
Mignon, & Meyer, 2009). 
Concerning lifestyle-related factors, people with schizophrenia have unhealthy lifestyles 
behaviours, including lack of physical activity (PA) (Faulkner, Cohn, & Remington, 2006; 
Stubbs, Firth, et al., 2016; Stubbs, Williams, Gaughran, & Craig, 2016), poor sleep quality 
(Cohrs, 2008; Wulff, Dijk, Middleton, Foster, & Joyce, 2012), high rates of tobacco 
smoking (Kalman, Morissette, & George, 2005; Lasser et al., 2000; McCreadie, 2002), 
alcohol consumption and substances abuse (Brown, Birtwistle, Roe, & Thompson, 1999) 
and poor diet quality (Brown et al., 1999; Dipasquale et al., 2013; McCreadie, 2003; 
Stokes & Peet, 2004). In this population, dietary habits are generally characterized by a 
high intake of saturated fat (Amani, 2007; Brown et al., 1999; Henderson et al., 2010; 
Strassnig, Brar, & Ganguli, 2005), sugar (Stokes & Peet, 2004) and low intake of fibre, 
fruit and vegetables (Brown et al., 1999; Gupta & Craig, 2009; Henderson et al., 2006; 
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McCreadie, 2003). In addition, a significantly increased intake of energy (Strassnig, Brar, 
& Ganguli, 2003) and a low consumption of both monounsaturated and polyunsaturated 
fatty acids (Henderson et al., 2006) were also reported.  
In people with schizophrenia, some factors could influence the adherence to a healthy 
dietary pattern. Although there is a consensus regarding the influence of low 
socioeconomic status (Roick et al., 2007; Samele et al., 2007), data on gender and 
smoking behaviours remain inconsistent (Dipasquale et al., 2013). Moreover, differences 
between inpatients and outpatients have been unexplored. Regarding smoking 
behaviours, current smoking was found to be significantly associated with increased 
prevalence of caffeine consumption, in inpatients and outpatients with schizophrenia 
(Arrojo-Romero et al., 2015). There is an increasing body of evidence concerning the 
influence of antipsychotic treatment in increase hunger and decrease satiety (Blouin et 
al., 2008; Treuer et al., 2009). Specifically, second-generation antipsychotics are 
associated with an increase in appetite and food intake that can contribute to weight gain 
(Cuerda, Velasco, Merchan-Naranjo, Garcia-Peris, & Arango, 2014; Fountaine et al., 
2010). Additionally, adverse eating styles including disordered eating habits, fast-eating 
syndrome, and increased consumption of junk food and low food literacy were also 
observed (Blouin et al., 2008; Hardy & Gray, 2012; Treuer et al., 2009). Concerning that, 
and due to the role of healthy diet on weight lost, insulin resistance, dyslipidemia and 
hypertension (Bonfioli, Berti, Goss, Muraro, & Burti, 2012; Bruins et al., 2014; Wu, Wang, 
Bai, Huang, & Lee, 2007), traditional dietary patterns with proven benefits on health may 
be recommended for people with mental illness (Teasdale, Samaras, Wade, Jarman, & 
Ward, 2017). Additionally, it is important to highlight that extensive evidence supporting 
an association between healthy dietary patterns and a decreased risk of morbidity and 
mortality (Estruch, Ros, & Martinez-Gonzalez, 2013; Harmon et al., 2015; Sofi, Macchi, 
Abbate, Gensini, & Casini, 2014; Sotos-Prieto et al., 2017). Specifically, a meta-analyses 
showed that higher diet quality score measured with Mediterranean diet was 8% 
reduction of overall mortality, and a 10% reduced risk of cardiovascular disease (Sofi et 
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al., 2014). More recently Sotos-Prieto et al. (2017) found consistent associations 
between improved diet quality and a reduced risk of death. In contrast, worsening diet 
quality over 12 years was associated with an increase in mortality of 6 to 12%. 
The Mediterranean diet is a dietary pattern characterized by the by high intake of 
legumes, fruits, nuts, cereals and olive oil, moderate intake of fish, seafood, poultry, dairy 
products, eggs and wine, and low intake of red meat. In the general population, an 
adequate adherence to the Mediterranean diet has found to reduce all-cause mortality 
and cardiovascular morbidity (Mitrou et al., 2007; Sotos-Prieto et al., 2017; Trichopoulou 
et al., 1995), reduce some types of cancer (de Lorgeril & Salen, 2006; Trichopoulou et 
al., 1995) and improve metabolic syndrome factors (Hill & Kris-Etherton, 2008; 
Panagiotakos, Chrysohoou, Pitsavos, & Stefanadis, 2006; Papakonstantinou et al., 
2005). In mental heath field, namely in depression, a systematic review of randomised 
controlled trials (Opie, O'Neil, Itsiopoulos, & Jacka, 2015) and a recent randomised 
controlled trial (Jacka et al., 2017; Parletta et al., 2017) showed that dietary interventions 
can result in improved depression scores among different clinical and healthy 
populations. However, for people with schizophrenia there are minimal studies 
incorporating validated diet quality scores as outcomes in people with schizophrenia and 
none investigating Mediterranean diet applications and possible benefits.  
A better understanding of the characteristics of dietary patterns in people with 
schizophrenia revealed great importance because diet are major and modifiable cause 
of cardiovascular disease (Dipasquale et al., 2013). Furthermore, interventions targeting 
dietary patterns in people with schizophrenia could offer a greater benefit if synergetic 
effects can be detected in relation to metabolic syndrome-related conditions. Therefore, 
the current study has three major aims. The first aim involved assessing the dietary 
intake of people with schizophrenia in a Portuguese population. The second aim was to 
determine the adherence to Mediterranean diet in this population, specifically analysing 
the difference between treatment setting (i.e., inpatients and outpatients). Finally, the 
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third aim was to explore the adherence to Mediterranean diet in relation with lifestyle-
related factors (PA, tobacco smoking and sleep quality). 
 
2. Method  
2.1. Study design: participants and procedures 
The study was planned and implemented using the guidelines of the Strengthening the 
Reporting of Observational Studies in Nutritional Epidemiology (STROBE-nut) 
Statement (Lachat et al., 2016). People diagnosed with schizophrenia from seven 
psychiatric centres, located in the northern region of Portugal, were invited to participate. 
Inclusion criteria were: (i) 18 years of age or older, and (ii) stabilised on psychotropic 
medication, defined as no medication changes within the last month. Exclusion criteria 
included: (i) an inability to provide informed consent, (ii) an inability to speak Portuguese, 
iii) an inability to concentrate for at least 20 minutes (as determined by the treating 
psychiatrist), (iv) diagnosed with a neurological disorder, or (v) diagnosis of substance 
abuse or dependence in the previous six months. Psychiatric diagnosis of the 
participants was based on the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) (American Psychiatric Association, 2013) criteria and was determined by 
treating psychiatrists. The study procedure was approved by the Faculty Ethics 
Committee (CEFADE 13.2014) and by each one of the seven psychiatric centres. All 
participants provided written informed consent. 
  
2.2. Instruments  
2.2.1. Demographic and anthropometric  
Socio-demographic details (e.g., age, educational level, current antipsychotic 
medication) and anthropometric measures (i.e., weight, height and waist circumference) 
were taken. Current antipsychotic medication was recorded for each participant and 
converted into a daily equivalent dosage of chlorpromazine (Gardner, Murphy, 
O'Donnell, Centorrino, & Baldessarini, 2010). Weight was measured to the nearest 0.1 
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kg using a Tanita scale (BC-418MA, Tanita Corporation, Tokyo, Japan). Height was 
measured to the nearest 0.1 cm using a portable stadiometer (Siber Hegner). Waist 
circumference was taken horizontally at the halfway point between the patients’ lowest 
rib and top of the iliac crest. Waist circumference was classified in ideal or in increased 
risks, according to Alberti et al. (2005). In all procedures, participants wore light clothing 
with shoes removed. Body mass index (BMI) (kg/m2) was calculated and classified 
according to the World Health Organisation (2016) categories of underweight, normal, 
overweight or obese (class I, II or III). 
 
2.2.2. Lifestyle-related factors  
Moderate to vigorous PA [MVPA (min/week)] was determined using the Portuguese 
version of the Short-Form International Physical Activity Questionnaire (IPAQ-SF) (Craig 
et al., 2003). A cut-off ≥ 150 minutes of MVPA per week discriminate between patients 
that follows the public health recommendation for adults (American College of Sports 
Medicine, 2016). Sleep quality was measured with the Portuguese version of Pittsburgh 
Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).  A 
global PSQI score higher than 5 indicates clinical levels of sleep disturbances (Waters, 
Naik, & Rock, 2013), which represents poor sleep quality. 
Tobacco smoking was assessed by two verbal questions from the investigator; (i) does 
the patient smoke, and (if the patient did smoke) (ii) how many cigarettes the patient 
smoked per day. 
 
2.2.3. Dietary assessment 
Dietary intake was recorded using a semi quantitative food frequency questionnaire 
(FFQ) of the previous 12 months, designed according to Willett (1998) and adapted to 
include a variety of typical Portuguese food items (Lopes, Aro, Azevedo, Ramos, & 
Barros, 2007). The FFQ comprises 86 food items or beverage categories, with a 
frequency section with nine possible responses (i.e., never to six or more times per day). 
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Two previous studies have used the FFQ to assess the dietary intake in people with 
schizophrenia (Amani, 2007; Henderson et al., 2006). Food Processor Plus Software 
(ESHA Research, Salem, Oregon) was used based on values from the US Department 
of Agriculture. Values for typical Portuguese foods were computed using the Portuguese 
Tables of Food Composition (Porto & Oliveira, 2006). Nutrient intake data were obtained 
by multiplying the frequency of consumption of each food item by the nutrient content of 
the specified portion size, with once a day equal to one. 
Adherence to the Mediterranean diet was determined according to the method 
developed by Trichopoulou et al. (1995), and revised to include fish intake (Trichopoulou, 
Costacou, Bamia, & Trichopoulos, 2003). Each of the nine components was assigned a 
value of 0 or 1, using sex-specific median as the cut-off. For beneficial components (i.e., 
vegetables, legumes, fruits and nuts, cereal, and fish), value of 0 was assigned when 
consumption was below the median and value of 1 was assigned when consumption 
was at or above the median. For components presumed to be detrimental (i.e., meat, 
poultry, and dairy products), a value of 0 was assigned when consumption was at or 
above the median and a value of 1 was assigned when consumption was below the 
median. For alcohol, a value of 1 was assigned when consumption ranged between 5 
and 25 g per day for women, and when consumption ranged between 10 and 50 g per 
day for men. For fat intake, the ratio of monounsaturated lipids to saturated lipids was 
used. Thus, the total Mediterranean diet score (MDS) ranged from 0 (minimal adherence 
to Mediterranean diet) to 9 (maximal adherence). 
Estimated energy requirement (EER) was calculated for each subject using the Schofield 
equation (Schofield, 1985) to determine basal metabolic rate (BMR) based on age, sex 
and weight, utilising adjusted body weight where appropriate (Krenitsky, 2005). Each 
individuals BMR was then multiplied by a physical activity level to determine the EER 
(Black, 2000). To assess for implausible data, the Goldberg et al. (1991) cut-off was 
utilised, with an estimated energy intake (EEI)/BMR ratio of <0.9 considered to be 
underreporting (Goldberg et al., 1991). 
 115 
 
For males and females, the average daily intakes of energy, macro- and selected micro 
nutrients were compared to the follow references values: European Food Safety 
Authority (2017), Babor et al. (2001), and European Food Safety Authority (2015). 
 
2.3. Statistical analysis  
Descriptive statistics were summarized for the demographic characteristics, dietary 
intake and lifestyle-related factors of the participants. The mean and standard deviation 
were reported for continuous variables, and count and percentage was reported for 
categorical variables. For continuous variables, data were tested for normality using the 
Kolmogorov-Smirnov test. Independent sample t-test was used to calculate the 
difference between energy intake and calculated energy requirement. Mann–Whitney U-
test was used to calculate the difference between caffeine consumption in smokers and 
non-smokers. For categorical variables, chi-square test was performed to identify 
differences between lifestyle-related factors. Statistical significance was set at p < 0.05. 
SPSS version 24.0 was used in all analyses (Chicago, IL, USA).  
 
3. Results  
A total of 115 Portuguese patients with a DSM-5 (American Psychiatric Association, 
2013) diagnosis of schizophrenia were initially included in the analysis. A total of 15 
(13.04%) patients were considered to be reporting implausible data (EI/BMR ratio of 
<0.9), and consequently were excluded from the analysis. The final sample 
characteristics are presented in Table 1. Results shows that 50% of the sample were 
inpatients. The majority of the sample (46%) had elementary level of education and 24% 
were employed. Regarding anthropometric characteristics, only 22% presented a normal 
weight, and 26% an ideal waist circumference. 
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Table 1. Demographic, anthropometric, clinical and lifestyle characteristics of people with 
schizophrenia (n=100). 
 Mean (SD)  
Age (years) 44.57 (9.68) 
Sex   
     Female (%) 28% 
Employment situation   
     With employment (%) 24% 
Educational level   
     Primary school (%) 17% 
     Elementary school (%) 46% 
     High school (%) 28% 
     University education (%) 9% 
Treatment condition   
    Inpatients (%) 50% 
Weight (kg) 80.92 (17.12) 
BMI (kg/m2) 28.95 (5.67)  
Weight status  
    Underweight (%) 2 % 
    Normal weight (%) 22 % 
    Overweight (%) 32 % 
    Obesity class I (%) 29% 
    Obesity class II (%) 12% 
    Obesity class III (%) 3% 
Waist circumference (cm) 99.62 (16.70) 
     Ideal (%) 26% 
     Increased risks  
          Male >94 cm (%) 53% 
          Female ≥ 80 cm (%) 21% 
Chlorpromazine equivalent dose (mg/day) 573.38 (537.58) 
Antipsychotic medication  
     No antipsychotic (%) 5% 
     Monotherapy first-generation (%) 5% 
     Monotherapy second-generation (%) 31% 
     Combination of antipsychotics  
          First-generation (%) 11% 
          Second-generation (%) 17% 
          First- and second generation (%) 31% 
MVPA (min/week) 42.07 (55.64) 
     ≥ 150 minutes PA per week (%) 5% 
Sleep quality global score 7.9 (4.1) 
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     Poor sleepers (%) 57% 
Smokers (%) 65% 
     Cigarettes per day 10.4 (10.8) 
 
SD = standard deviation; mg/day = milligram per day; BMI = body mass index; MVPA = moderate 
to vigorous physical activity; PA = physical activity. 
 
 
Average daily intakes of energy, macro- and selected micro-essential nutrients and 
reference values for males and females are presented in Table 2. Results showed that 
female reported an energy intake higher and males slightly lower than reference values. 
In both genders, values reported for proteins and the majority of the vitamins were higher 
than reference values. Values reported for total carbohydrates and total fats were 
consistent with reference values. In addition, energy intake was lower than calculated 
energy requirement 230 ± 551 kcal (t= 4.18 p= <0.001).  
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Table 2. Average daily intakes of energy, macro- and selected micro nutrients for the study participants. 
 
 Male 
Reference 
value 
Female 
Reference 
value c 
Energy intake, kcal/day 2166 ± 378 2221 c 2039 ± 548 1791 c 
Proteins, g/day 99 ± 21 70 c 98 ± 29 60 c 
Total carbohydrates, g/day 
%EI 
279 ± 51 
51 ± 5 
 
45-60 c 
256 ± 74 
50 ± 6 
 
45-60 c 
     Sugar, g/day 114 ± 38  106 ± 40  
     Complex Carbohydrate, g/day 87 ± 20  82 ± 25  
Fibres, g/day 21 ± 6 25 c 22 ± 8 25 c 
Cholesterol, mg/day 321 ± 101  308 ± 120  
Total fats, g/day 
                                        %EI 
74 ± 18 
31 ± 3 
20-35 c 
72 ± 24 
32 ± 5 
20-35 c 
     Saturated fats, g/day 
                                        %EI 
23 ± 7 
10 ± 1.5 
 
< 10 c 
21 ± 8 
9 ± 2 
 
< 10 c 
     Trans fat g/day 
                                        %EI 
1 ± 0.3 
< 1 
 
< 1 c 
0.9 ± 0.5 
< 1 
 
< 1 c 
     Monounsaturated fats, g/day 32 ± 8  33 ± 12  
     Polyunsaturated fats, g/day 13 ± 4  12 ± 4  
          Omega 3 
EPA + DHA 
ALA 
1 ± 0.4 
0.381 ± 0.249 
1.5 ± 0.4 
 
0.250 c 
0.5 c 
1 ± 0.4 
0.440 ± 0.314 
1.2 ± 0.5 
 
0.250 c 
0.5 c 
          Omega 6/Omega 3 ratio 7.3 ± 1.6  7.0 ± 2.1  
Caffeine, mg/day 969 ± 53 400 e 679 ± 49 400 e 
Alcohol, g/day 0.5 ± 1 < 20 d 0.3 ± 1 < 10 d 
Vitamin A, RE μg/day 1837 ± 846 750 a 1674 ± 1095 650 a 
Vitamin B1 (Thiamine), mg/day 2 ± 0.4 0.1 a 2 ± 0.5 0.1 a 
Vitamin B2 (Riboflavin), mg/day 2 ± 0.5 1.6 a 2 ± 0.9 1.6 a 
Vitamin B3 (Niacin), mg/day 24 ± 5 1.6 a 23 ± 7 1.6 a 
Vitamin B5 (Pantothenic acid), mg/day 5 ± 1 5 b 5 ± 2 5 b 
Vitamin B6, mg/day 2 ± 0.6 1.7 a 2 ± 0.6 1.6 a 
Vitamin B9 (Folate), μg/day 315 ± 102 330 a 296 ± 113 330 a 
Vitamin B12, μg/day 11 ± 6 4.0 b 10 ± 6 4.0 b 
Vitamin C, mg/day 113 ± 45 110 a 130 ± 46 95 a 
Vitamin D, μg/day 4 ± 2  4 ± 2  
Calcium, mg/day 878 ± 332 950 a 1028 ± 477 950 a 
Iron, mg/day 16 ± 3 11 a 14 ± 4 16 a 
Magnesium, mg/day 308 ± 74 350 b 323 ± 95 300 b 
Sodium, mg/day 2157 ± 578 2000 c 1852 ± 715 2000 c 
Phosphorous, mg/day 1379 ± 340 550 b 1446 ± 464 550 b 
Potassium, mg/day 3350 ± 843 3500 b 3629 ± 1116 3500 b 
Zinc, mg/day 12 ± 3 7.5-12.7 c 12 ± 4 7.5-12.7 c 
 
EI = energy intake; RE = retinol activity equivalents. a RI – reference intake; b AI – adequate intake; c European 
Food Safety Authority (2017); d Babor et al. (2001); e European Food Safety Authority (2015). 
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The consumption of each of the 9 components of the Mediterranean diet, for total 
sample, and the difference of food components between inpatients and outpatients are 
presented on Table 3. Between inpatients and outpatients, statistical differences were 
found in meat and meat products group and fruits and nuts group. However no significant 
difference was found in total score MDS. 
 
Table 3. Components of the MDS, for total sample, and the difference between inpatients and 
outpatients. 
 
Components of the  
MDS (g/day) 
Total sample 
M ± SD 
Inpatients 
M ± SD 
Outpatients 
M ± SD 
p-value η2 
Fish 66.12 ± 36.70 62.14 ± 33.37 70.10 ± 39.69 0.32 0.012 
Meat and meat products 121.25 ± 45.59 109.69 ± 41.90 132.81 ± 46.59 0.002 0.065 
Dairy products 382.22 ± 267.13 364.06 ± 191.03 400.38 ± 327.12 0.46 0.005 
Legumes 43.75 ± 40.42 46.83 ± 34.37 40.68 ± 45.82 0.06 0.006 
Vegetables 123.32 ± 79.33 113.72 ± 70.98 132.93 ± 86.53 0.28 0.015 
Cereals  296.91 ± 79.80 281.89 ± 53.42 311.94 ± 97.73 0.14 0.036 
Fruits and nuts 221.62 ± 123.04 186.62 ± 107.83 256.62 ± 128.30 0.001 0.082 
Ethanol 0.42 ± 1.25 0.27 ± 0.96 0.58 ± 1.48 0.17 0.016 
Ratio of monounsaturated 
fatty acids to saturated 
fatty acids 
1.48 ± 0.28 1.48 ± 0.27 1.48 ± 0.30 0.83 0.000 
 Total score MDS 4.33 ± 1.64 4.18 ± 1.45 4.48 ± 1.82 0.21 0.008 
 
M = mean; SD = standard deviation; MDS = Mediterranean Diet Score 
 
Finally, regarding lifestyle-related factors, total score MDS was significantly higher in 
non-smokers (5.20 ± 1.18), compared with smokers (3.86 ± 1.67) (p<0.001; η2= 0.152). 
Additionally, results showed that caffeine consumption in non-smokers (56.84 ± 47.65 
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mg/day) is significantly lower compared with smokers (104.22 ± 48.57 mg/day) (Z = -
3.62 p<0.001). No significant differences were found between good (4.41 ± 1.78) and 
poor sleepers (4.26 ± 1.54) (p= 0.46; η2= 0.002). Due to the small number of patients 
(8%) that follow the public health recommendations of MVPA per week (American 
College of Sports Medicine, 2016) comparative analyses were not performed on PA 
behaviour.  
 
4. Discussion 
The knowledge about dietary patterns in people with schizophrenia could help to reduce 
risks factors, improving physical health in this population. Some studies have examined 
dietary habits in this population, however more research is needed, specifically in the 
Portuguese context. To the authors’ knowledge, the present study is the first to analyse 
dietary patterns in Portuguese people with schizophrenia and to compare the difference 
in quality of diet between inpatients and outpatients with schizophrenia.  
In the present study, demographic characteristics of the participants showed higher rates 
of both elementary education level and unemployment. These factors could be barriers 
in achieving adequate dietary intakes, since socioeconomic status is associated with 
poor diet in people with schizophrenia (Roick et al., 2007; Samele et al., 2007). In this 
population, low socioeconomic status could compromise access to nutritious food, and 
instead provide easy access to fast food and pre-prepared convenience foods 
(Henderson et al., 2006). In addition to benefits, such as access to financial resources, 
employment is also associated with less severe symptoms (Bond et al., 2001; Mueser et 
al., 1997) and reduced hospital readmission rates (Rummel-Kluge, Pitschel-Walz, 
Bauml, & Kissling, 2006).  
Anthropometric characteristics revealed that only a small number of participants 
presents a normal weight status as well as an ideal waist circumference, values that are 
consistent with the literature (De Hert et al., 2011). Several factors can justify this 
situation, namely, adverse effect of antipsychotic medication (De Hert et al., 2011; De 
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Hert et al., 2012; Leucht et al., 2009), psychological factors (Daumit et al., 2013; Manu 
et al., 2015; Thornicroft, Brohan, Rose, Sartorius, & Leese, 2009) and unhealthy lifestyle 
(Cohrs, 2008; Dipasquale et al., 2013; Faulkner et al., 2006; Kalman et al., 2005; Lasser 
et al., 2000; McCreadie, 2002; Stubbs, Firth, et al., 2016; Stubbs, Williams, et al., 2016; 
Wulff et al., 2012). Antipsychotic medication can increase hunger and decrease satiety 
(Blouin et al., 2008; Treuer et al., 2009). Specifically the effects of second generation of 
antipsychotic medication on appetite and energy intake are likely key driving factors for 
elevated weight and waist circumference in people with schizophrenia (Elman, Borsook, 
& Lukas, 2006). Furthermore, other medications (i.e., mood stabilizers and 
antidepressants) can also contribute to weight gain, and adversely affect lipid and 
glucose metabolism (Torniainen et al., 2015). Despite the evidence, limited information 
has been reported on the influence of antipsychotic medication on diet in people with 
schizophrenia (Dipasquale et al., 2013). Psychosocial factors have influence on the 
aetiology of obesity in people with schizophrenia by restricting food choices and 
decreasing caloric expenditure (Daumit et al., 2013). Together with low education and 
unemployed status, as previously mentioned, negative discrimination and social isolation 
could limit opportunities for access to healthier food and adopt adequate PA behaviours 
(Centorrino et al., 2006; Daumit et al., 2013; Thornicroft et al., 2009). 
Concerning unhealthy lifestyles, in the present study, results showed that total minutes 
of MVPA per week were lower than public health recommendations of 150 minutes. This 
situation has already has been reported in previous study (Faulkner et al., 2006). 
Regarding sleep quality, more than a half of the sample were considered as poor 
sleepers, consistently with Cohrs (2008) that indicated that 30 to 80% of people with 
schizophrenia present with sleep disturbances. Finally, consistently with the literature, 
high rates of tobacco smoking were reported (Kalman et al., 2005; Lasser et al., 2000; 
McCreadie, 2002). 
In the present study, participants reported less energy intake that the calculated for 
energy requirement. In general population, under-reporting of dietary intake is a common 
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problem in nutritional research and has been observed to persist across diet assessment 
methods (e.g., FFQ, 24 h recalls, food records) (Crispim et al., 2012; Freedman et al., 
2014; Trabulsi & Schoeller, 2001; Trijsburg et al., 2017). Several determinants are 
associated with underreporting of energy intake, namely gender, older age, weight status 
and smoking. In schizophrenia there is a lack of evidence regarding this problem. Given 
the cognitive, memory and motivational challenges in schizophrenia it is possible that 
under-reporting could be a significant issue. Identifying the determinants associated with 
under-reporting of dietary intake in people with schizophrenia may help to facilitate the 
adjustment of dietary assessment methods and the development of correction methods. 
Additionally, preliminary evidence (Cuerda et al., 2011; Cuerda et al., 2014; Nilsson, 
Forslund, Olsson, Hambraeus, & Wiesel, 2006) has found that people with schizophrenia 
receiving antipsychotic medication have a reduced basal metabolic rate, suggesting that 
current formulas over estimate energy requirements. Further studies need to investigate 
this and develop modified formulas specific to this population if indicated. 
The present results revealed that, comparing with the reference values, female reported 
higher consumptions energy intake. Contrarily, Jahrami et al. (2017) reported higher 
values for men (2904 ± 745 kcal) compared with female (2772 ± 713 kcal) patients with 
schizophrenia. In the study of Amani (2007) it was reported that female patients 
compared with healthy controls, revealed lower dietary pattern scores. Results from this 
study showed that both men and female reported lower consumption of fibres. Similarly, 
Fusar-Poli et al. (2009) revealed that in patients with psychosis, including schizophrenia, 
the fibre consumption was lower than recommended. In addition, studies revealed that 
patients presented lower consumption of fibres when compared with control groups 
(Brown et al., 1999; Gupta & Craig, 2009; Henderson et al., 2006; Osborn, Nazareth, & 
King, 2007; Roick et al., 2007).  
Regarding the values for total fat, participants reported an adequate consumption. 
However, in the literature inconsistencies in the results were found. For one hand some 
studies (Amani, 2007; Archie et al., 2007; Brown et al., 1999; Ryan, Flanagan, Kinsella, 
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Keeling, & Thakore, 2004) demonstrated that total fat intake was higher in patients 
compared with controls. One study (Henderson et al., 2006) demonstrated that total fat 
intake was lower in patients compared with controls. In contrast, other studies (Blouin et 
al., 2008; Gupta & Craig, 2009; McCreadie, 2003; Roick et al., 2007; Samele et al., 2007) 
reported non difference between patients and control groups for fat intake.  
In the present study, both male and female patients showed deficits in vitamin B9 (folate), 
which is consistent with a meta-analyses study in long-term schizophrenia (Wang, Zhai, 
& Liu, 2016). Similarly, female patients showed deficits in vitamin C, as has previously 
been observed in this population (Flatow, Buckley, & Miller, 2013). Contrarily, compared 
to health recommendations higher values of vitamin B12 was reported in both sexes, 
which is inconsistent with previously reported in long-term schizophrenia (Cao et al., 
2016). The lack of comparative studies for some nutrients, and the inconsistencies 
demonstrated for others nutrients reveals the need for more research in this field.  
Finally, higher consumption of caffeine was reported in the present study. These results 
are well established in the literature, which reveals that both inpatients and outpatients 
with schizophrenia presented higher caffeine consumption compared with the general 
population (Gurpegui et al., 2006; Strassnig, Brar, & Ganguli, 2006). Since caffeine 
consumption is associated with tobacco smoking (Gurpegui et al., 2007; Zimmermann, 
Lubman, & Cox, 2012), findings of the present study are consistent with the literature, 
showing that caffeine consumption in non-smokers was significantly lower compared 
with smokers. According to Arrojo-Romero et al. (2015), even after controlled for 
confounders, smoking was strongly and consistently associated with caffeine use and 
high caffeine use in both inpatients and outpatients with schizophrenia. In fact, tobacco 
smoking is associated with an induction of caffeine metabolism, and smokers tend to 
need two to three times more caffeine than non-smokers to reach the same plasma 
caffeine levels (Gurpegui, Aguilar, Martinez-Ortega, Diaz, & de Leon, 2004). Therefore, 
the high rates of caffeine intake reported for the participants could be related with the 
high prevalence of smoking in our sample. In addition, high caffeine intake could be 
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explain by the availability of caffeine in form of coffee, soft drinks, chocolate and tea both 
for inpatients and outpatients conditions.  
When compared the adherence to Mediterranean diet, results demonstrated that 
outpatients showed a significant higher consumption of meat and meat products, and 
fruits and nuts, compared with inpatients. Comparative studies are non-existent. It is 
important to highlight that both inpatients in outpatients reported a high consumption of 
meat products. A meta-analysis of colorectal cancer in ten cohort studies reported a 
statistically significant dose–response relationship, with a 17% increased risk per 100 g 
per day of red meat and an 18% increase per 50 g per day of processed meat (Chan et 
al., 2011). Despite the difference between inpatients and outpatients in some 
components of Mediterranean diet, the total score was similar, both presented a mean 
score of 4 that represents low to moderate adherence. Outpatients could have less 
structured time, increased opportunities to sleep, and miss meals resulting in lower 
dietary intake (Henderson et al., 2006). On another hand in inpatient conditions, the 
hospital environment naturally influenced the patients’ nutrition and eating habits. Dietary 
intake could be more easily supervised. Therefore more research is necessary in order 
to explore the differences between treatment conditions characteristics. 
When analysed risk factors, results demonstrated that non-smokers present a higher 
adherence to Mediterranean diet, compared with smokers. These results are consistent 
with the literature, with non-smokers showed healthier eating habits than smokers 
(Bobes, Arango, Garcia-Garcia, & Rejas, 2010; McCreadie, 2003). According to Bobes 
et al. (2010), smokers’ patients were more likely to use salt, saturated fat and were less 
likely to follow a high-fibre and low-caloric diet. Is important to note that the relationship 
between MDS and PA was not possible to explore, due to the small sample size and the 
low MVPA levels of the participants. Regarding the importance of both health behaviours 
(i.e., diet and PA) for physical and mental conditions of people with schizophrenia, future 
studies should explore this interaction.  
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4.1. Limitations and strengths of the study  
The strengths of this study include the innovative approach concerning dietary intake in 
people with schizophrenia, namely collected information, adherence to Mediterranean 
diet and the inclusion of both treatment condition.  
Assessing dietary patterns in people with schizophrenia presents a challenge due to 
intake variability and the wide range of nutrients to consider. FFQ’s represent a 
subjective and retrospective method, for that reason misreporting of portion size, food 
type and preparation methods occurs. According to Henderson et al. (2006), people with 
schizophrenia presents higher risk for making reporting errors. This situation highlight 
the significant gap in the literature regarding the non-existence of a valid nutrition 
assessment tool for people with schizophrenia or other mental disorder (Teasdale, Ward, 
Rosenbaum, Samaras, & Stubbs, 2017), therefore it is unclear how closely the FFQ 
analyses reflect actual intake. Although the recognized limitations of FFQ, it is commonly 
used in people with schizophrenia (Amani, 2007; Archie et al., 2007; Chuang, Mansell, 
& Patten, 2008; Henderson et al., 2006; Roick et al., 2007; Samele et al., 2007) as gold 
standard measures such as doubly-labelled water or weighed-food records are not 
considered feasible. 
In addition, lack of reference values or an incongruence on reference values reported 
can also represent a barrier for a possible understanding about nutritional patterns in 
people with schizophrenia. For instance, in most countries, separate dietary 
recommendations exist for total fat intake, saturated fatty acids, monounsaturated fatty 
acids, polyunsaturated fatty acids, and trans fatty acids (EFSA Panel on Dietetic 
Products Nutrition and Allergies, 2010). Another example are the reference values for 
water consumption of 2 litres per day for female and 2.5 for male (European Food Safety 
Authority, 2017) includes water from beverages of all kind, including drinking and mineral 
water, and from food moisture. However, through the FFQ, only water present on food 
moisture is considered and therefore adequacy of intake was not able to be assessed. 
The FFQ does not account for nutritional supplements and therefore the nutrient intakes 
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displayed in the tables may not be a true indication of overall intake but do demonstrate 
rates of dietary adequacy. 
In this sense, as with any cross-sectional analysis, the results of this study should be 
interpreted carefully. The relationship between smoking and diet quality and caffeine 
consumptions requires further investigation. Longitudinal studies should provide 
significant additional information about the contribution of dietary intake in 
symptomatology and in lifestyle behaviours in this population. Participants may make 
errors in reporting portion size or underreport foods consumed. In addition, desired 
response behaviour or minimizing existing problems, as with alcohol consumption, for 
instance, cannot be excluded. 
 
4.2. Study implications 
As dietary patterns could be a therapeutic target to control metabolic abnormalities in 
patients with schizophrenia (Dipasquale et al., 2013), it is important to identify the main 
characteristics of these behaviours. Due to the limited literature concerning dietary 
practices and nutritional requirements in people with schizophrenia, the present findings 
could be important for clinical practice. The results found in this study revealed that 
people with schizophrenia need counselling concerning dietary intake, namely regarding 
caffeine consumption, energy intake, fibre and folate. At the same time intervention 
targets should also focus on better dietary pattern, for example increase the 
consumptions of fruit, vegetables and wholegrains, as well as in the reduction of 
processed and sweetened foods. Therefore, the results suggested that dietary and PA 
interventions targeting weight management, cardiometabolic health, diet quality, 
sedentary behaviour and cardiorespiratory fitness should be included in this population. 
To ensure the effectiveness of these interventions, the integration of dietitians and PA 
professionals (with experience in mental illness) into multidisciplinary mental health 
teams should be considered. This because, only qualified professionals will ensure an 
adequate management of barriers, challenges, symptoms characteristics and effects of 
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antipsychotic medications in people with schizophrenia, or other mental illness 
(Teasdale, Ward, et al., 2017). 
 
5. Conclusion 
The present research showed that, compared with reference values, female patients 
reported a high energy intake. Both female and male patients reported a high 
consumption of caffeine, while deficits were evident for fibre and folate intakes. 
Outpatients showed a significant higher consumption of meat and meat products, and 
fruits and nuts, compared with inpatients. Both inpatients and outpatients presented a 
low to moderate adherence to Mediterranean diet. Finally, non-smokers patients 
presented high adherence to Mediterranean diet. This study provided new evidence 
regarding dietary intake in people with schizophrenia. The knowledge about the 
characteristics of diet in inpatients and outpatients provides targets for lifestyle 
interventions. 
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Abstract 
In people with schizophrenia several factors are associated with poor quality of life (QoL), 
namely, lifestyle-related factors and psychological factors. However, there has been little 
research on the impact of these factors on QoL. Therefore, the relation between lifestyle-
related factors, psychological factors, and QoL in people with schizophrenia was 
assessed. A cross-sectional study was conducted among 115 persons with 
schizophrenia (25% women and 50% inpatients). QoL was measured by World Health 
Organisation Quality of Life- Brief Version. Lifestyle-related factors were assessed, 
namely physical activity (International Physical Activity Questionnaire- Short Form), 
sleep quality (Pittsburgh Sleep Quality Index) and dietary intake (Mediterranean Diet 
score). Psychological factors such as self-esteem (Rosenberg Self-Esteem Scale) and 
autonomous motivation (Behavioural in Regulation Questionnaire- version 3) were also 
measured. Regression analyses were performed to identify significant predictors of QoL. 
Results showed that physical activity behaviours and self-esteem predicted better QoL 
across all domains. Autonomous motivation predicted better physical, psychological and 
environmental QoL. Identifying predictors of QoL has implication for the effective design 
and delivery of lifestyles interventions, including physical activity, dietary education and 
smoking cessation in people with schizophrenia. Adopting healthy lifestyles behaviours 
may lead to improved physical health, psychological well-being and QoL in people in 
schizophrenia. 
 
Keywords: quality of life, lifestyle, physical activity, motivation, self-esteem, 
schizophrenia.  
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1. Introduction  
People with schizophrenia are at high risk of developing a range of physical health 
conditions, such as cardiovascular disease, obesity, cancer, metabolic syndrome and 
diabetes (Cimo, Stergiopoulos, Cheng, Bonato, & Dewa, 2012; Correll et al., 2017; 
Crump, Winkleby, Sundquist, & Sundquist, 2013). Behavioural and lifestyle-related 
factors appear to be significant contributors for poor physical health (Leas & McCabe, 
2007), namely insufficient engagement in moderate and vigorous physical activity 
(Stubbs, Firth, et al., 2016), poor sleep quality (Cohrs, 2008; Wulff, Dijk, Middleton, 
Foster, & Joyce, 2012), unhealthy dietary habits (Brown, Birtwistle, Roe, & Thompson, 
1999; Dipasquale et al., 2013; Peet, 2004; Teasdale, Samaras, Wade, Jarman, & Ward, 
2017) and tobacco smoking (Brown et al., 1999; Kalman, Morissette, & George, 2005). 
People with schizophrenia are more sedentary than the general population (Stubbs, 
Firth, et al., 2016; Stubbs, Williams, Gaughran, & Craig, 2016). Only a minority (about 
25%) of persons with schizophrenia adhere to public health recommendations of 150 
minutes of physical activity per week (Faulkner, Cohn, & Remington, 2006). Similarly, 
around 30 to 80% of people with schizophrenia present with sleep disturbances (Cohrs, 
2008), that are negatively associated with greater positive symptoms (Afonso, Brissos, 
Figueira, & Paiva, 2011) and difficulties in activities of daily living (Waters, Faulkner, 
Naik, & Rock, 2012). Unhealthy dietary habits are also common in this population 
(Dipasquale et al., 2013), characterized by a high intake of fat and sugar (Stokes & Peet, 
2004) and low intake of dietary fibre (Brown et al., 1999), fruits and vegetables 
(McCreadie, 2003). People with schizophrenia also smoke tobacco at a rate 3-4 times 
greater than the general population (Kalman et al., 2005; Lasser et al., 2000; McCreadie, 
2002).  
The adoption of a healthy lifestyle is a process that also involves motivation to plan 
change, in addition to physical, psychological and material resources to adhere to the 
plan. Due to illness characteristics (i.e., impairments in cognition, perception, affect and 
volition) people with schizophrenia may experience difficulties in each step of this 
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process (Hasnain, Victor, & Vieweg, 2011). In people with schizophrenia, low self-
esteem is associated with negative symptoms (Frank & Davidson, 2012). In addition, a 
reduction of these symptoms is positively associated with improvements in self-esteem 
(Jones, Hansen, Moskvina, Kingdon, & Turkington, 2010). In the general population, self-
esteem processes are also associated with motivation to physical activity (Biddle & 
Mutrie, 2008). When people are physically active in an environment that is perceived as 
supportive, they are more likely to be autonomously motivated and experience increased 
levels of well-being. However, if the environment is perceived as not being supportive, 
more controlled types of motivation, known to be associated with lower rates of physical 
activity participation, would be expected. In addition, in controlled motivation, one's 
behaviour is a function of external contingencies of punishment or reward, that may 
encourage the person to be more active (Deci & Ryan, 2000). In people with 
schizophrenia, controlled motivation is related to the tendency to feel, think, or behave 
in particular ways (e.g., guilt or seeking social approval), which in turn is associated with 
lower physical activity participation (Vancampfort et al., 2013). On the other hand, 
autonomous motivation towards physical activity is associated with voluntary exercise 
over longer periods of time, and people who experience this are therefore more likely to 
experience the multitude of health benefits conferred by an active lifestyle (Vancampfort, 
Vansteenkiste, et al., 2014). 
These lifestyle-related factors and psychological factors lead to a decrease in 
functionality and a reduction in quality of life (QoL) (Chan & Yu Iu, 2004). QoL is a 
multidimensional construct that comprises subjective well-being and objective mental 
and physical indicators. Over time, people with schizophrenia may experience a 
reduction in the ability to perform activities of daily living, which can promote financial 
difficulties (Awad & Voruganti, 2012). In addition, they often suffer stigma and social 
discrimination, which affects the ability to maintain social relationships and an adequate 
social functioning (Lysaker, Yanos, Outcalt, & Roe, 2010). All these factors make it 
difficult for people with schizophrenia to self-manage the illness (Allison, Mackell, & 
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McDonnell, 2003) and, consequently, they tend to have a poorer QoL, when compared 
to general population.  
In people with schizophrenia several factors are associated with poor QoL, such as 
severity of psychopathology and pharmacotherapy (Fitzgerald et al., 2001; Pinikahana, 
Happell, Hope, & Keks, 2002; Michael Ritsner et al., 2002; Tomotake, 2011), 
demographic (Munikanan et al., 2017; Pinikahana et al., 2002), psychological (Brekke, 
Kohrt, & Green, 2001; Gureje, Harvey, & Herrman, 2004; M. Ritsner, Lisker, & 
Grinshpoon, 2014), and clinical factors, including obesity, hypertension and metabolic 
syndrome (Allison et al., 2003; Malhotra, Kulhara, Chakrabarti, & Grover, 2016), as well 
as unhealthy lifestyles (Deenik et al., 2017; Hofstetter, Lysaker, & Mayeda, 2005; M. 
Ritsner, Kurs, Ponizovsky, & Hadjez, 2004; Vancampfort et al., 2011). 
Regarding psychopathology, depressive and negative symptoms were associated with 
poor QoL (Browne et al., 1998; Dickerson, Ringel, & Parente, 1998; Fitzgerald et al., 
2001; Norman et al., 2000; Tomotake, 2011), while the association of positive symptoms 
is scarce and controversial (Fitzgerald et al., 2001; Norman et al., 2000; M. S. Ritsner & 
Gibel, 2007).  Side effects of antipsychotic agents also have been found to play a 
significant role in QoL (Michael Ritsner et al., 2002). On demographic variables, male 
gender was associated with poor QoL in psychological domain (Li et al., 2017), while 
female gender significantly predicted better QoL in physical and psychological domains 
(Munikanan et al., 2017). However others studies (Chou, Ma, & Yang, 2014; 
Wartelsteiner et al., 2016) reported no effect of gender on QoL. Being unemployed was 
associated with poor QoL in the majority of the studies (Cai & Yu, 2017; Chou et al., 
2014; Li et al., 2017; Marwaha et al., 2008), while in others studies (Munikanan et al., 
2017; Wartelsteiner et al., 2016) no associations were found. On educational level, 
patients with higher levels of education reported lower QoL (Caron, Mercier, Diaz, & 
Martin, 2005; Ruggeri et al., 2005). Treatment setting, namely living arrangements was 
also associated with better QoL (Caron et al., 2005). On psychological variables, some 
factors such as low self-esteem and self-efficacy were also associated with poor QoL 
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(Brekke et al., 2001; Gureje et al., 2004; M. Ritsner et al., 2014). In the study of 
Wartelsteiner et al. (2016) self-esteem was significantly correlated with QoL. In the same 
study, self-esteem was also identified as a predictor of QoL. On clinical variables, the 
association between BMI and QoL domains in the literature is inconsistent, the majority 
of previous studies reported that overweight and/or higher BMI was associated with 
impairments in the physical aspects of QoL (Bressington et al., 2016; Faulkner, Cohn, 
Remington, & Irving, 2007; Vancampfort et al., 2011). Other studies (Kolotkin et al., 2008; 
Sugawara et al., 2013), reported that both physical and psychological aspects of QoL 
were significantly and positively associated with an overweight status in this population. 
On lifestyle-related factors, poor sleep quality (Hofstetter et al., 2005; M. Ritsner et al., 
2004), and lack of physical activity (Vancampfort et al., 2011) were associated with poor 
QoL in people with schizophrenia. Recent research (Deenik et al., 2017) demonstrated 
that physical activity is a significant predictor of some domains of QoL including physical, 
psychological and social domains. There is a lack of research evaluating the associations 
between diet quality and QoL in people with schizophrenia. However, in non-clinical 
populations the diet quality was associated with a better QoL (Henriquez Sanchez et al., 
2012; Munoz, Fito, Marrugat, Covas, & Schroder, 2009).  
Despite the high prevalence of poor lifestyle behaviours in people with schizophrenia 
and high rates of physical health comorbidity, there has been limited research on the 
contribution of lifestyle-related factors to the domains of QoL. To the best of our 
knowledge, there has not been any study which has simultaneously analysed lifestyle-
related factors (i.e., physical activity, sleep quality, smoking and dietary habits) as 
predictive factors of QoL in people with schizophrenia. Identification of predictors of QoL 
would be helpful in designing more effective psychoeducational interventions to reduce 
lifestyle-related risk in people with schizophrenia. Therefore, the present study aimed to 
assess the association between lifestyle-related factors, psychological factors, and QoL 
in a sample of people with schizophrenia.  
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2. Method  
 
2.1. Participants and study sites  
All participants in this cross-sectional study were recruited using convenience sampling 
determined by recruitment opportunities in seven psychiatric centres (see 
acknowledgments), located in the northern region of Portugal. Inpatients were long-term 
hospitalized patients recruited from four psychiatric hospitals. In these hospitals, mental 
healthcare and residence is provided when even clinically stable patients are unable to 
live independently or in sheltered homes (e.g., lack of social support, lack of family 
members, or financial conditions). Outpatients were recruited from three community 
mental health centres where therapeutic approaches are provided. 
All participants met the following inclusion criteria: 18 years of age or older, acute 
symptoms (at least partially) remitted and, prescribed a stable medication regimen (i.e., 
no medication changes within the last month). Exclusion criteria included an inability to 
provide informed consent, or to speak Portuguese, an inability to concentrate for at least 
20 minutes (as determined by the treating psychiatrist), neurological disorders, and a 
diagnosis of substance abuse or dependence in the previous six months. Psychiatric 
diagnosis of the participants was based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-V) (American Psychiatric Association, 2013) criteria and was 
established by experienced psychiatrists. The study procedure was approved by the 
Faculty Ethics Committee (CEFADE 13.2014) and by all seven ethics committees. All 
participants provided written informed consent. 
 
2.2. Assessment measures 
 
2.2.1. Demographic, anthropometric and clinical factors 
Demographic variables included gender, age and anthropometric measures. Weight was 
measured to the nearest 0.1 kg using a Tanita scale (BC-418MA, Tanita Corporation, 
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Tokyo, Japan). Height was measured to the nearest 0.1 cm using a portable stadiometer 
(Seca 213, Hamburg, Germany). In both procedures, participants wore light clothing with 
shoes removed. Body mass index (BMI) (kg/m2) was then calculated. 
Dichotomous variables categorised employment status (currently employed or 
unemployed), educational level (lower: basic education [i.e., grade 1 to grade 9] versus 
higher [secondary education or college], physical activity participation (participation at 
least 1-2 times per week versus non-participation) and treatment setting (in-patient 
versus out-patient treatment). 
Current antipsychotic medication use was recorded for each participant and converted 
into a daily equivalent dosage of chlorpromazine (Gardner, Murphy, O'Donnell, 
Centorrino, & Baldessarini, 2010).  
 
2.2.2. Quality of life 
QoL was assessed using the Portuguese version of the World Health Organization 
Quality of Life Scale – Brief version (WHOQOL-BREF) (Vaz-Serra et al., 2006). 
WHOQOL-BREF includes 26 items categorised into four domains: i) physical (e.g., pain, 
mobility, energy and fatigue); ii) psychological (e.g., memory and concentration, positive 
and negative feelings); iii) social relationships (e.g., social support and personal 
relationships); and iv) environment (e.g., physical safety and security; health and social 
care; leisure activities) and two questions related to global perception of QoL and health. 
Each domain consists of three to eight items and each item is assigned a score on a 
five-point Likert scale. Higher scores mean better QoL. The Portuguese version of 
WHOQOL-BREF was found to be a valid and reliable instrument for clinical population 
(including psychiatric population), with an intra-class correlation coefficient (R) of 0.65 
and a Cronbach's alpha of .92 (Vaz-Serra et al., 2006). 
 
2.2.3. Lifestyle related factors 
Physical Activity 
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Total minutes of physical activity per week and sedentary time per day were determined 
using the Portuguese version of the short-form of the International Physical Activity 
Questionnaire (IPAQ-SF) (Craig et al., 2003). IPAQ-SF provides information on time 
spent walking, in vigorous- and moderate intensity activity and in sedentary activity. Data 
from the IPAQ-SF were summed within each item (i.e., vigorous intensity, moderate 
intensity, and walking) to estimate the total amount of time spent in physical activity per 
week. The IPAQ-SF sitting question is an additional indicator variable of time spent in 
sedentary activity and is not included as part of any summary score of physical activity. 
Validity and reliability data from 12 countries (including Portugal) showed that the IPAQ-
SF is a valid and reliable measure of physical activity in general population (Craig et al., 
2003). Previous research in people with schizophrenia  (Faulkner et al., 2006) shows 
that the IPAQ-SF is a reliable and valid tool to assess physical activity levels in this 
population. 
 
Sleep quality 
Sleep quality was measured with the Pittsburgh Sleep Quality Index (PSQI) (Buysse, 
Reynolds, Monk, Berman, & Kupfer, 1989). This self-report questionnaire rates sleep 
quality and patterns during the previous month, and evaluates seven components of 
sleep: subjective quality, latency, duration, habitual efficiency, sleep disturbances, 
medication use, and daytime dysfunction. A global score of < 5 is used to discriminate 
between good and poor sleep quality. PSQI is a valid, reliable and standardised measure 
of sleep quality to be used in psychiatric patients (Buysse et al., 1989). This 
questionnaire has favourable psychometric properties, with internal consistency 
reliability of .83 and test-retest reliability of .85 (Buysse et al., 1989). PSQI has been 
previously used in Portuguese with people with schizophrenia (Afonso, Brissos, Canas, 
Bobes, & Bernardo-Fernandez, 2014; Afonso et al., 2011). 
 
Adherence to the Mediterranean diet 
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Dietary intake was recorded using a semi-quantitative food frequency questionnaire 
(FFQ), designed according to Willett (1998) and adapted to include a variety of typical 
Portuguese food items (Lopes, Aro, Azevedo, Ramos, & Barros, 2007). The FFQ 
comprised 86 food items or beverage categories, with a frequency section with nine 
possible responses (i.e., never to six or more times per day). Previous studies have used 
the FFQ to assess dietary intake in individuals with schizophrenia (Amani, 2007; 
Henderson et al., 2006). To the best of our knowledge no validation studies were 
conducted in this population. Nutrient intake data were obtained by multiplying the 
frequency of consumption of each food item by the nutrient content of the specified 
portion size, with once a day equal to one. The software program Food Processor Plus 
(ESHA Research, Salem, Oregon) was used, based on values from the US Department 
of Agriculture. Values for typical Portuguese foods were computed using the Portuguese 
Tables of Food Composition (Porto & Oliveira, 2006). Adherence to the Mediterranean 
diet was calculated according to the method developed by Trichopoulou et al. (1995), 
revised to include fish intake (Hu, Cho, Rexrode, Albert, & Manson, 2003). Each of the 
nine components was assigned a value of 0 or 1, using sex-specific median as the cut-
off. For beneficial components (i.e., vegetables, legumes, fruits and nuts, cereal, and 
fish), value of 0 was assigned when consumption was below the median and value of 1 
was assigned when consumption was at or above the median. For components 
presumed to be detrimental (i.e., meat, poultry, and dairy products), a value of 0 was 
assigned when consumption was at or above the median and a value of 1 was assigned 
when consumption was below the median. For alcohol, a value of 1 was assigned when 
consumption ranged between 5 and 25 g per day for women, and when consumption 
ranged between 10 and 50 g per day for men. For fat intake, the ratio of monounsaturated 
lipids to saturated lipids was used. Thus, the total Mediterranean diet score (MDS) 
ranged from 0 (minimal adherence to Mediterranean diet) to 9 (maximal adherence). 
 
Tobacco smoking behaviour 
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Tobacco smoking behaviour was recorded as smoking status, and for smokers, the 
number of cigarettes smoked per day. 
 
2.2.4. Psychological factors 
Self-esteem  
Self-esteem was assessed using the Portuguese version of the Rosenberg Self-Esteem 
Scale (Vasconcelos-Raposo, Fernandes, Teixeira, & Bertelli, 2012). The scale consists 
of 10 items (five positively and five negatively-coded items) measured on a 4-point Likert-
scale, from 1 (“strongly disagree”) to 4 (“strongly agree”). Negatively-worded items were 
reversed before subsequent analysis, allowing the calculation of a global score with 
values ranging between 10 and 40, where higher values represent higher levels of self-
esteem. This questionnaire was found to be valid and reliable in persons with severe 
mental illness (Torrey, Mueser, McHugo, & Drake, 2000). Specifically, in people with 
schizophrenia the questionnaire has successfully been used with both national (Salgado, 
Rocha, & Marques, 2008) and international samples (Jones et al., 2010; Kumar & 
Mohanty, 2016).  
 
Controlled and autonomous motivation 
Motivation towards physical activity was assessed using the Portuguese version of 
Behavioural in Regulation Questionnaire – version 3 (BREQ-3) (Cid et al., 2016). The 
BREQ-3 comprises 24-items related to six motivation subscales (amotivation, external 
regulation, introjected regulation, identified regulation, integrated regulation and intrinsic 
regulation). Each item was measured on a five-point Likert-scale, from 0 (“Not true for 
me”) to 4 (“Very true to me”). The mean of the six subscales was calculated on a five-
point scale to score the extent of each motivation type. 
This questionnaire was found to be valid and reliable in patients with schizophrenia 
(Costa et al., 2017). Following the previously mentioned study methodology, motivation 
towards physical activity was calculated according to controlled (i.e., external and 
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introjected regulation) and autonomous (i.e., identified, integrated and intrinsic 
regulation) motivation.  
 
2.3. Statistical analyses  
Demographic and clinical characteristics of the sample were expressed as either means 
and standard deviations or proportions, depending on the data type. Simple and multiple 
linear regression models were constructed where the dependent variable was QoL. 
Independent variables included: i) demographic, anthropometric and clinical measures 
(i.e., gender, employee, educational level, treatment condition, BMI and chlorpromazine 
-equivalent antipsychotic dosage); ii) lifestyle measures (i.e., physical activity 
behaviours, sleep quality, adherence to MDS and smoking habits) and; iii) psychological 
measures (i.e., self-esteem, autonomous motivation and controlled motivation). The 
MDS score was divided into tertiles. The respective tertiles of the score ranged from 0 to 
3 (tertile 1 – low) (reference), 4 to 5 (tertile 2 – moderate) and higher than 5 (tertile 3 – 
high).  
Stepwise multiple regression analyses were used to select the statistically significant 
variables to enter/remove in the final multivariable model. At each step, the independent 
variable not in the model that had the smallest p-value was entered, and variables 
already in the model were removed if their p-value was greater than the significance 
level. The model was terminated when no further variables were eligible for inclusion or 
removal. Regression coefficients and respective 95% confidence intervals (CI) were 
estimated. A significance level of p < 0.05 was used. SPSS version 24.0 was used in all 
analyses.  
 
 
3. Results  
3.1. Sample characteristics  
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A total of 115 Portuguese patients with a DSM-5 (American Psychiatric Association, 
2013) diagnosis of schizophrenia were include in the analysis. The sample 
characteristics are presented in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
 
Table 1. Demographic, anthropometric, clinical, lifestyle and psychological factors characteristics 
of people with schizophrenia (n=115). 
 
Variables M ± SD 
      - Demographic, anthropometric and clinical factors 
Age (years) 44.51 ± 9.81  
Sex n (%) female 29 (25%) 
Employment status n (%) employee 29 (25%) 
Educational level n (%) low 48 (42%) 
Treatment condition n (%) inpatients 58 (50%) 
BMI (kg/m2) 28.78 ± 5.47  
     Underweight and normal weight n (%) 27 (24%) 
     Overweight n (%) 41 (37%) 
     Obesity n (%) 47 (39%) 
Chlorpromazine-equivalent AP dose (mg/day) 565.87 ± 509.90  
      - Lifestyle-related factors 
Participation in PA  80 (70%) 
PA minutes per week 74.51 ± 64.453  
Sitting (min/ day) 343.21 ± 166.91  
Good Sleep quality n (%) 37 (32%) 
Mediterranean Diet score 4.04 ± 1.80  
Smoking habits n (%) smokers 75 (65%) 
Cigarettes per day 15.82 ± 9.07  
      - Psychological factors 
Self-esteem 29.44 ± 4.41  
Controlled motivation 1.34 ± 0.84  
Autonomous motivation 2.67 ± 0.82  
     - Quality of life 
Global domain 63.95 ± 21.40  
Physical domain 67.15 ± 13.60  
Psychological domain 65.81 ± 16.69  
Social domain 60.49 ± 19.75  
Environmental domain 63.11 ± 14.96  
 
M= mean; SD = standard deviation; mg/day = milligram per day; BMI = body mass index; PA = physical 
activity AP = antipsychotic. 
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3.2. Predictors of Global domain of QoL (multiple linear regression analyses: enter 
and stepwise method) 
 
Crude and adjusted coefficients and 95% CI with global domain of QoL as the dependent 
variable in multiple linear regression analyses are presented in Table 2. Total minutes of 
physical activity per week, sedentary time (i.e. minutes sitting per day), good sleep 
quality and self-esteem were significant predictive factors of global domain of QoL. 
Using stepwise multiple regression analysis, total minutes of physical activity per week 
(B = 0.10, p = 0.004), and self-esteem (B = 1.30, p = 0.02) were significant predictive 
factors of global domain of QoL, that explained 15.7% of this variance.  
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Table 2. Results multiple linear regression analyses: enter and stepwise method, with global 
domain of QoL as the dependent variable and demographical, anthropometric, clinical, lifestyle 
and psychological factors as independent variables. 
 
 
BMI = body mass index; PA = physical activity; min = minutes; (Gender: female = 0, male = 1; 
Educational level: lower = 0, higher = 1; Employment: without = 0, with = 1; Treatment condition: 
inpatient = 0, outpatient = 1; Sleep quality: poor sleep = 0, good sleep = 1; Tobacco smoking 
status: no = 0, yes = 1). 
Explanatory variable 
QoL Global domain 
Crude 
B (95% CI) 
 
p-value Adjusted 
B (95% CI) 
p-value 
- Demographic, anthropometric and clinical factors 
Gender  -3.57 (-12.96 to 5.81) 0.45   
Employee  8.75 (-0.63 to 18.14) 0.06   
Educational level 1.03 (-7.17 to 9.24) 0.80   
Treatment setting* -0.72 (-8.77 to 7.33) 0.85   
BMI (Kg/m2) 0.009 (-0.74 to 0.76) 0.98   
Chlorpromazine (mg/day) -0.007 (-0.01 to 0.00) 0.06   
- Lifestyle related factors 
Participation in PA  8.41 (0.19 to 17.03) 0.06   
PA min. total week 0.11 (0.05 to 0.17) <0.001 0.10 (0.03 to 0.16) 0.004 
Sitting min/ day -0.02 (-0.04 to 0.00) 0.04   
Sleep quality 10.95 (2.64 to 19.25) 0.01   
Adherence to Mediterranean Diet     
    Tertil 1 (low) Reference 63.06 (56.61 to 69.51)    
    Tertil 2 (moderate) 1.75 (-7.41 to 10.93) 0.70   
    Tertil 3 (high) 0.93 (-9.78 to 11.64) 0.86   
Tobacco smoking status 4.68 (-3.72 to 13.09) 0.27   
Cigarettes per day -0.24 (-0.82 to 0.33) 0.39   
     - Psychological factors 
Self-esteem 1.43 (0.55 to 2.31) 0.002 1.30 (0.18 to 2.42) 0.02 
Controlled motivation -1.40 (-6.16 to 3.35) 0.55   
Autonomous motivation 3.64 (-1.21 to 8.49) 0.14   
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3.2. Predictors of Physical, Psychological, Social and Environmental domains of 
QoL (multiple linear regression analyses: enter and stepwise method) 
 
Crude (multiple linear regression analyses: enter method) and adjusted (multiple linear 
regression analyses: stepwise method) coefficients and 95% CI with physical, 
psychological, social and environmental domains of QoL as the dependent variables are 
presented in Table 3. Participation in physical activity, total minutes of physical activity 
per week, good sleep quality, moderate adherence to MDS, when compared to low 
adherence, self-esteem and autonomous motivation were significant predictive factors 
of the physical domain of QoL. However, after using stepwise multiple regression 
analysis only participation in physical activity (B = 8.35, p = 0.004), good sleep quality (B 
= 7.43, p = 0.01) and self-esteem (B = 7.43, p = 0.01) contributed to predict the physical 
domain of QoL, that explained 35.3% of this variance.  
Total minutes of physical activity per week, sedentary time, good sleep quality, high 
adherence to MDS, tobacco smoking, self-esteem and autonomous motivation were 
significant predictive factors of the psychological domain of QoL. However, after using 
stepwise multiple regression analysis only autonomous motivation (B = 1.75, p = <0.001) 
and self-esteem (B = 4.56, p = 0.02) contributed to predict the psychological domain of 
QoL, that explained 30.8% of this variance. 
Employment status, sedentary time and self-esteem were significant predictive factors 
of the social domain of QoL. However, after using stepwise multiple regression analysis 
only employment status (B = 12.62, p = 0.01) was a significant predictive factor of the 
social domain of QoL, that explained 7% of this variance. 
Finally, employment status, total minutes of physical activity per week, number of 
cigarettes smoked per day, self-esteem and autonomous motivation were significant 
predictive factors of the environmental domain of QoL. However, after using stepwise 
multiple regression analysis only sedentary time (B = -0.02, p = 0.03), tobacco smoking 
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(B = -0.54, p = 0.004) and self-esteem (B = 0.81, p = 0.04) were significant predictive 
factors of the environmental domain of QoL, that explained 18.3% of this variance. 
 
 
 157 
 
Table 3. Results multiple linear regression analyses: enter and stepwise method, with the domains of QoL as the dependent variables and demographical, anthropometric, clinical, 
lifestyle and psychological factors as independent variables. 
BMI = body mass index; PA = physical activity; min = minutes; (Gender: female = 0, male = 1; Educational level: lower = 0, higher = 1; Employment: without = 0, with = 1; Treatment 
condition: inpatient = 0, outpatient = 1; Sleep quality: poor sleep = 0, good sleep = 1; Tobacco smoking status: no = 0, yes = 1). 
 Physical domain  Psychological domain 
 B (95% CI) p 
Adjusted 
B (95% CI) 
p 
 
B (95% CI) p 
Adjusted 
B (95% CI) 
p 
      - Demographic, anthropometric and clinical factors        
Gender  2.32 (-3.64 to 8.28) 0.44    -4.77 (-12.05 to 2.51) 0.19   
Employee  3.78 (-2.23 to 9.80) 0.21    3.61 (-3.79 to 11.02) 0.33   
Educational level -0.64 (-5.86 to 4.57) 0.80    2.12 (-4.26 to 8.52) 0.51   
Treatment setting* -1.12 (-6.23 to 3.99) 0.66    -2.42 (-8.68 to 3.84) 0.44   
BMI (Kg/m2) -0.27 (-0.74 to 0.20) 0.25    -0.56 (-1.14 to -0.01) 0.06   
Chlorpromazine (mg/day) -0.004 (-0.009 to 0.001) 0.13    -0.003 (-0.009 to 0.003) 0.36   
      - Lifestyle related factors        
Participation in PA  8.49 (3.16 to 13.82) 0.002 8.35 (2.72 to 13.99) 0.004  -0.18 (-7.01 to 6.65) 0.95   
PA min per week 0.06 (0.02 to 0.10) 0.001    0.05 (0.002 to 0.09) 0.04   
Sitting (min/ day) -0.01 (-0.02 to 0.00) 0.08    -0.02 (-0.03 to -0.002) 0.03   
Sleep quality 10.99 (5.96 to 16.02) <0.001 7.43 (1.70 to 13.16) 0.01  7.15 (0.61 to 13.69) 0.03   
 Adherence to Mediterranean Diet         
 Tertil 1 (low) Ref. 64.52 (60.50 to 68.55)     67.14 (62.27 to 72.00)    
 Tertil 2 (moderate) 5.89 (0.17 to 11.62) 0.04    1.85 (-5.06 to 8.77) 0.59   
 Tertil 3 (high) 1.61 (-5.06 to 8.30) 0.63    -9.14 (-17.22 to -1.06) 0.02   
Tobacco smoking status 2.99 (-2.34 to 8.33) 0.26    10.16 (3.85 to 16.47) 0.002   
Cigarettes per day -0.21 (-0.56 to 0.13) 0.22    0.01 (-0.37 to 0.41) 0.93   
      - Psychological factors        
Self-esteem 1.55 (1.04 to 2.05) <0.001 1.17 (0.56 to 1.78) <0.001  1.93 (1.31 to 2.55) <0.001 1.75 (1.05 to 2.44) <0.001 
Controlled motivation -1.04 (-4.06 to 1.97) 0.49    -2.11 (-5.80 to 1.58) 0.26   
Autonomous motivation 3.67 (0.63 to 6.71) 0.01    5.47 (1.79 to 9.15) 0.004 4.56 (0.82 to 8.29) 0.02 
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Table 3. Continued 
BMI = body mass index; PA = physical activity; min = minutes; (Gender: female = 0, male = 1; Educational level: lower = 0, higher = 1; Employment: without = 0, with = 1; Treatment 
condition: inpatient = 0, outpatient = 1; Sleep quality: poor sleep = 0, good sleep = 1; Tobacco smoking status: no = 0, yes = 1). 
 Social domain  Environmental domain 
 B (95% CI) p 
Adjusted 
B (95% CI) 
p 
 
B (95% CI) p 
Adjusted 
B (95% CI) 
p 
      - Demographic, anthropometric and clinical factors        
Gender  5.69 (-2.92 to 14.31) 0.19    -1.42 (-7.99 to 5.15) 0.66   
Employee  11.38 (2.85 to 19.92) 0.009 12.62 (2.75 to 2.49) 0.01  8.43 (1.96 to 14.90) 0.01   
Educational level -2.27 (-9.83 to 5.29) 0.55    -2.70 (-8.41 to 3.01) 0.35   
Treatment setting* -2.60 (-10.02 to 4.80) 0.48    -3.82 (-9.40 to 1.75) 0.17   
BMI (Kg/m2) -0.56 (-1.25 to 0.11) 0.10    -0.01 (-0.54 to 0.50) 0.94   
Chlorpromazine (mg/day) -0.002 (-0.01 to 0.005) 0.50    0.002 (-0.003 to 0.008) 0.45   
      - Lifestyle related factors        
Participation in PA  4.50 (-3.52 to 12.54) 0.26    0.89 (-5.22 to 7.01) 0.77   
PA min per week 0.02 (-0.02 to 0.08) 0.33    0.05 (0.008 to 0.09) 0.01   
Sitting (min/ day) -0.02 (-0.05 to -0.007) 0.009    -0.01 (-0.03 to 0.003) 0.10 -0.02 (-0.04 to -0.002 0.03 
Sleep quality 5.52 (-2.30 to 13.35) 0.16    4.00 (-1.93 to 9.93) 0.18   
 Adherence to Mediterranean Diet         
 Tertil 1 (low) Ref. 60.98 (55.06 to 66.91)     63.92 (59.42 to 68.42)    
 Tertil 2 (moderate) -2.65 (-11.08 to 5.77) 0.53    -2.22 (-8.62 to 4.17) 0.49   
 Tertil 3 (high) 2.35 (-7.49 to 12.19) 0.63    0.19 (-7.27 to 7.67) 0.95   
Tobacco smoking status 3.96 (-3.79 to 11.73) 0.31    -0.65 (-6.56 to 5.25) 0.82 -0.54 (-0.90 to -0.17) 0.004 
Cigarettes per day -0.17 (-0.67 to 0.33) 0.49    -0.58 (-0.96 to -0.20) 0.003   
      - Psychological factors        
Self-esteem 0.83 (0.001 to 1.67) 0.05    0.93 (0.32 to 1.55) 0.003 0.81 (0.04 to 1.58) 0.04 
Controlled motivation 0.67 (-3.71 to 5.07) 0.76    1.87 (-1.43 to 5.18) 0.26   
Autonomous motivation 3.66 (-0.80 to 8.13) 0.10    4.09 (0.75 to 7.43) 0.01   
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4. Discussion  
The influence of lifestyle-related factors on QoL in people with schizophrenia is an 
important issue in clinical practice. However there have been few studies that have 
examined role of lifestyle-related factors (i.e., physical activity, sleep quality, smoking 
and dietary habits) and their impact on QoL in this population. Results of this study 
demonstrated that, physical activity behaviours and self-esteem predicted better QoL 
across all domains in people with schizophrenia. In addition, good sleep quality was a 
significant predictor of global, physical and psychological domains of QoL. Finally, 
autonomous motivation was identified as an important predictor of physical, 
psychological and environmental domains of QoL. After controlling variables, self-
esteem was identified as the most significant predictor of QoL (with exception of social 
domain) in this population. 
 
4.1 Demographic, anthropometric and clinical measures 
Of all the demographic variables, employment status was the only parameter significantly 
associated with QoL. Results demonstrated that employment status was a significant 
predictor of better QoL across both social and environmental domains. In addition, after 
controlling all variables, employment status was the only significant predictor of social 
domain.  These results support the findings of previous studies (Cai & Yu, 2017; Chou 
et al., 2014; Li et al., 2017; Marwaha et al., 2008; Priebe, Warner, Hubschmid, & Eckle, 
1998) which found that current employment is associated with better QoL in people with 
schizophrenia. In addition to benefits such as access to financial resources, employment 
is also associated with reduced hospital readmission rates (Rummel-Kluge, Pitschel-
Walz, Bauml, & Kissling, 2006), less severe symptoms (Bond et al., 2001; Mueser et al., 
1997), improved positive affect (Priebe et al., 1998), self-esteem, self-efficacy (Bond et 
al., 2001; Mueser et al., 1997; Priebe et al., 1998), feelings of a socially valued role 
(McGurk, Mueser, DeRosa, & Wolfe, 2009) and personal safety and leisure satisfaction 
(Priebe et al., 1998). It is likely that people with schizophrenia who are employed are 
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more likely to have a more positive perception regarding the social and environmental 
domains of QoL.  
Contrarily to previous studies (Bressington et al., 2016; Faulkner et al., 2007; Kolotkin et 
al., 2008; Sugawara et al., 2013; Vancampfort et al., 2011) in the present study, BMI was 
not found as a significant predictor of QoL. Although, in the psychological domain results 
of linear regression was near the significant value. In people with schizophrenia the 
ethology of weight gain and obesity includes adverse effects of antipsychotics, unhealthy 
lifestyle behaviours, and psychosocial and socioeconomic risk factors (Manu et al., 
2015). Specifically regarding psychosocial factors, low interest in social achievement, 
social isolation, and unemployment can lead to decreased levels of participation in 
physical activity (Daumit et al., 2013). In addition, due to the physical, psychological and 
social consequences of obesity, it is important to highlight that obesity may directly, and 
also indirectly, influence QoL in people with schizophrenia. Therefore, clinicians should 
support and motivate persons to participate in weight reduction programmes, and these 
should be included as part of routine care. 
 
4.2 Lifestyle-related factors 
This study revealed that physical activity behaviour was a significant predictor of better 
QoL in all domains of the WHOQOL-BREF. Additionally, total minutes of physical activity 
per week was a significant predictor of global QoL, even when gender, BMI and smoking 
were included in the regression model. These results were similar to the recent study of 
Dennik et al. (2017), where the authors reported that physical activity was associated 
with QoL in people with severe mental illness (about 77% of the sample had 
schizophrenia). In the Dennik study, physical activity was found to be a significant 
predictor of physical, psychological and social QoL. The results obtained in the present 
study were also consistent with previous findings, where active behaviours are positively 
associated with better QoL in people with schizophrenia (Acil, Dogan, & Dogan, 2008; 
E. Gomes et al., 2014; Vancampfort et al., 2011). The present study highlights the 
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importance of physical activity for people with schizophrenia. It is recognized that 
physical activity should be prescribed as an adjunct treatment in psychiatric rehabilitation 
(Vera-Garcia, Mayoral-Cleries, Vancampfort, Stubbs, & Cuesta-Vargas, 2015), due to 
the psychological (Dauwan, Begemann, Heringa, & Sommer, 2016) and physical 
benefits (Gorczynski & Faulkner, 2010).  
Good sleep quality was found to be associated with global, physical and psychological 
domains of QoL. Previous research reported significant associations between these two 
variables in people with schizophrenia. Afonso et al. (2014) and Ritsner et al. (2004) 
found that lower values of QoL correlated with worse sleep quality. Li et al. (2017) found 
that patients with sleep problems presented poorer Qol, compared to those without sleep 
problems. In multiple regressions analyses, Hofstetter et al. (2005) reported that poor 
sleep quality predicted low QoL. Therefore, sleep quality should be considered a critical 
factor for QoL in people with schizophrenia, and clinicians should provide specific 
interventions to address sleep problems (e.g., avoiding naps, and training regular waking 
and sleep times), in order to improve QoL in this population. 
Moderate to high adherence to MDS was associated with better QoL in physical and 
psychological domains. However, after including the remaining variables in the 
regression analysis, significant results were not found. We were not able to identify 
comparable studies from other clinical samples. Two studies with non-clinical 
populations showed that the adherence to the MDS seems to be an important factor 
associated with a better QoL (Henriquez Sanchez et al., 2012; Munoz et al., 2009). MDS 
has been associated with lower cardiovascular risk, prevention of cognitive deterioration 
and decreased all-cause mortality (Feart et al., 2009). Specifically, cardiovascular 
disease is highly prevalent among people with schizophrenia, and is the leading cause 
of death in this population (Brown, Kim, Mitchell, & Inskip, 2010).  MDS has also been 
associated with lower odds of depression and favourable mental and physical health 
outcomes in a sample of obese and type 2 diabetes patients (Schroder, 2007). Therefore 
it is possible that benefits related to adherence to MDS could positively affect QoL in 
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people with schizophrenia. The MDS refers to not only the type of food consumed, but 
also lifestyle and social customs associated with eating.  
Despite the impact of an adequate diet on the burden of preventable diseases, 
knowledge regarding the dietary habits of people with schizophrenia or other severe 
mental illness is limited (Teasdale, Ward, & Samaras, 2017). This population infrequently 
receive evidence-based dietary advice (Teasdale, Ward, & Samaras, 2017). In fact, 
although limited randomized controlled trials actually measured changes in food intake, 
those that did tended to find improvements in dietary intake in severe mental illness 
population (Teasdale, Ward, Rosenbaum, Samaras, & Stubbs, 2017). Therefore, more 
research is needed and feasible and acceptable dietary interventions should be 
provided. 
In the present study tobacco smoking habits were found to be associated with better 
QoL, in the psychological domain. In the study of Munikanan et al. (2017), multiple 
regression analyses showed that smoking habits predicted better QoL, reaching 
statistical significance in the physical domain. It is possible that tobacco smoking could 
alleviate schizophrenia symptomatology, particularly negative symptoms, by improving 
the sensory gating and cognitive deficits (Kumari & Postma, 2005; Winterer, 2010). In 
the present study tobacco smoking habits were also found to be associated with poor 
QoL in the environmental domain. Results showed that smokers presented poor QoL in 
this domain, when compared to non-smokers. Specifically in the smokers’ sample, a 
higher the number of cigarettes smoked per day was associated to a poor QoL in the 
environmental domain. The environmental domain of WHOQOL-BREF represents, 
among others, the perception concerning the physical environment. Therefore, smokers 
can perceive their physical environment as unhealthy and also restricted, due to the 
increased rates of smoking-restricted environments prevalent in the community, and 
consequently reported poor QoL in this domain.  
 
4.3 Psychological factors 
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Regarding psychological factors, this study revealed that self-esteem predicted QoL in 
all domains of the WHOQOL-BREF. Additionally, after controlling variables self-esteem 
was found to be a significant predictor of global, physical, psychological and 
environmental domain. These results are consistent with previous findings, regarding the 
relationship between low self-esteem and low QoL in people with schizophrenia (Brekke 
et al., 2001; Gureje et al., 2004). Chou et al. (2014) analysed five factors including 
sociodemographic, clinical, psychopathological, neurocognitive, and psychosocial 
factors as potential determinants of QoL in people with schizophrenia. They found that 
QoL was most strongly affected by psychosocial factors, when self-esteem, self-efficacy 
and social stigma was included. People with schizophrenia with high self-esteem 
experienced confidence and optimism, exhibit better adaptation abilities, are highly 
motivated and have a greater chance of succeeding in work tasks and achieving their 
goals (Jones et al., 2010). When experiencing low self-esteem, they experience feelings 
of loneliness, adopt a defensive attitude towards others, suffer from anxiety and 
underestimate their actual capabilities (Jones et al., 2010). All these characteristics 
highlight the importance of self-esteem in relation to QoL in people with schizophrenia. 
Therefore, rehabilitation should focus on improving self-esteem, self-worth and self-
efficacy, to positively impact QoL in people with schizophrenia.   
Finally, autonomous motivation was associated with better QoL in physical, 
psychological and environmental domains. In addition, together with self-esteem, 
autonomous motivation was a significant predictor of the psychological domain of QoL. 
Autonomous motivation is related to a sense of security, connectedness and lower 
feelings of shame, self-worth and depression (Ryan & Deci, 2000). These feelings may 
explain why people with schizophrenia who are more autonomously motivated report a 
better physical, psychological and environmental QoL.   
In the present study, autonomous motivation is presented as an index incorporating 
identified, integrated and intrinsic regulations, which it is related with more self-
determined forms of behavioural regulation (Deci & Ryan, 2000). In rehabilitation and 
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healthcare settings, autonomous motivation has been linked to positive behavioural 
health outcomes, such as improved diabetes self-management and vocational 
rehabilitation engagement, increased physical activity and smoking cessation (Fortier, 
Sweet, O'Sullivan, & Williams, 2007; Moran, Russinova, Yim, & Sprague, 2014; Williams 
et al., 2006; Williams, McGregor, Zeldman, Freedman, & Deci, 2004). Specifically, in 
people with schizophrenia, autonomous motivation is known to be related to fewer 
negative symptoms (Vancampfort et al., 2015), higher physical activity participation 
(Vancampfort et al., 2013) and long-term maintenance of physical activity (Vancampfort, 
Vansteenkiste, et al., 2014).  
Improve physical health (e.g., weight lost) and psychological well-being (e.g., reduction 
of mood and stress) were identified as the most common motivating factors to participate 
in physical activity in people with severe mental illness (predominantly schizophrenia) 
(Firth et al., 2016). Therefore, due to the importance that autonomous motivation can 
have in the adoption and maintenance of health-promoting behaviours (Vancampfort et 
al., 2013; Vancampfort, Vansteenkiste, et al., 2014) and in the QoL of people with 
schizophrenia, clinical practice guidelines should highlight the importance of more self-
determined forms of behavioural regulation.  
 
 
4.4 Limitations and future research 
A number of methodological limitations need to be considered when interpreting these 
findings. This study is a cross-sectional study and therefore directionality of the 
relationships observed cannot be determined. The participants were recruited using 
convenience sampling, therefore sample size was not priori calculated. Consequently, 
further studies with a larger sample and including a balance number of female 
participants are recommended.  
Self-report measures can result in inaccurate assessment of variables of interest. For 
example, in the IPAQ-SF, people with schizophrenia might experience difficulties in 
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properly identifying the frequency, duration and intensity of physical activity. Therefore, 
accurate self-report measures of physical activity levels among this population is crucial 
(Rosenbaum, Ward, & International Working, 2016). Additionally, future studies can 
incorporate an objective measure of PA (e.g., pedometers or accelerometers). 
Regarding the assessment of QoL, it is recognized that there is still a need for 
standardized disease specific QoL measures for people with schizophrenia (Awad & 
Voruganti, 2012; Karow, Wittmann, Schottle, Schafer, & Lambert, 2014). There is no 
consensus about which instrument should be used for measuring QoL in this population 
(Karow et al., 2014). WHOQOL-BREF was identified as one of the generic QoL scales 
most often used in research with people with schizophrenia (Karow et al., 2014). The 
Portuguese version of WHOQOL-BREF was found to be a valid and reliable instrument 
in clinical population (Vaz-Serra et al., 2006) and was previously used in people with 
schizophrenia (E.  Gomes et al., 2016; E. Gomes et al., 2014). Future studies should 
provide a combination of standardized generic and disease specific QoL instruments.  
The Mediterranean Diet Score is determined on the sex-specific median value of 9 food 
groups assigning equal weights for individual components of the score and presumed 
the same importance for every component.  However, this is acknowledge as a study 
limitation, Mediterranean Diet Score have been widely used and associated to reduction 
of mortality and no communicable diseases (Feart et al., 2009; Schroder, 2007). 
The positive relationship between physical activity behaviours and QoL found in the 
present study should also need to be interpreted with caution, due to the lack of direct 
mechanisms between physical activity and schizophrenia. For example, biochemical 
changes (e.g., increased levels of neurotransmitters) and psychological changes (e.g., 
sense of autonomy, social support and self-efficacy) can explain improvements in 
positive and negative symptoms through physical activity (Firth, Cotter, Elliott, French, & 
Yung, 2015; Vancampfort et al., 2010; Vancampfort, Probst, et al., 2014). Pajonk et al. 
(2010) also reported that aerobic fitness improvements following physical activity were 
associated with enhancements in short-term memory, along with increases in 
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hippocampal volume. However, more interventional and longitudinal research regarding 
the physical activity mechanisms is needed. 
The specific psychopathological symptoms of the sample and medication were not 
formally assessed, and the impact of these could not be examined, which another 
limitation of present study. Namely depressive and negative symptoms have been 
described as associated with poor QoL (Fitzgerald et al., 2001; Norman et al., 2000; 
Tomotake, 2011).Regarding medication, some psychotropic medications can influence 
the lifestyle-related factors of people with schizophrenia. For example in the sleep, it is 
recognized that to deal with sleep disturbances sleep-inducing medication is often 
prescribed or antipsychotics are chosen because of their enhanced sedative properties 
(Wilson & Argyropoulos, 2012). In physical activity, the sedative effects of psychotropic 
medications can inhibit an active behaviour (Soundy, Stubbs, Probst, Hemmings, & 
Vancampfort, 2014). Therefore, future research should examine whether the impact of 
psychopathology and medication as a modifying variable.  
 
 
5. Conclusion 
This study investigated the effects of lifestyle-related factors and psychological factors 
on QoL in people with schizophrenia. The results demonstrated that all these factors had 
comparatively large influence in the QoL of this population, highlighting the importance 
of physical activity behaviours and self-esteem. 
To the best of our knowledge, this study was the first to a simultaneously evaluate 
lifestyle-related factors and psychological factors and their relationship with QoL in 
people with schizophrenia. The present findings have implications for psychosocial and 
psycho-educational treatments aimed at increasing the self-esteem and motivation 
towards physical activity, as well as improving positive lifestyle behaviours in people with 
schizophrenia. Clinicians should consider using routine lifestyle risk stratification in this 
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population and work to develop and implement individualized physical health promotion 
interventions targeting modifiable lifestyle factors. 
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General discussion  
 
 Main findings 
 
This doctoral thesis deals in more detail with issues in the dimension of lifestyle-related 
factors that generate a lower level of physical health, influencing the QoL of patients with 
schizophrenia. Therefore, the general purpose of this doctoral thesis was to explore 
lifestyle-related factors and psychological determinants, and to analyse the impact of 
these in QoL of patients with schizophrenia. Due to the fact that the research questions 
and respective results have already been extensively reported in previously studies, only 
a brief summary is provided here. 
 
Despite the promising evidence that PA is an effective non-pharmacological intervention 
to reduce comorbidities in patients with schizophrenia (Beebe et al., 2005; Cimo et al., 
2012; Dauwan et al., 2016; Vancampfort, Probst, et al., 2013), only a minority of patients 
practice PA at a level compatible with public health recommendations (Sharpe et al., 
2006). One explanation for this is that many patients lack sufficient motivation to adopt 
and maintain an active lifestyle (Soundy et al., 2014; Vancampfort, De Hert, et al., 2015; 
Vancampfort, De Hert, et al., 2013). Nevertheless, a better understanding of the 
motivational deficits in patients with schizophrenia, may hold the key to increasing PA in 
this population. Although a theoretically based research investigating the motivational 
processes linked to the adoption and maintenance of PA in patients with schizophrenia 
is needed, there is a lack of reliable and valid instruments to determine the processes 
that motivate this patients to practice PA. Therefore, due to the limited comprehensive 
psychometric analyses of the BREQ-2 in patients with schizophrenia, specifically in the 
Portuguese context, the purpose of the Study 1 was to examine the construct validity of 
the Portuguese version of the BREQ-2 and the Portuguese version of the BREQ-3 in this 
population. Results demonstrated that the Portuguese BREQ-2 has acceptable construct 
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validity and is adequate to be used in clinical and research settings. The preliminary 
analysis of the construct validity of the Portuguese version of the BREQ-3 revealed that 
this version is an appropriate measure to assess controlled and autonomous motivation 
for PA in patients with schizophrenia. The findings achieved in this study revealed special 
importance in clinical practice, because it will allow mental health professionals to identify 
and follow the motivational processes related to PA in patients with schizophrenia, and 
consequently, to promote interventions that are experienced as pleasant and enjoyable 
so that patients are engaged for intrinsic reasons. 
 
In addition to the lack of motivation, others several factors (e.g., lower education and 
socio-economic status, longer illness duration, presence of negative symptoms, side-
effects of antipsychotic medication, cardio-metabolic comorbidity, lack of social support 
and lower self-efficacy) could be identified as determinants to achieve active behaviours 
in patients with schizophrenia (Johnstone, Nicol, Donaghy, & Lawrie, 2009; McDevitt et 
al., 2006; Soundy et al., 2014; Vancampfort, Knapen, et al., 2012). For that reason, in 
the Study 2 we aimed to explore the association between factors which are recognized 
as a determinants to PA. Demographic, anthropometric, clinical, physical and 
psychological factors were included. Results revealed that of all the candidate factors to 
predict PA, autonomous motivation and global domain of QoL were found as significant 
predictors. These results highlight the importance of autonomous motivation and QoL in 
order to improve PA behaviour in patients with schizophrenia. Therefore, the achievements 
of this study could contribute to the effectiveness of PA interventions, which must 
adequately address the barriers to activity and promote factors that enable it. 
 
Another factor that could influence PA behaviours in patients with schizophrenia is the 
sleep quality. In general population, sleep and PA influence each other through complex, 
reciprocal interactions including multiple physiological and psychological pathways 
(Chennaoui et al., 2015). Specifically, insufficient sleep has been identified as an 
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associated risk factor for major public health concerns namely obesity, type 2 diabetes, 
cardiovascular diseases and depression (Cappuccio, D'Elia, Strazzullo, & Miller, 2010; 
Grandner, Hale, Moore, & Patel, 2010; Knutson, 2010), comorbidities that are prevalent 
in patients with schizophrenia (Cimo et al., 2012; Correll et al., 2017; Crump et al., 2013). 
In addition to poor physical health, poor sleep quality is also prevalent in this patients, 
affecting activities of daily living, psychiatric symptoms (e.g., positive symptoms) and 
QoL (Afonso et al., 2011; Brissos et al., 2013; Hofstetter et al., 2005; Ritsner et al., 2004; 
Waters et al., 2012). A significant body of research confirmed the effects of PA on sleep 
in general population (Chennaoui et al., 2015; Kredlow et al., 2015). However, 
comparable data for patients with schizophrenia are lacking. Therefore, the Study 3 had 
as main purpose to assess the associations between PA levels and sleep quality. The 
results revealed that sleep quality was positively associated with time of moderate and 
total PA per week. In the same line, in the Study 4 we found that patients of regular 
physical active group have better quality of sleep and QoL. These achievements 
highlights the importance of PA as a non-pharmacological approach for sleep quality in 
patients with schizophrenia. Although pharmacological approach is the main strategy 
used to tackle sleep problems for these patients (Wilson & Argyropoulos, 2012), patients 
prefers to take less medication (Peacey et al., 2012) and are interested in behavioural 
sleep interventions (Huthwaite, Miller, McCartney, & Romans, 2014). Therefore, PA 
should be include in the treatment of sleeping problems, to reduce sleep medication, and 
to improve sleep quality and quality of life in patients with schizophrenia.  
 
In addition to PA and sleep, an adequate diet is also considered as highly important to a 
healthy lifestyle. Unhealthy diet is leading global risks to health (World Health 
Organisation, 2015). Contrarily, an adequate diet improve weight lost, insulin resistance, 
dyslipidemia and hypertension in people with mental illness (Bonfioli et al., 2012; Bruins 
et al., 2014; Wu et al., 2007). For these reasons, diet and factors underlying poor dietary 
patterns may represent an important therapeutic target to control metabolic 
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abnormalities in patients with schizophrenia (Dipasquale et al., 2013). Therefore, Study 
5 was carried out to deal with the lack of research regarding dietary intake, diet quality 
and schizophrenia in Portuguese reality, and also to promote new evidence regarding 
the relationship between diet quality and lifestyle-related factors in patients with 
schizophrenia. Results revealed that analysing macro- and selected micro-essential 
nutrients patients reported higher values of proteins and the majority of the vitamins 
compared with reference values. Contrarily, values reported for total carbohydrates and 
total fats were consistent with reference values. In the adherence to Mediterranean diet, 
results demonstrated that outpatients reported significant higher consumptions of meat 
and meat products group and fruits and nuts group, compared with inpatients. Finally, 
regarding lifestyle-related factors, results showed that adherence to Mediterranean diet 
was significantly higher in non-smokers, compared with smokers. These findings 
represent an added value for existing literature. Due to the limited information concerning 
dietary practices and nutritional requirements in patients with schizophrenia, the findings 
could positively influence clinical practice. Specifically, the new evidence about the 
characteristics of diet in inpatients and outpatients provides targets for lifestyle 
interventions. 
 
The previous studies (Study 3, 4 and 5) confirmed the existent literature, revealing that 
patients with schizophrenia presents inadequate lifestyles (Deuschle et al., 2013; 
Gardner-Sood et al., 2015; Gutierrez-Rojas et al., 2016; Olsson et al., 2015). The results 
of these studies demonstrated the need to understand the underlying lifestyle-related 
factors associated with QoL in patients with schizophrenia. Therefore, Study 6 was 
carried out, in order to simultaneously analysed lifestyle-related factors (i.e., PA, sleep 
quality, smoking and dietary habits) and psychological determinants on QoL of patients 
with schizophrenia. Results demonstrated that PA behaviours and self-esteem predicted 
better QoL across all domains. In addition, positive sleep behaviours were a significant 
predictor of global, physical and psychological domains of QoL. Finally, autonomous 
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motivation was identified as an important predictor of physical, psychological and 
environmental domains of QoL. The results achieved have implications for psychosocial 
and psycho-educational treatments aimed at increasing the self-esteem and motivation 
towards PA, as well as improving healthy lifestyle behaviours in patients with 
schizophrenia. 
 
 
Practical implications  
 
First of all, and regarding the importance of autonomous motivation for a healthy and 
active lifestyle in patients with schizophrenia (Soundy et al., 2014; Vancampfort, De Hert, 
et al., 2015; Vancampfort, De Hert, et al., 2013), clinical practice guidelines should 
highlight the importance of autonomous motivation. Based on SDT, the transition from 
controlled to autonomous motivation can be facilitated in environments that support three 
psychological constructs, namely need for autonomy (i.e., experiencing a sense of 
psychological freedom when engaging in PA), competence (i.e., ability to attain desired 
outcomes) and relatedness (i.e., being socially connected) (Deci & Ryan, 1985, 2000). 
Regarding autonomy, it is important that clinicians support the needs for autonomy of 
the patients. For example, to take the perspective of the patient, support their choices, 
minimize pressure, offering relevant information for changing PA behaviour and using 
autonomy supportive language (Farholm & Sorensen, 2016; Vancampfort, De Hert, et 
al., 2015; Vancampfort, De Hert, et al., 2013). Concerning competence, feelings of 
competence are obtained when patients are succeed in PA tasks. For that reason is 
important to offer activities that are experienced as pleasant and enjoyable as well as 
provide optimally challenging tasks tailored to the capabilities of the patient (Sorensen, 
2006; Vancampfort, De Hert, et al., 2013). Sufficient instructions and positive feedback 
are also needed. Finally, regarding relatedness it is important that clinicians create an 
empathetic and positive environment, to show unconditional regard, enthusiasm and 
 185 
 
interest in their patients. Increase the feeling of relatedness and decrease de the feeling 
of being isolated can be promoted by offering group session of PA (Farholm & Sorensen, 
2016; Vancampfort, De Hert, et al., 2015; Vancampfort, De Hert, et al., 2013).  
 
Secondly, to improve sleep quality in patients with schizophrenia, attention for sleep 
disturbances should be incorporated into standard clinical care. The importance of non-
pharmacological interventions, namely PA should be highlighted by clinicians, offering 
psycho-education sessions that are considered as an essential component of the therapy 
program. Other strategies, focusing on regular waking and sleep times, avoiding naps 
and morning bright light are also recommend (Afonso, Figueira, & Paiva, 2014; 
Klingaman, Palmer-Bacon, Bennett, & Rowland, 2015). 
 
Third, regarding the importance of diet quality and factors underlying dietary patterns for 
metabolic abnormalities in patients with schizophrenia, some interventions (e.g., weight 
management, cardiometabolic intervention strategies, PA interventions, dietary 
assessment and specific nutritional cares) should be include on psycho-educational 
treatments in this population. It was demonstrated that patients with schizophrenia need 
counselling concerning dietary intake, namely regarding caffeine consumption, energy 
intake, fibre and folate. At the same time intervention targets should also focus on better 
dietary pattern, for example increase the consumptions of fruit, vegetables and 
wholegrains, as well as in the reduction of processed and sweetened foods. Is important 
to highlight that, in order to ensure the effectiveness of these interventions, the 
integration of dietitians and PA professionals (with qualification in mental illnesses) within 
the interdisciplinary mental health teams should be considered. Only these qualified 
professionals will ensure an adequate management of barriers, challenges, symptoms 
characteristics and effects of antipsychotic medications in patients with schizophrenia. 
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Lastly, the results achieved in Study 6, showing that self-esteem is a predictor of all 
domains of QoL, suggests that assessment of self-esteem should be conducted as part 
of outcome evaluations (Gureje et al., 2004). In patients with schizophrenia, PA 
participation could leads to appropriate psychosocial adjustment, which consequently is 
linked to body weight and image, self-value and physical well-being of each patient 
(Maggouritsa et al., 2014). These improvements could help the patients to adopt more 
healthy attitudes as part of their everyday routine improving their psychological well-
being. For these reasons, PA should be provided as pleasant and enjoyable in order to 
ensure adherence, allowing physical self-perception enhancement to take place. To 
ensure this, the goals of PA should be concrete, specific, and short-range provide greater 
motivation, and evidence of efficacy, allowing patients with schizophrenia to identify the 
specific behaviours needed for successful achievement of their objectives. In this sense, 
clinicians should provide a PA intervention focus on confidence in the physical self, in 
goal achievement and success experiences and on perceived improvements in physical 
fitness (Vancampfort, De Hert, et al., 2011). In addition, clinicians should try to anticipate 
the detrimental effects of a low physical self-perception. This can be ensure, for example 
in conversations about barriers that patient perceived for PA participation. An individual 
treatment plan taking into account these barriers will increase the confidence of the 
patient and consequently will promote the success of PA participation (Vancampfort, De 
Hert, et al., 2011). 
 
 
This doctoral thesis is among the first Portuguese data on lifestyle-related factors and 
psychological determinants, therefore is a first step in achieving culture change and to 
ensure that physical health in Portuguese patients with schizophrenia is looked after. 
Namely the importance of PA for physical and mental health, which should be integrated 
in educational and intervention programs regarding lifestyle behaviours, to increase and 
assist health-promoting behaviours among patients with schizophrenia. This because in 
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Portugal there is still a significant lack of awareness regarding the benefits of PA for 
patients with schizophrenia.  
In the last decades, a growing evidence base has shown the importance of PA for 
physical, physiological, psychological and social domains in patients with schizophrenia. 
However there still a gap between research and changes in clinical practice. In fact, 
integrating PA as a therapeutic intervention requires a shift in culture and system reform, 
from the design of mental health facilities through to changing staff attitudes 
(Vancampfort, Stubbs, Ward, Teasdale, & Rosenbaum, 2015). Concerning that, for a 
successful incorporation of PA into standard clinical care for this population, changes in 
the health care system are needed. In order to achieve the progress and consequently 
increase the credibility of PA as a therapeutic modality in mental health services, 
important challenges should be considered, namely, i) not to underestimate the value of 
PA as a therapeutic approach in promoting physical and mental well-being; ii) mental 
health should have the same priority as physical health; iii) to ensure the integration of 
PA professionals (with qualification in mental illnesses) within the interdisciplinary mental 
health teams and; iv) an optimal alliance between mental health services and society 
(e.g., promote PA events to facilitate the reduction of individual and social stigma towards 
mental illness, acting as an instrument to fight discrimination and promote the inclusion 
of patients with schizophrenia in the community).  
 
Methodologic considerations  
 
Strengths of this doctoral thesis include the instrument validation, exploring new 
variables that are undeveloped in this population and novelty of the analyses of 
combined associations of lifestyle-related factors and psychological determinants in QoL 
of patients with schizophrenia. The findings highlight the importance to considered 
adequate lifestyle behaviours, specifically an active behaviour, in order to have an impact 
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on physical health and consequently on QoL. Therefore, we hope that our outcomes can 
influence interventions integrated in patient’s treatment. For this, evidence-based 
practice sustain that clinicians should considerer, for one hand research evidence, and 
for another hand take into consideration preferences and patient’s choices and also their 
own clinical expertise. As such, standardized assessment tools are likely to become 
increasingly important in daily clinical practice. In fact, integrating standardized 
assessment of for example PA behavior, motivation to PA, self-esteem, sleep quality, 
dietary intake and QoL into clinical practice and using this information to guide monitor 
clinical decisions will improve the quality, efficiency and effectiveness of the psychiatric 
treatment. However, the equipment required for an assessment of these variables is 
often expensive and very sophisticated and may not always be available to the clinician. 
In light of this demands, the present thesis was based in instruments that can be easily 
administrated in psychiatry centers and allow a large number of participants to be tested 
simultaneously, without financial costs.  
 
Some limitations can be drawn from this doctoral thesis. First, all the studies are cross-
sectional and therefore directionality of the relationships observed cannot be determined. 
Second, the selection of subjects was also a limitation as patients with low symptoms 
are not likely to be representative of the patient population as a whole. Therefore, these 
results may not be extrapolated to patients whose symptoms are severe. Third, self-
report measures can result in inaccurate assessment of variables of interest. 
Notwithstanding the reliability and validity of the IPAQ-SF in patients with schizophrenia 
(Faulkner et al., 2006), they might experience difficulties to properly identify the 
frequency, duration and intensity of PA. Regarding Rosenberg Self-esteem Scale, is a 
method that has received some criticism (Andrews & Brown, 1993; Barrowclough et al., 
2003b) and has not been specifically validated for use in this population. Nevertheless, 
although there are limitations to this questionnaire, it is the most widely used self-report 
measure of self-esteem and is sensitive to change. Concerning dietary patterns, semi 
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quantitative food frequency questionnaire (FFQ) represent a subjective and retrospective 
method, for that reason misreporting of portion size, food type and preparation methods 
occurs. Lack of reference values or an incongruence on reference values reported can 
represent a barrier for a possible understanding about nutritional patterns in people with 
schizophrenia. In addition, current formulas for under-reporting of dietary intake can over 
estimate energy requirements in this population.  Although all participants were informed 
about the anonymously analyze of the data, a bias in the sense of social desirability 
cannot be ruled out. Finally, the specific psychopathological symptoms (e.g., medication 
side effects, length of illness, depressive symptomatology) of the sample were not 
formally assessed, and the impact of these could not be examined on our analyses. This 
situation was more visible on Study 6, when the levels of explained variance of the 
models confirm the complex constructs of QoL, in which many individual aspects of 
psychopathological symptoms may play a role. 
 
 
Future research directions 
 
Future research should aim to improve the poor health status of patients with 
schizophrenia, by increasing the adoption of positive lifestyle behaviours. Longitudinal 
(prospective) studies should be conducted in order to tease apart more in detail cause 
and effect among the identified variables. Further studies should expand sample sizes 
and representativeness (i.e., severe symptomatology), address concerns related to 
multiple comparisons, and incorporate different instruments from those used in the 
current study, namely objective measure of PA (e.g., pedometers or accelerometers). 
More research is needed to explore the role of self-esteem in PA behaviours and QoL in 
this population. Due to the importance of the psychopathological symptoms in the 
outcomes of the disorder, future studies should examine the impact of psychopathology 
as a modifying variable. 
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Conclusion 
 
This doctoral thesis provided new and relevant evidence regarding lifestyle-related 
factors and psychological determinants in patients with schizophrenia. As summary of 
the findings found in the studies presented in this research, some conclusions are 
possible highlight, namely, the importance of autonomous motivation as a determinant 
for an active PA behaviour and better QoL, the reciprocal interactions between sleep 
quality and PA behaviours, the poor dietary patterns (in both inpatients and outpatients), 
and finally, the importance of self-esteem on QoL of patients with schizophrenia.  
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